"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,MX,A,MX PA02002142 A,010-520-365-873-309,2003-04-10,2003,MX PA02002142 A,2000-02-02,US 15162199 P;;US 0002409 W,1999-08-31,CELL SPECIFIC AND OR TUMOR SPECIFIC PROMOTER RETARGETING OF HERPES GAMMA 34.5 GENE EXPRESSION.,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor specific and or cell specific promoters to drive expression of the herpes ggr;34.5 gene.,GEN HOSPITAL CORP,E ANTONIO CHIOCCA,,https://lens.org/010-520-365-873-309,Patent Application,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C12N15/09;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
2,AU,A1,AU 2021/206256 A1,106-595-542-960-874,2022-07-28,2022,AU 2021/206256 A,2021-01-08,US 202062959625 P;;US 2021/0012746 W,2020-01-10,Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer,"The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).",BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,,https://lens.org/106-595-542-960-874,Patent Application,no,0,0,11,11,0,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,A61K39/00,,0,0,,,,PENDING
3,WO,A2,WO 2021/142300 A2,169-668-828-624-93X,2021-07-15,2021,US 2021/0012746 W,2021-01-08,US 202062959625 P,2020-01-10,METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER,"The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier, compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM).",BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,,https://lens.org/169-668-828-624-93X,Patent Application,yes,0,0,11,11,117,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,A61K39/00,,0,0,,,,PENDING
4,CA,A1,CA 3167290 A1,146-097-813-711-677,2021-07-15,2021,CA 3167290 A,2021-01-08,US 202062959625 P;;US 2021/0012746 W,2020-01-10,METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER,"The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).",BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,,https://lens.org/146-097-813-711-677,Patent Application,no,0,0,11,11,117,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,A61K39/00,,0,0,,,,PENDING
5,EP,A4,EP 4087602 A4,059-989-321-435-709,2023-11-29,2023,EP 21738480 A,2021-01-08,US 202062959625 P;;US 2021/0012746 W,2020-01-10,METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER,,BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,,https://lens.org/059-989-321-435-709,Search Report,no,1,0,11,11,0,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,A61P35/00;;C07K16/00;;C07K16/28;;C12N7/00;;C12N15/864,,3,3,086-227-909-159-504;;079-025-679-676-610;;025-730-954-427-665,10.3389/fonc.2019.00052;;pmc6382738;;30838171;;10.1007/978-1-60761-919-2_33;;21053150;;pmc3703514;;10.1016/j.biomaterials.2018.05.041;;pmc5999585;;29860139,"REUL JOHANNA ET AL: ""Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors"", FRONTIERS IN ONCOLOGY, vol. 9, 14 February 2019 (2019-02-14), XP055817129, DOI: 10.3389/fonc.2019.00052;;""Cell-Penetrating Peptides : Methods and Protocols : Methods and Protocols"", vol. 683, 8 July 2013, HUMANA PRESS, Totowa, NJ, ISBN: 978-1-60761-919-2, ISSN: 1064-3745, article GOMEZ JOSE ET AL: ""Cell-Penetrating Penta-Peptides and Bax-Inhibiting Peptides: Protocol for Their Application : Methods and Protocols"", pages: 465 - 471, XP093093676, DOI: 10.1007/978-1-60761-919-2_33;;ZHANG XINTAO ET AL: ""Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration"", BIOMATERIALS, vol. 176, 1 September 2019 (2019-09-01), AMSTERDAM, NL, pages 71 - 83, XP093093678, ISSN: 0142-9612, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999585/pdf/nihms972282.pdf> DOI: 10.1016/j.biomaterials.2018.05.041",PENDING
6,WO,A1,WO 2020/081585 A1,023-945-550-202-422,2020-04-23,2020,US 2019/0056362 W,2019-10-15,US 201862745554 P,2018-10-15,THE LONG NON-CODING RNA INCA1 AND HOMO SAPIENS HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN H1 (HNRNPH1) AS THERAPEUTIC TARGETS FOR IMMUNOTHERAPY,"Compositions comprising inhibitory nucleic acids targeting the long non-coding RNA INCA1, and methods of use thereof, e.g., in combination with immunotherapy, to treat cancer.",BRIGHAM & WOMENS HOSPITAL INC,MINEO MARCO;;CHIOCCA E ANTONIO,,https://lens.org/023-945-550-202-422,Patent Application,yes,2,3,2,2,56,A61K31/712;;A61K31/713;;A61P35/00;;C12N15/113;;C12N2310/14;;C12N2310/531;;C12N2310/11;;C12N2310/315;;C12N2310/322;;A61K45/06;;C07K2319/03;;C07K14/7051;;A61K39/4631;;A61K2239/38;;A61K39/4611;;A61K2239/31;;A61K39/464404;;A61K45/06;;C12N15/113;;C12N2310/11;;C12N2310/14;;C12N2310/315;;C12N2310/3181;;C12N2310/3231,C12N15/113;;A61K31/7088;;A61K31/712;;A61K31/713;;A61P35/00;;C12Q1/68;;G01N33/50,,1,1,049-210-680-807-311,pmc3151066;;10.1074/jbc.m110.203471;;21540187,"BAUMER ET AL.: ""Inhibitor Of Cdk Interacting With Cyclin A1 (INCA1) Regulates Proliferation And Is Repressed By Oncogenic Signaling"", J. BIOL. CHEM., vol. 286, no. 32, 3 May 2011 (2011-05-03) - 12 August 2011 (2011-08-12), pages 28210 - 28222, XP055702072",PENDING
7,US,A1,US 2023/0053817 A1,071-655-052-097-063,2023-02-23,2023,US 202117791261 A,2021-01-08,US 202117791261 A;;US 202062959625 P;;US 2021/0012746 W,2020-01-10,METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER,"The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).",BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2021-01-14),https://lens.org/071-655-052-097-063,Patent Application,yes,0,1,11,11,117,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,C07K14/005;;A61K31/175;;A61K31/495;;A61K39/395;;A61P25/00;;A61P35/00;;A61P37/04;;C07K16/28,,8,5,008-928-144-627-267;;144-823-634-965-883;;117-333-710-008-815;;012-675-071-791-462;;052-242-769-660-920,pmc4393649;;24840552;;10.1038/nrg3742;;10.17226/18577;;33558455;;10.1038/s41392-021-00487-6;;pmc7868676;;10.1042/bst20150135;;26517916;;10.1007/978-1-4939-7231-9_5;;28986783,"Yu et al., 2021 (US 2021/0301024 A1, effective filing date, 7-4-18).;;Kotterman et al., 2014 (Nature Reviews, Vol. 15, p. 445-451).;;Shim et al., 2017 (Current Gene Therapy, Vol. 17, No. 5, p. 1-18).;;Lenzi et al., 2014 (NCBI Bookshelf, A Service of the National Library of Medicine, National Institute of Health, Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Advisory Committee. Washington (DC): National Academies Press (US), pages 1-16).;;Bulcha et al., 2021 (Signal Transduction and Targeted Therapy, 6:53, p. 1-24).;;Bryan et al., 2013 (http://www.elsevierblogs.com/currentcomments/?p=962, Implications of protein fold switching, p. 1-4).;;Maqbool et al., 2015 (Biochemical Society Transactions, Vol. 43, No. 5, p. 1011-1017).;;Cruz et al., 2017 (Methods in Molecular Biology, Vol. 1654, Chapter 5, pp. 55-75).",PENDING
8,EP,A2,EP 4087602 A2,066-145-500-061-419,2022-11-16,2022,EP 21738480 A,2021-01-08,US 202062959625 P;;US 2021/0012746 W,2020-01-10,METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER,,BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,,https://lens.org/066-145-500-061-419,Patent Application,yes,0,0,11,11,117,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,A61K39/00,,0,0,,,,PENDING
9,WO,A3,WO 2021/142300 A3,166-724-867-607-424,2021-08-26,2021,US 2021/0012746 W,2021-01-08,US 202062959625 P,2020-01-10,METHODS AND COMPOSITIONS FOR DELIVERY OF IMMUNOTHERAPY AGENTS ACROSS THE BLOOD-BRAIN BARRIER TO TREAT BRAIN CANCER,"The present application relates to sequences that enhance permeation of immunotherapy agents across the blood brain barrier (BBB), compositions comprising the sequences, and methods of use thereof to treat brain cancer, e.g., glioblastoma (GBM). Further disclosed are a number of potential targeting peptide sequences identified that enhance permeation through the BBB, when inserted into the capsid of an adeno-associated virus (AAV).",BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,,https://lens.org/166-724-867-607-424,Search Report,yes,6,0,11,11,117,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,A61K39/00,,2,2,046-945-053-925-798;;019-730-591-445-057,pmc5948233;;29766031;;10.1016/j.omtm.2018.03.004;;26796040;;pmc4940329;;10.1016/j.jconrel.2016.01.001,"WANG ET AL.: ""A Rationally Engineered Capsid Variant of AAV9 for Systemic CNS-Directed and Peripheral Tissue-Detargeted Gene Delivery in Neonates"", MOL THER METHODS CLIN DEV, vol. 9, 2018, pages 234 - 246, XP055753221, DOI: 10.1016/j.omtm.2018.03.004;;SANTIAGO-ORTIZ ET AL.: ""Adeno-Associated Virus (AAV) Vectors in Cancer Gene Therapy"", J CONTROL RELEASE, vol. 240, 2016, pages 287 - 301, XP029759411, DOI: 10.1016/j.jconrel.2016.01.001",PENDING
10,KR,A,KR 20220127847 A,046-307-672-753-298,2022-09-20,2022,KR 20227027150 A,2021-01-08,US 202062959625 P;;US 2021/0012746 W,2020-01-10,뇌암을 치료하기 위해 혈액-뇌 장벽을 통해 면역요법제를 전달하기 위한 방법 및 조성물,"본 출원은 혈액 뇌 장벽 (BBB)을 통한 면역요법제의 투과를 증진시키는 서열, 상기 서열을 포함하는 조성물, 및 뇌암, 예컨대, 교모세포종 (GBM)을 치료하기 위한 그의 사용 방법에 관한 것이다. 추가로, 아데노-연관 바이러스 (AAV)의 캡시드 내로 삽입되었을 때, BBB를 통한 투과를 증진시키는 것으로 확인된 다수의 잠재적 표적화 펩티드 서열을 개시한다.",BRIGHAM & WOMENS HOSPITAL INC,BEI FENGFENG;;CHIOCCA E ANTONIO,,https://lens.org/046-307-672-753-298,Patent Application,no,0,0,11,11,228,A61P35/00;;C12N2750/14143;;C12N15/86;;C07K14/005;;C12N2750/14122;;C12N2750/14145;;A61K48/005;;A61K48/0075;;A61K2039/505;;C07K16/2827;;A61K39/0011;;A61K2039/6075;;A61K48/0075;;A61K48/0008;;A61K39/00;;A61K39/3955;;A61P35/00;;C12N15/86;;C07K14/005;;C07K16/2827;;A61K2039/6075;;A61K2039/505;;A61K2039/54;;A61K2039/585;;A61K2039/5256;;C12N2750/14143;;C12N2750/14133;;A61P37/04;;A61P25/00;;A61P35/00;;A61K31/175;;A61K31/495;;A61K39/3955;;A61K2039/505;;A61K2039/54;;C07K14/005;;C07K16/2818;;C07K16/2827;;C12N2750/14122;;C12N2750/14143;;C12N2750/14171,A61K48/00;;A61K39/00;;A61K39/395;;A61P35/00;;C07K14/005;;C07K16/28;;C12N15/86,,0,0,,,,PENDING
11,US,A1,US 2021/0380978 A1,102-680-763-848-043,2021-12-09,2021,US 201917284919 A,2019-10-15,US 201917284919 A;;US 201862745554 P;;US 2019/0056362 W,2018-10-15,The long non-coding RNA INCA1 and Homo sapiens heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) as therapeutic targets for immunotherapy,"Compositions comprising inhibitory nucleic acids targeting the long non-coding RNA INCA1, and methods of use thereof, e.g., in combination with immunotherapy, to treat cancer.",BRIGHAM & WOMENS HOSPITAL INC,MINEO MARCO;;CHIOCCA E ANTONIO,THE BRIGHAM AND WOMEN'S HOSPITAL INC (2021-07-13),https://lens.org/102-680-763-848-043,Patent Application,yes,1,0,2,2,56,A61K31/712;;A61K31/713;;A61P35/00;;C12N15/113;;C12N2310/14;;C12N2310/531;;C12N2310/11;;C12N2310/315;;C12N2310/322;;A61K45/06;;C07K2319/03;;C07K14/7051;;A61K39/4631;;A61K2239/38;;A61K39/4611;;A61K2239/31;;A61K39/464404;;A61K45/06;;C12N15/113;;C12N2310/11;;C12N2310/14;;C12N2310/315;;C12N2310/3181;;C12N2310/3231,C12N15/113;;A61K45/06,,5,0,,,"Rao, Donald D et al. “siRNA vs. shRNA: similarities and differences.” Advanced drug delivery reviews vol. 61,9 (2009): 746-59. doi:10.1016/j.addr.2009.04.004 (Year: 2009);;Liu M, Yang L, Liu X, et al. HNRNPH1 Is a Novel Regulator Of Cellular Proliferation and Disease Progression in Chronic Myeloid Leukemia. Front Oncol. 2021;11:682859. Published 2021 Jul 6. doi:10.3389/fonc.2021.682859 (Year: 2021);;Estey, Elihu H et al. “Current challenges in clinical development of ""targeted therapies"": the case of acute myeloid leukemia.” Blood 125 16 (2015): 2461-6 . (Year: 2015);;Li Y, Bakke J, Finkelstein D, Zeng H, Wu J, Chen T. HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis. 2018;7(1):9. Published 2018 Jan 24. doi:10.1038/s41389-017-0024-4 (Year: 2018);;Bäumer N, Tickenbrock L, Tschanter P, et al. Inhibitor of cyclin-dependent kinase (CDK) interacting with cyclin A1 (INCA1) regulates proliferation and is repressed by oncogenic signaling. J Biol Chem. 2011;286(32):28210-28222. doi:10.1074/jbc.M110.203471 (Year: 2011)",PENDING
12,WO,A1,WO 2001/016331 A1,030-853-786-308-210,2001-03-08,2001,US 0002409 W,2000-02-02,US 15162199 P,1999-08-31,CELL-SPECIFIC AND/OR TUMOR-SPECIFIC PROMOTER RETARGETING OF HERPES GAMMA 34.5 GENE EXPRESSION,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes η34.5 gene.,GEN HOSPITAL CORP;;CHIOCCA E ANTONIO;;CHUNG RICHARD Y,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/030-853-786-308-210,Patent Application,yes,4,18,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C12N15/09;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,6,6,016-857-056-204-779;;009-715-658-834-906;;008-152-329-341-999;;006-965-348-959-327;;037-230-075-698-623;;052-187-065-750-38X,9414254;;10.1089/hum.1997.8.17-2057;;10.1073/pnas.92.5.1411;;pmc42529;;7877992;;10.1128/jvi.69.5.3033-3041.1995;;7707530;;pmc189003;;10.1016/0378-1119(95)00184-8;;7642110;;10.1128/jvi.73.9.7556-7564.1999;;10438845;;pmc104282;;10.2165/00128413-200012390-00013,"C.M. KRAMM ET AL.: ""Therapeutic and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy"", HUMAN GENE THERAPY, vol. 8, no. 17, 20 November 1997 (1997-11-20), MARY ANN LIEBERT, INC. PUBLISHERS, NEW YORK, US, pages 2057 - 2068, XP000929872;;CHAMBERS R ET AL: ""Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, no. 5, 28 February 1995 (1995-02-28), pages 1411 - 1415, XP002090032, ISSN: 0027-8424;;PERNG ET AL: ""AN AVIRULENT ICP34.5 DELETION MUTANT OF HERPES SIMPLEX VIRUS TYPE 1 IS CAPABLE OF IN VIVO SPONTANEOUS REACTIVATION"", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 69, no. 5, 1 May 1995 (1995-05-01), pages 3033 - 3041, XP002090031, ISSN: 0022-538X;;LAM E W -F ET AL: ""Cell-cycle regulation of human B-myb transcription"", GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 160, no. 2, 28 July 1995 (1995-07-28), pages 277 - 281, XP004042159, ISSN: 0378-1119;;CHUNG R Y ET AL: ""B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells."", JOURNAL OF VIROLOGY, (1999 SEP) 73 (9) 7556-64. JOURNAL CODE: KCV., XP002144570;;NAKAMURA HIDEO ET AL: ""Oncolysis of colon carcinoma liver metastasis in genetically-engineered HSV-1 vector Myb34.5."", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 466, XP002144571, ISSN: 0197-016X",PATENTED
13,WO,A1,WO 1999/055345 A1,028-185-465-342-087,1999-11-04,1999,US 9909376 W,1999-04-30,US 8366398 P,1998-04-30,COMBINATION VIRAL-BASED AND GENE-BASED THERAPY OF TUMORS,The present invention relates to viral mutants and methods of using these viral mutants for selectively killing neoplastic cells. The viral mutants of the invention are capable of selectively killing neoplastic cells by a combination of viral mediated oncolysis and anti-cancer ('suicide') gene therapy.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;BREAKFIELD XANDRA O,,https://lens.org/028-185-465-342-087,Patent Application,yes,0,11,5,5,0,A61K35/763;;A61K48/00;;B82Y5/00;;C12N7/00;;C12N15/86;;C12N2710/16332;;C12N2710/16632;;C12N2710/16643;;A61K38/415;;A61K38/44;;A61K45/06;;C12Y117/04001;;C12Y114/14;;A61K31/675;;A61K47/6891;;B82Y5/00;;C12N7/00;;C12N2710/16632;;C12N15/86;;A61K35/763;;A61K48/00;;C12N2710/16332;;C12N2710/16643;;A61K38/415;;A61K45/06;;A61K38/44;;C12Y114/14;;C12Y117/04001;;A61K31/675;;A61K47/6891,A61K35/76;;A61K35/763;;A61K47/48;;A61K48/00;;C12N7/00;;C12N15/869,,2,1,068-120-985-008-609,10.1093/infdis/164.6.1091;;1659596,"BREAKEFIELD X O, ET AL.: ""GENE THERAPY FOR BRAIN TUMORS USING HERPES VIRUS VECTORS ABSTRACT"", ANNALS OF ONCOLOGY., KLUWER, DORDRECHT., NL, vol. 07, no. SUPPL.01, 1 January 1996 (1996-01-01), NL, pages COMPLETE, XP002919707, ISSN: 0923-7534;;YAMADA Y, ET AL.: ""THE PATHOGENICITY OF RIBONUCLEOTIDE REDUCTASE-NULL MUTANTS OF HERPES SIMPLEX VIRUS TYPE 1 IN MICE"", JOURNAL OF INFECTIOUS DISEASES. JID, UNIVERSITY OF CHICAGO PRESS., CHICAGO, IL., vol. 164, 1 January 1991 (1991-01-01), CHICAGO, IL., pages 1091 - 1097, XP002919708, ISSN: 0022-1899",PENDING
14,SI,T1,SI 1212428 T1,169-016-621-528-795,2005-06-30,2005,SI 200030611 T,2000-02-02,US 0002409 W;;US 15162199 P,1999-08-31,CELL-SPECIFIC AND/OR TUMOR-SPECIFIC PROMOTER RETARGETING OF HERPES GAMMA 34.5 GENE EXPRESSION,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/169-016-621-528-795,Granted Patent,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;C12N15/09;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
15,CA,C,CA 2383372 C,078-811-203-580-009,2010-04-13,2010,CA 2383372 A,2000-02-02,US 15162199 P;;US 0002409 W,1999-08-31,CELL-SPECIFIC AND/OR TUMOR-SPECIFIC PROMOTER RETARGETING OF HERPES GAMMA 34.5 GENE EXPRESSION,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes .gamma.34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/078-811-203-580-009,Granted Patent,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;C12N15/38;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N7/04;;C12N15/86;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
16,EP,A1,EP 1212428 A1,191-780-239-373-666,2002-06-12,2002,EP 00913305 A,2000-02-02,US 0002409 W;;US 15162199 P,1999-08-31,CELL-SPECIFIC AND/OR TUMOR-SPECIFIC PROMOTER RETARGETING OF HERPES GAMMA 34.5 GENE EXPRESSION,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/191-780-239-373-666,Patent Application,yes,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
17,PT,E,PT 1212428 E,034-466-259-352-231,2005-03-31,2005,PT 00913305 T,2000-02-02,US 15162199 P,1999-08-31,REDIRECCIONAMENTO DA EXPRESSAO DO GENE GAMA 34.5 DE HERPES ATRAVES DE UM PROMOTOR ESPECIFICO DE CELULAS E/OU ESPECIFICO DE TUMORES,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA ANTONIO E;;CHUNG RICHARD Y,,https://lens.org/034-466-259-352-231,Granted Patent,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;C12N15/09;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
18,ES,T3,ES 2233349 T3,149-903-444-928-290,2005-06-16,2005,ES 00913305 T,2000-02-02,US 15162199 P,1999-08-31,"REORDENACION POR PROMOTORES ESPECIFICOS PARA UNA CELULA Y/O ESPECIFICOS PARA UN TUMOR DE LA EXPRESION DEL GEN GAMMA 34,5 HERPETICO.",The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/149-903-444-928-290,Granted Patent,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
19,US,B1,US 6602499 B1,090-933-199-793-959,2003-08-05,2003,US 30295299 A,1999-04-30,US 30295299 A;;US 8366398 P,1998-04-30,Combination viral-based and gene-based therapy of tumors,"
    The present invention relates to viral mutants and methods of using these viral mutants for selectively killing neoplastic cells. The viral mutants of the invention are capable of selectively killing neoplastic cells by a combination of viral mediated oncolysis and anti-cancer (suicide) gene therapy. 
",GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;BREAKEFIELD XANDRA O,GENERAL HOSPITAL CORPORATION THE (1999-06-21),https://lens.org/090-933-199-793-959,Granted Patent,yes,8,8,5,5,7,A61K35/763;;A61K48/00;;B82Y5/00;;C12N7/00;;C12N15/86;;C12N2710/16332;;C12N2710/16632;;C12N2710/16643;;A61K38/415;;A61K38/44;;A61K45/06;;C12Y117/04001;;C12Y114/14;;A61K31/675;;A61K47/6891;;B82Y5/00;;C12N7/00;;C12N2710/16632;;C12N15/86;;A61K35/763;;A61K48/00;;C12N2710/16332;;C12N2710/16643;;A61K38/415;;A61K45/06;;A61K38/44;;C12Y114/14;;C12Y117/04001;;A61K31/675;;A61K47/6891,A61K35/76;;A61K35/763;;A61K47/48;;A61K48/00;;C12N7/00;;C12N15/869,424/93.2;;424/93.1;;435/320.1;;435/325;;514/44,106,100,035-209-026-470-578;;046-759-373-855-603;;009-416-320-508-847;;072-842-887-187-745;;083-214-553-213-597;;010-020-719-364-675;;134-725-164-032-429;;068-120-985-008-609;;039-257-615-308-052;;104-964-283-913-819;;046-347-440-046-988;;006-808-500-178-359;;053-774-110-438-540;;012-491-128-947-215;;090-216-380-961-601;;009-967-950-291-84X;;056-664-199-171-214;;042-719-805-570-571;;039-796-353-798-401;;024-973-164-046-593;;138-036-512-631-113;;013-571-395-488-216;;000-534-137-091-617;;038-446-868-055-096;;083-366-647-068-936;;027-435-622-442-317;;069-981-066-527-898;;039-372-021-206-247;;009-715-658-834-906;;062-832-175-705-848;;081-388-049-836-987;;015-585-302-194-72X;;134-738-047-141-91X;;049-870-597-924-772;;010-020-719-364-675;;110-392-285-101-597;;055-276-462-185-410;;018-024-066-836-75X;;057-490-251-759-365;;004-189-135-234-849;;007-762-686-010-84X;;016-171-978-858-692;;091-890-938-877-101;;129-007-299-920-530;;038-391-977-482-366;;063-703-895-010-986;;082-113-153-908-681;;009-797-632-957-766;;022-313-131-002-600;;029-335-357-819-228;;024-896-536-081-888;;031-818-712-694-764;;025-534-886-435-277;;018-538-384-825-51X;;141-196-327-223-098;;127-499-456-300-150;;098-483-195-240-041;;111-147-303-778-188;;023-511-604-385-36X;;126-253-284-563-23X;;048-967-556-184-67X;;139-786-090-268-324;;052-507-092-115-672;;054-481-398-737-44X;;069-634-607-125-845;;114-957-834-836-766;;044-986-423-610-506;;023-013-375-450-444;;009-804-034-362-036;;056-447-493-020-483;;080-592-565-709-011;;051-704-281-873-401;;045-087-390-059-179;;061-186-977-056-712;;003-273-587-266-097;;035-309-018-576-696;;026-710-333-198-810;;007-439-820-967-512;;015-469-298-896-80X;;027-374-789-634-250;;067-084-366-852-796;;000-292-590-592-47X;;016-190-545-942-040;;098-345-270-654-450;;077-528-432-594-48X;;044-601-835-834-83X;;011-813-528-085-143;;123-472-487-545-585;;014-216-752-035-849;;031-118-187-392-620;;096-032-891-527-198;;002-067-583-917-127;;025-667-654-178-004;;011-656-526-671-070;;024-522-213-521-061;;090-048-542-836-687;;046-720-321-052-712;;039-790-799-566-253;;063-935-944-274-471;;041-173-624-680-036,10.1073/pnas.94.2.690;;pmc19575;;9012846;;10.1126/science.270.5235.404;;7569994;;9305836;;10.1038/38410;;10.1089/hum.1996.7.16-1989;;8930659;;pmc1235374;;8813260;;10.1097/00000658-199609000-00008;;8640822;;10463570;;10.1093/infdis/164.6.1091;;1659596;;10.1016/s0889-8588(05)70011-3;;9684101;;9224416;;10.1006/jsre.1997.5089;;10.1126/science.288.5466.669;;10784449;;8178460;;10.1006/viro.1994.1242;;10741699;;10794295;;10.3171/jns.2000.92.5.0804;;10.1016/0042-6822(88)90287-5;;2833019;;10.1038/11320;;10426310;;10775615;;10.1128/jvi.74.10.4765-4775.2000;;pmc111999;;10845725;;10.1038/sj.gt.3301205;;10749560;;10.1172/jci9744;;pmc382984;;10850415;;10845724;;10.1038/sj.gt.3301184;;8186287;;10.1089/hum.1993.4.6-725;;10.1097/00005072-198105000-00001;;6260907;;10.1126/science.274.5286.373;;8832876;;7954393;;10.1007/bf02935741;;10.1007/978-1-4612-4604-6_12;;3077063;;6294260;;10.3171/jns.1983.58.2.0159;;2844969;;10.1099/0022-1317-69-10-2607;;10.1073/pnas.92.5.1411;;pmc42529;;7877992;;1656596;;10.1016/0042-6822(91)90794-c;;8242617;;10.1038/nbt0598-444;;9592392;;10.1073/pnas.91.8.3054;;8159705;;pmc43513;;7834628;;8640822;;1314384;;pmc48847;;10.1073/pnas.89.8.3266;;2664191;;10.1093/jnci/81.15.1133;;2706622;;10.1126/science.3018926;;3018926;;10.1007/s002800050771;;9554593;;7049370;;10.1093/clinchem/40.4.510;;8149602;;9426050;;7623816;;pmc230660;;10.1128/mcb.15.8.4215;;2997476;;pmc252613;;10.1128/jvi.56.2.558-570.1985;;10.1099/0022-1317-64-3-513;;6298343;;7958856;;10.1101/gad.8.15.1772;;10.1093/jac/12.suppl_b.9;;6313600;;10.1073/pnas.93.7.2909;;pmc39733;;8610141;;9536271;;10.1038/sj.gt.3300569;;1323709;;10.1128/jvi.66.9.5509-5515.1992;;pmc289109;;2245487;;10.1007/bf00689268;;10.1016/0042-6822(88)90144-4;;2842955;;2824847;;pmc250519;;10.1128/jvi.62.1.196-205.1988;;10.1023/a:1018901619230;;7870673;;9253508;;8487757;;10.1007/bf00926090;;10.1099/0022-1317-78-12-3341;;9400986;;9006938;;10.1074/jbc.272.5.2927;;6261008;;pmc171045;;10.1128/jvi.37.2.580-588.1981;;10.1016/0042-6822(89)90244-4;;2554573;;10.1002/(sici)1097-0215(19970127)70:3<335::aid-ijc15>3.3.co;2-b;;9033637;;10.1002/(sici)1097-0215(19970127)70:3<335::aid-ijc15>3.0.co;2-e;;1373198;;10.1128/jvi.66.5.2952-2965.1992;;pmc241054;;10.1007/bf01306455;;7964989;;7474937;;7605047;;10.1007/bf02368317;;2680389;;10.3109/03602538909103550;;8135768;;10.1002/bies.950150808;;8040891;;10.1093/jnci/86.16.1228;;10.1128/mcb.16.3.1047;;8622649;;pmc231087;;10.1023/a:1005941603420;;9547679;;8840992;;1326612;;10.3171/jns.1992.77.4.0590;;10.1097/00006123-199304000-00016;;10.1227/00006123-199304000-00016;;8386343;;1851332;;10.1126/science.1851332;;6311955;;10.1099/0022-1317-64-10-2261;;2535723;;pmc247652;;10.1128/jvi.63.1.18-27.1989;;10.1099/0022-1317-64-5-997;;6302217;;pmc555393;;6315408;;10.1002/j.1460-2075.1983.tb01684.x;;10.1099/0022-1317-69-7-1531;;2839594;;3005980;;pmc339569;;10.1093/nar/14.4.1727;;2984429;;10.1016/0022-2836(85)90320-1;;8033122;;8542424;;7585221;;10.1038/nm0995-938;;6253078;;10.1016/0092-8674(80)90172-5;;3019523;;1964092;;10.1089/hum.1990.1.2-125;;10.1093/jnci/82.4.297;;2299679;;7543006;;pmc1869962;;7495307;;1729703;;pmc48169;;10.1073/pnas.89.1.33;;8280797;;10.1089/hum.1993.4.5-589;;8895767;;10.1007/bf00698289;;3993331;;10.1089/dna.1993.12.1;;7678494;;2835765;;10.1002/prot.340010411;;7568227;;pmc40896;;10.1073/pnas.92.21.9829;;10.1073/pnas.91.16.7727;;8052651;;pmc44475;;pmc363149;;10.1128/mcb.8.1.457;;2827006;;10.1128/mcb.8.1.457-460.1988,"Cheng et al. Proc. Natl. Acad. Sci. USA 94:690-694, 1997.*;;Crystal RG. Science 270:404-410 1995.*;;Verma IM and Somia N. Nature 389: 239-242. 1997.*;;Kramm CM et al. Human Gene Therapy 7:1989-1994, 1996.*;;Carroll NM et al. Annals of Surgery 224:323-330, 1996.*;;Chen et al. Cancer Research 56: 1331-1340, 1996.*;;Aghi M et al. Cancer Research 59:3861-3865, 1999.*;;Database Medline on Dialog, Abstract for Breakfield, X.O. et al., ""Gene therapy for brain tumors using herpes virus vectors (Meeting abstract),"" Ann. Oncol. 7:23, abstract (1996).;;Yamada, Y., et al., ""The Pathogenicity of Ribnonucleotide Reductase-Null Mutants of Herpes Simplex Virus Type 1 in Mice,"" J. Infect. Dis. 164:1091-1097 (1991).;;Virology, 3rd ed., Fields, B.N., Knipe, D.M., and Howley, P.M., eds., Lippincott-Raven Publishers, New York, vol. 2, pp. 2123-2126, 2346, 2452, 2529, and 2642 (1996).;;Alavi, J.B, and Eck, S.L., ""Gene Therapy for Malignant Gliomas,"" Hematology/Oncology Clinics of North America 12:617-629 (1998).;;Carroll, N.M., et al., ""The Effect of Ganciclovir on Herpes Simplex Virus-Mediated Oncolysis,"" J. Surg. Res. 69:413-417 (1997).;;Cavazzana-Calvo, M., et al., ""Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease,"" Science 288:669-672 (Apr. 2000).;;de Wind, N., et al., ""Mutagenesis and Characterization of a 41-Kilobase-Pair Region of the Pseudorabies Virus Genome: Transcription Map, Search for Virulence Genes, and Comparison with Homologs of Herpes Simplex Virus Type 1,"" Virology 200:784-790 (1994).;;Ganly, I., et al., ""A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer,"" Clin. Cancer Res. 6:798-806 (Mar. 2000).;;Harsh, G.R., et al., ""Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study,"" J. Neurosurg. 92:804-811 (May 2000).;;Huang, A., et al., ""Expression of the HSV-2 Ribonucleotide Reductase Subunits in Adenovirus Vectors or Stably Transformed Cells: Restoration of Enzymatic Activity by Reassociation of Enzyme Subunits in the Absence of Other HSV Proteins,"" Virology 163:462-470 (1988).;;Ikeda, K., et al., ""Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral repsonses,"" Nat. Med. 5:881-887 (Aug. 1999).;;Ikeda, K., et al., ""Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant,"" J. Virol. 74:4765-4775 (May 2000).;;Markert, J.M., et al., ""Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of phase I trial,"" Gene Therapy 7:867-874 (May 2000).;;Martuza, R.L., ""Conditionally replicating herpes vectors for cancer therapy,"" J. Clin. Invest. 105:841-846 (Apr. 2000).;;Pawlik, T.M., et al., ""Oncolysis of Diffuse Hepatocellular Carcinoma by Intravascular Administration of a Replication-competent, Genetically Engineered Herpesvirus,"" Cancer Res. 60:2790-2795 (Jun. 2000).;;Rampling, R., et al., ""Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma,"" Gene Therapy 7:859-866 (May 2000).;;Ausubel, F.M., et al., eds., ""Protein Expression,"" Chapter 16 in Short Protocols in Molecular Biology (4th ed.), John Wiley & Sons, Inc., New York, NY, pp. 16-1-16-107 (Apr. 1999).;;Bi, W.L., et al., ""In Vitro Evidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed in HSV tk Retroviral Gene Therapy,"" Human Gene Ther. 4:725-731 (1993).;;Bigner, D.D., et al., ""Heterogeneity of Genotypic and Phenotypic Characteristics of Fifteen Permanent Cell Lines Derived from Human Gliomas,"" J. Neuropathol. Exp. Neurol. 40:201-229 (1981).;;Bischoff, J.R., et al., ""An Adenovirus Mutant That Replicates Selectivity in p53-Deficient Human Tumor Cells,"" Science 274:373-376 (1996).;;Boviatsis, E.J., et al., ""Long-Term Survival of Rats Harboring Brain Neoplasms Treated with Ganciclovir and a Herpes Simplex Virus Vector That Retains an Intact Thymidine Kinase Gene,"" Cancer Res. 54:5745-5751 (1994).;;Breakefield, X.O. and Geller, A.I., ""Gene Transfer into the Nervous System,"" Molec. Neurobiol. 1:339-371 (1987).;;Burger, P.C., et al., ""Computerized tomographic and pathologic studies of the untreated quiescent, and recurrent glioblastoma multiforme,"" J. Neurosurg. 58:159-169 (1983).;;Cameron, J.M., et al., ""Ribonucleotide Reductase Encoded by Herpes Simplex Virus Is a Determinant of the Pathogenicity of the Virus in Mice and a Valid Antiviral Target,"" J. Gen. Virol. 69:2607-2612 (1988).;;Chambers, R. et al., ""Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in scid mouse model of human and malignant glioma,"" Proc. Natl. Acad. Sci. USA 92:1411-1415 (1995).;;Chang, J.Y., et al.,""A Gene Delivery/Recall System for Neurons Which Utilizes Ribonucleotide Reductase-Negative Herpes Simplex Viruses,"" Virol. 185:437-440 (1991).;;Chang, T.K.H., ""Differential Activation of Cyclophosphamide and Ifosphamide by Cyclochromes P-450 2B and 3A in Human Liver Microsomes,"" Cancer Res. 53:5629-5637 (1993).;;Chase, M. et al., ""An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,"" Nat. Biotech. 16:444-448 (1998).;;Chen, S.-H. et al., ""Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo,"" Proc. Natl. Acad. Sci. USA 91:3054-3057 (1994).;;Chen, L. and Waxman, D.J., ""Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfers: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy,"" Cancer Res. 55:581-589 (1995).;;Chen, L., et al., ""Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosamade by Transfer of a Liver Cytochrome P450 Gene,"" Cancer Res. 56:1331-1340 (1996).;;Chou, J. and Roizman, B., ""The Y1 34.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells,"" Proc. Natl. Acad. Sci. USA 89:3266-3270 (1992).;;Christian, M.C., et al., ""4-Ipomeanol: A Novel Investigational New Drug for Lung Cancer,"" J. Natl. Cancer Inst. 81:1133-1143 (1989).;;Clarke, L. and Waxman, D.J., ""Oxidative Metabolism of Cyclophosphamide: Identification of the Hepatic Monooxygenase Catalysts of Drug Activation,"" Cancer Res. 49:2344-2350 (1989).;;Coen, D.M., et al., ""A Genetic Approach to Promoter Recognition During trans Induction of Viral Gene Expression,"" Science 234:53-59 (1986).;;Coen, D.M., ""Molecular Genetics of Animal Viruses,"" Chapter 7 in Fundamental Virology (2nd ed.), Fields, B.N. et al., (eds.) Raven Press, New York, NY, pp. 123-151 (1990).;;Coggins, C.A., et al., ""Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents,"" Cancer Chemother. Pharmacol. 41:485-490 (May 1998).;;Colvin, M. and Hilton, J., ""Pharmacology of Cyclophosphamide and Metabolites,"" Cancer Treat. Rep. 65(Suppl. 3):89-95 (1981).;;Colvin, M., ""Alkylating Agents and Platinum Antitumor Compounds,"" in Cancer Medicine (3rd ed.), vol. 1, Holland, J.F., et al., eds., Lea & Febiger, Philadelphia, PA, pp. 733-754 (1993).;;Culver, K.W., ""Clinical Applications of Gene Therapy for Cancer,"" Clin. Chem. 40:510-512 (1994).;;Danks, M.K., et al., ""Overexpression of a Rabbit Liver Carboxylesterase Sensitizes Human Tumor Cells in CPT-11,"" Cancer Res. 58:20-22 (Jan. 1998).;;DeGregori, J., et al., ""Cellular Targets for Activation by the E2F1 Transcription Factor Include DNA Synthesis-and G1S-Regulatory Genes,"" Mol. Cell. Biol. 15:4215-4224 (1995).;;DeLuca, N.A., et al., ""Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4,"" J. Virol. 56:558-570 (1985).;;Dutia, B.M., ""Ribonucleotide Reductase Induced by Herpes Simplex Virus has a Virus-specified Constituent,"" J. Gen. Virol. 64:513-521 (1983).;;Dynlacht, B.D., et al., ""Differential regulation of E2F trans-activation by cyclin/cdk2 complexes,"" Genes Dev. 8:1772-1786 (1994).;;Elion, G.B., ""The biochemistry and mechanism of action of acyclovir,"" J. Antimicrob. Chemother. 12(Suppl. B):9-17 (1983).;;Fakhrai, H., ""Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy,"" Proc. Natl. Acad. Sci. USA 93:2909-2914 (1996).;;Friedlos, F., et al., ""Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase,"" Gene Ther. 5:105-112 (Jan. 1998).;;Gage, P.J., et al., ""A Cell-Free Recombination System for Site-Specific Integration of Multigenic Shuttle Plasmids into the Herpes Simplex Virus Type 1 Genome,"" J. Virol. 66:5509-5515 (1992).;;Genka, S., et al., ""Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat,"" Cancer Chemother. Pharmacol. 27:1-7 (1990).;;Glorioso, J.C., et al., ""Herpes simplex virus-based vectors,"" Seminars in Virol. 3:265-276 (1992).;;Goldstein, D.J. and Weller, S.K., ""Factor(s) Present in Herpes Simplex Virus Type 1-Infected Cells Can Compensate for the Loss of the Large Subunit of the Viral Ribonucleotide Reductase: Characterization of an ICP6 Deletion Mutant,"" Virol. 166:41-51 (1988).;;Goldstein, D.J. and Weller, S.K., ""Herpes Simplex Virus Type 1-Induced Ribonucleotide Reductase Activity Is Dispensible for Virus Growth and DNA Synthesis: Isolation and Characterization of an ICP6 1acZ Insertion Mutant,""0 J. Virol. 62:196-205 (1988).;;Göpferich, A., et al., ""Development and Characterization of Microencapsulated Microspheres,"" Pharma. Res. 11:1568-1574 (1994).;;Green, N.K. et al., ""Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene,"" Cancer Gene Ther. 4:229-238 (Jul. 1997).;;Hodgson, A.V., et al., ""Expression analysis of the mixed function oxidase system in rat brain by the polymerase chain reaction,"" Molec. Cell. Biochem. 120:171-179 (1993).;;Hossain, A., et al., ""Analysis of cyclin-dependent kinase activity after herpes simplex virus type 2 infection,"" J. Gen. Virol. 78:3341-3348 (Dec. 1997).;;Huang, H.-J.S., et al., ""The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling,"" J. Biol. Chem. 272:2927-2935 (Jan. 1997).;;Huszar, D. and Bacchetti, S., ""Partial Purification and Characterization of the Ribonucleotide Reductase Induced by Herpes Simplex Virus Infection of Mammalian Cells,"" J. Virol. 37:580-588 (1981).;;Jacobson, J.G., et al., ""A Herpes Simplex Virus Ribonucleotide Reductase Deletion Mutant Is Defective for Productive Acute and Reactivatable Latent Infections of Mice and for Replication in Mouse Cells,"" Virol. 173:276-283 (1989).;;Jansen, W.J.M., et al., ""CPT-11 in Human Colon-Cancer Cell Lines and Xenografts: Characterization of Cellular Sensitivity Determinants,"" Int. J. Cancer 70:335-340 (Jan. 1997).;;Johnson, P.A. et al., ""Cytotoxicity of a Replication-Defective Mutant of Herpes Simplex Virus Type 1,"" J. Virol. 66:2952-2965 (1992).;;Kaplitt, M.G., et al., ""Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats,"" J. Neuro-Oncol. 19:137-147 (1994).;;Kesari, S., et al., ""Therapy of Experimental Human Brain Tumors Using a Neuroattenuated Herpes Simplex Virus Mutant,"" Lab. Invest. 73:636-648 (1995).;;Langer, R., ""1994 Whitaker Lecture: Polymers for Drug Delivery and Tissue Engineering,"" Ann. Biomed. Eng. 23:101-111 (1995).;;Le Blanc, G.A. and Waxman, D.J., ""Interaction of Anticancer Drugs with Hepatic Monooxygenase Enzymes,"" Drug Metabol. Rev. 20:395-439 (1989).;;Leib, D.A. and Olivo, P.D., ""Gene Delivery to Neurons: Is Herpes Simplex Virus the Right Tool for the Job?,"" BioEssays 15:547-554 (1993).;;Lorence, R.M., et al., ""Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy,"" J. Natl. Cancer Inst. 86:1228-1233 (1994).;;Lukas, J., et al., ""Deregulated Expression of E2F Family Members Induces S-Phase Entry and Overcomes p16INK4A-Mediated Growth Suppression,"" Molec. Cell. Biol. 16:1047-1057 (1996).;;Macdonald, J.S., et al., ""Phase II evaluation of topotecan in patients with advanced colorectal cancer,"" Invest. New Drugs 15:357-359 (1997).;;Marais, R., et al., ""Gene-directed Enzyme Prodrug Therapy with a Mustard Prodrug/Carboxypeptidase G2 Combination,"" Cancer Res. 56:4735-4742 (1996).;;Markert, J.M., et al., ""Expanded spectrum of viral therapy in the treatment of nervous system tumors,"" J. Neurosurg. 77:590-594 (1992).;;Markert, J.M., et al., ""Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir,"" Neurosurg.32597-603 (1993).;;Martuza, R.L., et al., ""Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant,"" Science 252:854-856 (1991).;;Matz, B., et al., ""Physical Mapping of Temperature-sensitive Mutations of Herpes Simplex Virus Type 1 Using Cloned Restriction Endonuclease Fragments,"" J. Gen. Virol. 64:2261-2270 (1983).;;McCarthy, A.M., et al., ""Herpes Simplex Virus Type 1 ICP27 Deletion Mutants Exhibit Altered Patterns of Transcription and Are DNA Deficient,"" J. Virol. 63:18-27 (1989).;;McLauchlan, J. and Clements, J.B., ""Organization of the Herpes Simplex Virus Type 1 Transcription Unit Encoding Two Early Proteins with Molecular Weights of 140,000 and 40,000,"" J. Gen. Virol. 64:997-1006 (1983).;;McLauchlan J. and Clements, J.B., ""DNA sequence homology between two co-linear .loci on the HSV genome which have different transforming abilities,"" EMBO J. 2:1953-1961 (1983).;;McGeoch, D.J., et al., ""The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1,"" J. Gen. Virol. 69:1531-1574 (1988).;;McGeoch, D.J., et al., ""Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1,"" Nucl. Acids Res. 14:1727-1745 (1986).;;McGeoch, D.J., et al., ""Sequence Determination and Genetic Content of the Short Unique Region in the Genome of Herpes Simplex Virus Type 1,"" J. Mol. Biol. 181:1-13 (1985).;;Mineta, T., et al., ""Treatment of Malignant Gliomas Using Ganciclovir-hypersensitive, Ribonucleotide Reductase-deficient Herpes Simplex Viral Mutant,"" Cancer Res. 54:3963-3966 (1994).;;Mineta, T., et al., ""CNS Tumor Therapy by Attenuated Herpes Simplex Viruses,"" Gene Ther. 1(Suppl. 1):s78 (1994).;;Mineta, T., et al., ""Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas,"" Nat. Med. 1:938-943 (1995).;;Mocarski, E.S., ""Molecular Engineering of the Herpes Simplex Virus Genome: Insertion of a Second L-S Junction into the Genome Causes Additional Genome Inversions,"" Cell 22:243-255 (1980).;;Moolten, F.L., ""Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy,"" Cancer Res. 46:5276-5281 (1986).;;Moolten, F.L., et al., ""Lymphoma Regression Induced by Ganciclovir in Mice Bearing a Herpes Thymidine Kinase Transgene,"" Hum. Gene Ther. 1:125-134 (1990).;;Moolten, F.L. and Wells, J.M., ""Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors,"" J. Natl. Cancer Inst. 82:297-305 (1990).;;Moolten, F.L., ""Drug sensitivity (""suicide"") genes for selective cancer chemotherapy,"" Cancer Gene Therapy 1:279-287 (1994).;;Muldoon, L.L., et al., ""Comparison of Intracerebral Inoculation and Osmotic Blood-Brain Barrier Disruption for Delivery of Adenovirus, Herpesvirus, and Iron Oxide Particles to Normal Rat Brain,"" Am. J. Pathol. 147:1840-1851 (1995).;;Mullen, C.A., et al., ""Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system,"" Proc. Natl. Acad. Sci. USA 89:33-37 (1992).;;Mroz, P.J. and Moolten, F.L., ""Retrovirally Transduced Escherichia coli gpt Genes Combine Selectability with Chemosensitivity Capable of Mediating Tumor Eradication,"" Hum. Gene Ther. 4:589-595 (1993).;;Nagane, M., et al., ""A Common Mutant Epidermal Growth Factor Receptor Confers Enhanced Tumorigenicity on Human Glioblastoma Cells by Increasing Proliferation and Reducing Apoptosis,"" Cancer Res. 56:5079-5086 (1996).;;Nagashima, T. and Hoshino, T., ""Rapid Detection of S-Phase Cells by Anti-bromodeoxyuridine Monoclonal Antibody in 9L Brain Tumor Cells in vitro and in situ,"" Acta Neuropathol. 66:12-17 (1985).;;Nelson, D.R., et al., ""The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature,"" DNA Cell Biol. 12:1-51 (1993).;;Nikas, I., et al., ""Structural Features of Ribonucleotide Reductase,"" Proteins: Structure, Function, and Genetics 1:376-384 (1986).;;Nilaver, G., et al.,""Delivery of herpesvirus and adenovirus to nude rat intercerebral tumors after osmotic blood-brain barrier disruption,"" Proc. Natl. Acad. Sci. USA 92:9829-9833 (1995).;;Nishikawa, R., et al., ""A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity,"" Proc. Natl. Acad. Sci. USA 91:7727-7731 (1994).;;Palella, T.D., et al., ""Herpes Simplex Virus-Mediated Human Hypoxanthine-Guanine Phosphoribosyltransferase Gene Transfer into Neuronal Cells,"" Molec. Cell. Biol. 8:457-460 (1988).",EXPIRED
20,WO,A9,WO 1999/055345 A9,183-116-717-647-030,2000-04-13,2000,US 9909376 W,1999-04-30,US 8366398 P,1998-04-30,COMBINATION VIRAL-BASED AND GENE-BASED THERAPY OF TUMORS,"The present invention relates to viral mutants and methods of using these viral mutants for selectively killing neoplastic cells. The viral mutants of the invention are capable of selectively killing neoplastic cells by a combination of viral mediated oncolysis and anti-cancer (""suicide"") gene therapy.",GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;BREAKEFIELD XANDRA O,,https://lens.org/183-116-717-647-030,Patent Application,no,0,0,5,5,0,A61K35/763;;A61K48/00;;B82Y5/00;;C12N7/00;;C12N15/86;;C12N2710/16332;;C12N2710/16632;;C12N2710/16643;;A61K38/415;;A61K38/44;;A61K45/06;;C12Y117/04001;;C12Y114/14;;A61K31/675;;A61K47/6891;;B82Y5/00;;C12N7/00;;C12N2710/16632;;C12N15/86;;A61K35/763;;A61K48/00;;C12N2710/16332;;C12N2710/16643;;A61K38/415;;A61K45/06;;A61K38/44;;C12Y114/14;;C12Y117/04001;;A61K31/675;;A61K47/6891,A61K35/76;;A61K35/763;;A61K47/48;;A61K48/00;;C12N7/00;;C12N15/869,,0,0,,,,PENDING
21,EP,A1,EP 1073442 A1,175-980-834-122-673,2001-02-07,2001,EP 99920171 A,1999-04-30,US 9909376 W;;US 8366398 P,1998-04-30,COMBINATION VIRAL-BASED AND GENE-BASED THERAPY OF TUMORS,,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;BREAKEFIELD XANDRA O,,https://lens.org/175-980-834-122-673,Patent Application,yes,0,0,5,5,7,A61K35/763;;A61K48/00;;B82Y5/00;;C12N7/00;;C12N15/86;;C12N2710/16332;;C12N2710/16632;;C12N2710/16643;;A61K38/415;;A61K38/44;;A61K45/06;;C12Y117/04001;;C12Y114/14;;A61K31/675;;A61K47/6891;;B82Y5/00;;C12N7/00;;C12N2710/16632;;C12N15/86;;A61K35/763;;A61K48/00;;C12N2710/16332;;C12N2710/16643;;A61K38/415;;A61K45/06;;A61K38/44;;C12Y114/14;;C12Y117/04001;;A61K31/675;;A61K47/6891,A61K35/76;;A61K35/763;;A61K47/48;;A61K48/00;;C12N7/00;;C12N15/869,,0,0,,,,DISCONTINUED
22,US,B1,US 6897057 B1,108-606-111-264-483,2005-05-24,2005,US 65327700 A,2000-08-31,US 65327700 A;;US 15162199 P,1999-08-31,Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes γ34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,GENERAL HOSPITAL CORPORATION THE (2000-08-30),https://lens.org/108-606-111-264-483,Granted Patent,yes,12,8,3,24,2,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;C12N15/86;;A61K2039/525;;C12N2830/00;;A61K2039/5256;;C12N2710/16643;;C12N7/00;;C07K14/005;;A61K48/00;;C12N2710/16622,A61K48/00;;C07K14/035;;C12N7/00;;C12N15/869,435/235.1;;435/69.1;;435/325;;514/44,104,103,052-973-450-685-498;;092-118-862-731-992;;037-230-075-698-623;;009-715-658-834-906;;119-957-431-216-871;;019-439-346-335-619;;007-967-883-043-586;;015-666-200-040-978;;025-428-703-480-034;;004-094-157-936-153;;098-628-401-815-374;;038-446-868-055-096;;083-366-647-068-936;;034-656-178-512-093;;045-962-320-146-915;;037-401-867-644-969;;009-715-658-834-906;;015-585-302-194-72X;;134-738-047-141-91X;;065-274-516-392-305;;049-870-597-924-772;;010-020-719-364-675;;110-392-285-101-597;;082-308-124-700-865;;023-173-801-208-849;;047-360-148-496-677;;127-805-672-908-534;;005-279-713-790-659;;047-213-187-954-220;;045-171-698-135-82X;;016-171-978-858-692;;166-555-805-340-029;;054-488-247-087-541;;033-616-791-081-284;;019-691-355-788-075;;022-313-131-002-600;;101-176-387-365-494;;071-884-889-810-923;;093-644-165-171-316;;024-896-536-081-888;;062-062-357-731-897;;030-518-488-585-14X;;117-727-978-770-992;;018-538-384-825-51X;;136-740-729-110-737;;042-458-353-182-603;;087-460-061-778-670;;103-675-344-034-942;;012-508-370-118-261;;048-496-862-378-271;;057-524-635-047-941;;087-689-520-976-322;;014-055-151-986-708;;009-967-950-291-84X;;026-258-064-344-956;;108-841-138-394-210;;052-507-092-115-672;;073-579-333-616-852;;069-634-607-125-845;;073-957-137-341-99X;;016-857-056-204-779;;006-965-348-959-327;;069-201-580-559-411;;044-986-423-610-506;;009-804-034-362-036;;056-447-493-020-483;;006-094-893-306-822;;068-297-576-912-836;;075-446-171-092-446;;045-087-390-059-179;;003-273-587-266-097;;039-796-353-798-401;;075-630-552-888-747;;007-439-820-967-512;;106-386-562-055-571;;000-697-321-429-645;;016-190-545-942-040;;077-528-432-594-48X;;009-624-738-787-819;;073-207-123-392-582;;014-216-752-035-849;;031-118-187-392-620;;069-756-981-474-282;;036-583-381-962-32X;;035-323-175-823-719;;039-790-799-566-253;;173-216-758-750-312;;039-330-535-028-278;;107-408-321-102-833;;008-152-329-341-999;;015-723-513-532-306;;072-815-085-423-546;;135-929-415-919-181;;050-196-602-601-032;;024-159-223-922-842;;018-449-444-179-579;;072-672-534-953-687;;090-476-747-411-405;;008-963-463-995-669;;038-038-291-128-795;;017-422-113-127-954;;059-504-343-582-832;;072-098-975-088-373,pmc37516;;10.1073/pnas.161011798;;11438715;;pmc191798;;9188630;;10.1128/jvi.71.7.5560-5569.1997;;10.1128/jvi.73.9.7556-7564.1999;;10438845;;pmc104282;;10.1073/pnas.92.5.1411;;pmc42529;;7877992;;10657986;;10.1096/fasebj.14.2.301;;pmc45644;;10.1073/pnas.90.1.282;;8419933;;10218996;;10.1210/en.140.5.2415;;10.1210/endo.140.5.6682;;10.1172/jci3265;;9927498;;pmc407892;;pmc38054;;8876132;;10.1073/pnas.93.21.11313;;7489990;;10.1002/hep.1840220627;;10.1016/0270-9139(95)90207-4;;8806697;;10.1126/science.274.5286.373;;8832876;;7954393;;7584098;;pmc47282;;10.1073/pnas.90.17.8033;;8396259;;10.1073/pnas.90.15.7024;;8346212;;pmc47068;;10.1073/pnas.92.5.1411;;pmc42529;;7877992;;10.1038/nbt0598-444;;9592392;;10.1073/pnas.91.8.3054;;8159705;;pmc43513;;pmc185987;;8675647;;10.1172/jci118347;;7834628;;8640822;;1314384;;pmc48847;;10.1073/pnas.89.8.3266;;pmc40642;;7479831;;10.1073/pnas.92.23.10516;;9624219;;10.1016/s1055-3207(18)30262-x;;10.1016/s1055-3207(18)30260-6;;9624217;;10.1126/science.282.5392.1332;;9812900;;10.1038/sj.onc.1200826;;9010226;;9034594;;10.1007/bf00046345;;8750009;;10.1093/clinchem/40.4.510;;8149602;;9406237;;9270005;;7552983;;1655012;;10.1073/pnas.93.7.2909;;pmc39733;;8610141;;8607030;;9650617;;10.1089/hum.1998.9.9-1323;;9111301;;10.1021/jm960794l;;1323709;;10.1128/jvi.66.9.5509-5515.1992;;pmc289109;;10.1128/mcb.18.9.5208;;pmc109106;;9710605;;10.1146/annurev.mi.49.100195.003331;;8561476;;10.1146/annurev.micro.49.1.675;;8162589;;2824847;;pmc250519;;10.1128/jvi.62.1.196-205.1988;;10.1128/jvi.62.8.2970-2977.1988;;2839713;;pmc253735;;10079100;;10.1172/jci6017;;pmc408151;;10.1089/10430349950017725;;10428217;;8011700;;10.1097/00001622-199403000-00016;;8607025;;9694816;;10.1074/jbc.273.33.20737;;pmc413467;;8099545;;10.1002/j.1460-2075.1993.tb05891.x;;10400723;;10.1128/jvi.73.8.6319-6326.1999;;pmc112710;;pmc190890;;8892941;;10.1128/jvi.70.11.8138-8141.1996;;10.1038/11320;;10426310;;10.1126/science.271.5252.1079;;8599082;;10.1089/hum.1998.9.18-2653;;9874263;;1373198;;10.1128/jvi.66.5.2952-2965.1992;;pmc241054;;10361126;;10.1182/blood.v93.12.4284;;7474937;;10428757;;10.1096/fasebj.13.11.1325;;9414254;;10.1089/hum.1997.8.17-2057;;10.1016/0378-1119(95)00184-8;;7642110;;9331089;;2680389;;10.3109/03602538909103550;;8040891;;10.1093/jnci/86.16.1228;;10.1128/mcb.16.3.1047;;8622649;;pmc231087;;2472789;;10.1016/0006-291x(89)91362-4;;7711114;;10.1615/critrevoncog.v5.i4.30;;8789801;;1326612;;10.3171/jns.1992.77.4.0590;;1851332;;10.1126/science.1851332;;10749560;;10.1172/jci9744;;pmc382984;;9499088;;10.1128/jvi.72.3.2289-2296.1998;;pmc109527;;10.1099/0022-1317-64-5-997;;6302217;;7781922;;10.1096/fasebj.9.2.7781922;;10.1089/hum.1997.8.7-803;;9143906;;8033122;;7585221;;10.1038/nm0995-938;;9188579;;10.1128/jvi.71.7.5124-5132.1997;;pmc191747;;8887567;;pmc452208;;10.1002/j.1460-2075.1996.tb00853.x;;10.1093/jnci/82.4.297;;2299679;;7543006;;8137255;;10397242;;10.3892/ijo.2.5.731;;21573617;;7568227;;pmc40896;;10.1073/pnas.92.21.9829;;8620485;;10.1089/hum.1993.4.1-39;;8384892;;10.1016/0169-5002(95)99039-k;;10.1128/jvi.69.5.3033-3041.1995;;7707530;;pmc189003;;8035495;;10.1128/jvi.68.8.4963-4972.1994;;pmc236437;;10.1089/hum.1997.8.5-533;;9095405;;8729908;;9650611;;10.1089/hum.1998.9.9-1261;;9396605;;10.1038/nm1297-1354;;10.1006/jsre.1999.5642;;10357920;;9205053;;10.1126/science.2994215;;2994215;;10.1089/10430340050015536;;10779168;;10.1038/nm0996-985;;8782455;;8978404;;10.1093/jnci/89.1.21;;8986432;;9584951;;10.3109/13550289809114514,"Taneja et al., Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells; PNAS; Jul. 17, 2001; vol. 98, No. 15; pp 8804-8808.*;;Markovitz et al., The Range and Distribution of Murine Central Nervous System Cells Infected with the Y134.5-Mutant of Herpes Simplex Virus 1; Journal of Virology, Jul. 1997, p. 5560-5569, vol. 71, No. 7.*;;Chung et al., B-myb Promoter Retargeting of Herpes Simplex Virus y34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells; Journal of Virology, Sep. 1999, p. 7556-7564.*;;Chambers et al., Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma; Proc. Natl. Acad. Sci. USA; vol. 92, pp 1141-1415, Feb. 1995, Medical Sciences.*;;Yoon et al., An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma; The FASEB Journal, vol. 14, pp. 201-311.*;;Abe, M. and Kufe, D., ""Characterization of Cis-Acting Elements Regulating Transcription of the Human DF3 Breast Carcinoma-Associated Antigen (MUCl) Gene,"" Proc. Natl. Acad. Sci. USA 90:282-286 (1993).;;Albarracin, C.T., et al., ""The Gonadotropin-Releasing Hormone Receptor Gene Promoter Directs Pituitary-Specific Oncogene Expression in Transgenic Mice,"" Endocrinology 140:2415-2421 (May 1999).;;Amizuka, N., et al., ""Vitamin D3 Differentially Regulates Parathyroid Hormone/Parathyroid Hormone-Related Peptide Receptor Expression in Bone and Cartilage,"" J. Clin. Invest. 103:373-381 (Feb. 1999).;;Andreansky, S.S., et al., ""The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,"" Proc. Natl. Acad. Sci. USA 93:11313-11318 (1996).;;Arbuthnot, P., et al., ""Hepatoma Cell-Specific Expression of a Retrovirally Transferred Gene is Achieved by Alpha-Fetoprotein but not Insulinlike Growth Factor II Regulatory Sequences,"" Hepatology 22:1788-1796 (1995).;;Bennett, J.D., et al., ""E2F Binding is Required but Not Sufficient for Repression of B-myb Transcription in Quiescent Fibroblasts,"" Oncogene 13:1073-1082 (1996).;;Bischoff, J.R., et al., ""An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells,"" Science 274:373-376 (1996).;;Boviatsis, E.J., et al., ""Long-Term Survival of Rats Harboring Brian Neoplasms Treated with Ganciclovir and a Herpes Simplex Virus Vector that Retains an Intact Thymidine Kinase Gene,"" Cancer Res. 54:5745-5751 (1994).;;Boviatsis, E.J., et al., ""Antitumor Activity and Reporter Gene Transfer into Rat Brain Neoplasms Inoculated with Herpes Simplex Virus Vectors Defective in Thymidine Kinase to Ribonucleotide Reductase,"" Gene Ther. 1:323-331 (1994).;;Burns, J.C., et al., ""Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells,"" Proc. Natl. Acad. Sci. USA 90:8033-8037 (1993).;;Caruso, M., et al., ""Regression of established macroscopic liver metastases after in situ trasnduction of a suicide gene,"" Proc. Natl. Acad. Sci. USA 90:7024-7028 (1993).;;Chambers, R., et al., ""Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma,"" Proc. Natl. Acad. Sci. USA 92:1411-1415 (1995). (of record).;;Chase, M. et al., ""An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,"" Nature Biotechnol. 16:444-448 (1998).;;Chen, S.H., et al., ""Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene Transfer In Vivo,"" Proc. Natl. Acad. Sci. USA 91:3054-3057 (1994).;;Chen, L., et al., ""Breast Cancer Selective Gene Expression and Therapy Mediated by Recombinant Adenoviruses Containing the DF3/MUC1 Promoter,"" J. Clin. Invest. 96:2775-2782 (1995).;;Chen, L., and Waxman, D.J., ""Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy,"" Cancer Res. 55:581-589 (1995).;;Chen, L., et al., ""Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of a Liver Cytochrome P450 Gene,"" Cancer Res. 56:1331-1340 (1996).;;Chou, J. and Roizman, B., ""The gamma<SUB>1</SUB>(34.5) Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programed Cell Death in Neuronal Cells,"" Proc. Natl. Acad. Sci. USA 89:3266-3270 (1992).;;Chou, J., et al., ""Association of a M<SUB>r </SUB>90,000 Phosphoprotein with Protein Kinase PKR in Cells Exhibiting Enhanced Phosphorylation of Translation Initiation Factor eIF-2 Alpha and Premature Shutoff of Protein Synthesis After Infection with Gamma 134.5-Mutants of Herpes Simplex Virus 1,"" Proc. Natl. Acad. Sci. USA 92:10516-10520 (1995).;;Chung, R.Y. and Chiocca, E.A., ""Gene Therapy for Tumors of the Central Nervous System,"" Surg. Oncol. Clin. N. Am. 7:589-602 (1998).;;Clary, B.M., et al., ""Transcriptional Targeting for Cancer Gene Therapy,"" Surg. Oncol. Clin. N. Am. 7:565-574 (1998).;;Coffey, M.C., et al., ""Reovirus Therapy of Tumors with Activated Ras Pathway,"" Science 282:1332-1334 (1998).;;Coll-Fresno, P.M., et al., ""Cytotoxic Activity of a Diptheria Toxin/FGF6 Mitotoxin on Human Tumour Cell Lines,"" Oncogene 14:243-247 (1997).;;Colombo, M.P., et al., ""Immunotherapy. I: Cytokine Gene Transfer Strategies,"" Cancer Metastasis Rev. 16:421-432 (1997).;;Connors, T.A., ""The Choice of Prodrugs for Gene Directed Enzyme Prodrug Therapy of Cancer,"" Gene Ther. 2:702-709 (1995).;;Culver, K.W., ""Clinical applications of gene therapy for cancer,"" Clin. Chem 40:510-512 (1994).;;Dachs, G.U., et al., ""Targeting Gene Therapy to Cancer: A Review,"" Oncol. Res. 9:313-325 (1997).;;Dehal, S.S., et al., ""CYP2D6 Catalyzes Tamoxifen 4-hydroxylation in Human Liver,"" Cancer Res. 57:3402-3406 (1997).;;Deonarain, M.P., et al., ""Genetic Delivery of Enzymes for Cancer Therapy,"" Gene Therapy 2: 235-244 (1995).;;Ezzeddine, Z.D., et al., ""Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase gene,"" New Biol. 3:608-614 (1991).;;Fakhrai, H., et al., ""Eradication of Established Intracranial Rat Gliomas by Transforming Growth Factor beta Antisense Gene Therapy,"" Proc. Natl. Acad. Sci. USA 93:2909-2914 (1996).;;Freeman, S.M., et al., ""In Situ Use of Suicide Genes for Cancer Therapy,"" Semin. Oncol. 23:31-45 (1996).;;Freytag, S.O., et al., ""A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy,"" Hum. Gene Ther. 9:1323-1333 (1998).;;Friedlos, F. et al., ""Mustard Prodrugs for Activation by Escherichia coli Nitroreductase in Gene-Directed Enzyme Prodrug Therapy,"" J Med Chem 40:1270-1275 (1997).;;Gage, P.J., et al., ""A Cell-Free Recombination System for Site-Specific Integration of Multigenic Shuttle Plasmids Into the Herpes Simplex Virus Type 1 Genome,"" J. Virol. 66:5509-5515 (1992).;;Gale, M., et al., ""Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation,"" Mol. Cell. Biol. 18:5208-5218 (1998).;;Glorioso, J.C., et al., ""Herpes simplex virus-based vectors,"" Seminars in Virology 3:265-276 (1992).;;Glorioso, J.C., et al., ""Development and Application of Herpes Simplex Virus Vectors for Human Gene Therapy,"" Annu. Rev. Microbiol. 49:675-710 (1995).;;Goeptar, A.R., et al., ""Cytotoxicity of Mitomycin C and Adriamycin in Freshly Isolated Rat Hepatocytes: The Role of Cytochrome P450,"" Cancer Res. 54:2411-2418 (1994).;;Goldstein, D.J. and Weller, S.K., ""Herpes Simplex Virus Type 1-Induced Ribonucleotide Reductase Activity is Dispensable for Virus Growth and DNA Synthesis: Isolation and Characterization of an ICP6 lacZ Insertion Mutant,"" J. Virol. 62:196-205 (1988).;;Goldstein, D.J. and Weller, S.K., ""An ICP6::lacZ Insertional Mutagen is Used to Demonstrate That the UL52 Gene of Herpes Simplex Virus Type 1 is Required for Virus Growth and DNA Synthesis,"" J. Virol. 62:2970-2977 (1988).;;Guillot, P.V., et al., ""A Vascular Bed-Specific Pathway Regulates Cardiac Expression of Endothelial Nitric Oxide Synthase,"" J. Clin. Invest. 103:799-805 (Mar. 1999).;;Hallenbeck, P.L., et al., ""A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma,"" Hum. Gene Ther. 10:1721-1733 (Jul. 1999).;;Hart, I.R., et al., ""Targeted Therapy for Malignant Melanoma,"" Curr. Opin. Oncol. 6:221-225 (1994).;;Hart, I.R., ""Tissue Specific Promoters in Targeting Systemically Delivered Gene Therapy,"" Semin. Oncol. 23:154-158 (1996).;;He, B., et al., ""The gamma<SUB>1</SUB>34.5 Protein of Herpes Simplex Virus 1 Has the Structural and Functional Attributes of a Protein Phosphatase 1 Regulatory Subunit and is Present in a High Molecular Weight Complex with the Enzyme in Infected Cells,"" J. Biol. Chem. 273:20737-20743 (1998).;;Hollywood, D, and Hurst, H., ""A Novel Transcription Factor, OB2-1, is Required for Overexpression of the Proto-Oncogene c-erbB-2 in Mammary Tumour Lines,"" EMBO J 12:2369-2375 (1993).;;Hunter, W.D., et al., ""Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates,"" J. Virol. 73:6319-6326 (Aug. 1999).;;Hwang, J.J., et al., ""Novel Retroviral Vector Transferring a Suicide Gene and a Selectable Marker Gene with Enhanced Gene Expression by Using a Tetracycline-Responsive Expression System,"" J. Virol. 70:8138-8141 (1996).;;Ikeda, K., et al., ""Oncolytic Virus Therapy of Multiple Tumors in the Brain Requires Suppression of Innate and Elicited Antiviral Responses,"" Nat. Med. 5:881-887 (1999).;;Jain, R.K., ""Delivery of Molecular Medicine to Solid Tumors,"" Science 271:1079-1080 (1996).;;Jérôme, V., and Müller, R., ""Tissue-Specific, Cell Cycle-Regulated Chimeric Transcription Factors for the Targeting of Gene Expression to Tumor Cells,"" Hum. Gene Ther. 9:2653-2659 (1988).;;Johnson, P.A., et al., ""Cytotoxicity of a Replication-Defective Mutant of Herpes Simplex Virus Type 1,"" J. Virol. 66:2952-2965 (1992).;;Kappel, A., et al., ""identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice,"" Blood 93:4284-4292 (Jun. 1999).;;Kesari, S., et al., ""Therapy of Experimental Human Brain Tumors Using a Neuroattenuated Herpes Simplex Virus Mutant,"" Lab. Invest. 73:636-648 (1995).;;Kooby, D.A., et al., ""Oncolytic Viral Therapy for Human Colorectal Cancer and Liver Metastases Using a Multi-Mutated Herpes Simplex Virus Type-1 (G207),"" FASEB J. 13:1325-1334 (Aug. 1999).;;Kramm, C.M., et al., ""Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy,"" Hum. Gene Ther. 8:2057-2068 (1997).;;Lam, E.W., et al., ""Cell-cycle regulation of human B-myb transcription,"" Gene 160:277-281 (1995).;;Lan, K-H., et al., ""In Vivo Selective Gene Expression and Therapy Mediated by Adenoviral Vectors for Human Carcinoembryonic Antigen-producing Gastric Carcinoma,"" Cancer Res. 57:4279-4284 (1997).;;LeBlanc, G.A. and Waxman, D.J., ""Interaction of Anticancer Drugs with Hepatic Monooxygenase Enzymes,"" Drug Metab. Rev. 20:395-439 (1989).;;Lorence, R.M. et al., ""Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy,"" J. Natl. Cancer. Inst. 86:1228-1233 (1994).;;Lukas, J., et al., ""Deregulated Expression of E2F Family Members Induces S-phase Entry and Overcomes p16INK4A-Mediated Growth Suppression,"" Mol. Cell. Biol. 16:1047-1057 (1996).;;Lundwall, A., ""Characterization of the Gene for Prostate-Specific Antigen, a Human Glandular Kallikrein,"" Biochem. Biophys. Res. Commun. 161:1151-1156 (1989).;;Lyon, J., et al., ""The Role of Myb Proteins in Normal and Neoplastic Cell Proliferation,"" Crit. Rev.Oncogenesis 5:373-388 (1994).;;Manome, Y., et al., ""Gene therapy for malignant gliomas using replication imcompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide,"" Gene Therapy 3:513-520 (1996).;;Markert, J.M., et al. ""Expanded Spectrum of Viral Therapy in the Treatment of Nervous System Tumors,"", J. Neurosurg. 77:590-594 (1992).;;Martuza, R.L., et al., ""Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant,"" Science 252:854-856 (1991).;;Martuza, R.L., ""Conditionally Replicating Herpes Vectors For Cancer Therapy,"" J. Clin. Invest. 105:841-846 (Apr. 2000).;;Massie, B., et al., ""Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Regulatable Expression Cassette,"" J. Virol.72:2289-2296 (1998).;;McLauchlan, J., and Clements, J.B., ""Organization of the Herpes Simplex Virus Type 1 Transcription Unit Encoding Two Early Proteins with Molecular Weights of 140000 and 40000,"" J. Gen. Virol. 64:997-1006 (1983).;;Miller, N., and Vile, R., ""Targeted vectors for gene therapy,"" FASEB J. 9:190-199 (1995).;;Miller, N. and Whelan, J., ""Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic Therapy,"" Hum. Gene Ther. 8:803-815 (1997).;;Mineta, T., et al., ""Treatment of Malignant Gliomas Using Ganciclovir-Hypersensitive, Ribonucleotide Reduces-Deficient Herpes Simplex Viral Mutant,"" Cancer Res. 54:3969-3966 (1994).;;Mineta, T., et al., ""Attenuated Multi-Mutated Herpes Simplex Virus-1 for the Treatment of Malignant Gliomas,"" Nature Med 1:938-943 (1995).;;Miyatake, S., et al., ""Transcriptional Targeting of Herpes Simplex Virus for Cell-Specific Replication,"" J. Virol. 71:5124-5132 (1997).;;Mohr, I. and Bluzman, Y., ""A Herpesvirus Genetic Element Which Affects Translation in the Absence of the Viral GADD34 Function,"" EMBO J. 15:4759-4766 (1996).;;Moolten, F.L. and Wells, J.M., ""Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors,"" J. Natl. Cancer Inst. 82:297-300 (1990).;;Moolten, F.L., ""Drug sensitivity (""suicide"") genes for selective cancer chemotherapy,"" Cancer Gene Ther. 1:279-287 (1994).;;Mullen, C.A., et al., ""Tumors Expressing the Cytosine Deaminase Suicide Gene Can Be Eliminated in Vivo with 5-Fluorocytosine and induce protective immunity to Wild Type Tumor,"" Cancer Res. 54:1503-1506 (1994).;;Nagayama, Y., et al., ""Enhanced Efficacy of Transcriptionally Targeted Suicide Gene/Prodrug Therapy for Thyroid Carcinoma with the Cre-loxP System,"" Cancer Res. 59:3049-3052 (Jul. 1999).;;Ng, S.F. and Waxman D.J., ""Activation of thio-TEPA cytotoxicity toward human breast cancer cells by hepatic cytochrome P450,"" Intl. J. Oncology 2:731-738 (1993).;;Nilaver, G., et al., ""Delivery of Herpesvirus and Adenovirus to Nude Rat Intracerebral Tumors After Osmotic Blood-Brain Barrier Disruption,"" Proc. Natl. Acad. Sci. USA 92: 9829-9833 (1995).;;O'Malley, B.W., Jr., et al., ""Combination Gene Therapy for Oral Cancer in a Murine Model,"" Cancer Res. 56:1737-1741 (1996).;;Oldfield, E., et al., ""Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir,"" Hum. Gene Ther. 4:39-69 (1993).;;Osaki, T., et al., ""Gene Therapy for Carcinoembryonic Antigen-Producing Human Lung Cancer Cells by Cell Type-Specific Expression of Herpes Simplex Virus Thymidine Kinase Gene,"" Cancer Res. 54:5258-5261 (1994).;;Perng, G.-C., et al., ""An Avirulent ICP34.5 Deletion Mutant of Herpes Simplex Virus Type 1 Is Capable of In Vivo Spontaneous Reactivation,"" J. Virol. 69:3033-3041 (1995).;;Pyles, R.B. and Thompson, R.I., ""Evidence That the Herpes Simplex Virus Type 1 Uracil DNA Glycosylase is Required for Efficient Viral Replication and Latency in the Murine Nervous System,"" J. Virol. 68:4963-4972 (1994).;;Pyles, R.B., et al., ""A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain Tumors,"" Hum. Gene Ther. 8:533-544 (1997).;;Rainov, N.G., et al., ""Retrovirus-Mediated Gene Therapy of Experimental Brain Neoplasms Using the Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Paradigm,"" Cancer Gene Therapy 3:99-106 (1996).;;Rain, N.G., et al., ""New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol,"" Hum. Gene Ther. 9:1261-1273 (1998).;;Ram, Z., et al., ""Therapy of Malignant Brain Tumors by Intratumoral Implantation of Retroviral Vector-Producing Cells,"" Nature Medicine 3:1354-1361 (1997).;;Ray, M.K., et al., ""beta Cell-Specific Ablation of Target Gene USing Cre-loxP System in Transgenic Mice,"" J. Surg. Res. 84:199-203 (Jun. 1999).;;Rodriguez, R., et al., ""Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-Specific Antigen-Positive Prostate Cancer Cells,"" Cancer Res. 57:2559-2563 (1997).;;Roizman, B. and Jenkins, F.J., ""Genetic Engineering of Novel Genomes of Large DNA Viruses,"" Science 229:1208-1214 (1985).;;Rosenberg, S.A., et al., ""Human Gene Marker/Therapy Clinical Protocols,"" Hum. Gene Ther. 11:919-979 (Apr. 2000).;;Roth, J.A., et al., ""Retrovirus-mediated Wild-Type p53 Gene Transfer to Tumors of Patients with Lung Cancer,"" Nature Med. 2:985-991 (1996).;;Roth, J.A. and Cristiano, R.J., ""Gene Therapy for Cancer: What Have We Done and Where are We Going?"" J. Natl. Cancer Inst. 89:21-39 (1997).;;Schnierle, B.S. and Groner, B., ""Retroviral Targeted Delivery,"" Gene Therapy 3:1069-1073 (1996).;;Spear, M.A., et al., ""Targeting gene therapy vectors to CNS malignancies,"" J. NeuroVirol. 4:133-147 (1998).",EXPIRED
23,CA,A1,CA 2327506 A1,129-289-479-969-903,1999-11-04,1999,CA 2327506 A,1999-04-30,US 8366398 P;;US 9909376 W,1998-04-30,COMBINATION VIRAL-BASED AND GENE-BASED THERAPY OF TUMORS,"The present invention relates to viral mutants and methods of using these viral mutants for selectively killing neoplastic cells. The viral mutants of the invention are capable of selectively killing neoplastic cells by a combination of viral mediated oncolysis and anti-cancer (""suicide"") gene therapy.",GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;BREAKEFIELD XANDRA O,,https://lens.org/129-289-479-969-903,Patent Application,no,0,0,5,5,0,A61K35/763;;A61K48/00;;B82Y5/00;;C12N7/00;;C12N15/86;;C12N2710/16332;;C12N2710/16632;;C12N2710/16643;;A61K38/415;;A61K38/44;;A61K45/06;;C12Y117/04001;;C12Y114/14;;A61K31/675;;A61K47/6891;;B82Y5/00;;C12N7/00;;C12N2710/16632;;C12N15/86;;A61K35/763;;A61K48/00;;C12N2710/16332;;C12N2710/16643;;A61K38/415;;A61K45/06;;A61K38/44;;C12Y114/14;;C12Y117/04001;;A61K31/675;;A61K47/6891,A61K35/76;;A61K35/763;;A61K47/48;;A61K48/00;;C12N7/00;;C12N15/869,,0,0,,,,DISCONTINUED
24,AT,T1,AT E283921 T1,159-147-261-688-206,2004-12-15,2004,AT 00913305 T,2000-02-02,US 15162199 P;;US 0002409 W,1999-08-31,ZELL- UND/ODER TUMOR-SPEZIFISCHE PROMOTOR- ABHÄNGIGE ÄNDERUNG DER GEZIELTEN EXPRESSION DES HERPES GAMMA 34.5 GENS,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/159-147-261-688-206,Granted Patent,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,PENDING
25,US,B2,US 7514252 B2,005-128-666-668-715,2009-04-07,2009,US 4218905 A,2005-01-26,US 4218905 A;;US 65327700 A;;US 15162199 P,1999-08-31,Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes γ34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,THE GENERAL HOSPITAL CORPORATION (2000-08-30),https://lens.org/005-128-666-668-715,Granted Patent,yes,13,13,3,24,2,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;C12N15/86;;A61K2039/525;;C12N2830/00;;A61K2039/5256;;C12N2710/16643;;C12N7/00;;C07K14/005;;A61K48/00;;C12N2710/16622,C12N7/00;;A61K35/00;;A61K48/00;;C07K14/035;;C12N15/63;;C12N15/869,435/235.1;;435/320.1;;424/93.1,99,97,019-439-346-335-619;;007-967-883-043-586;;015-666-200-040-978;;025-428-703-480-034;;004-094-157-936-153;;098-628-401-815-374;;038-446-868-055-096;;083-366-647-068-936;;034-656-178-512-093;;045-962-320-146-915;;037-401-867-644-969;;009-715-658-834-906;;015-585-302-194-72X;;134-738-047-141-91X;;065-274-516-392-305;;049-870-597-924-772;;010-020-719-364-675;;110-392-285-101-597;;082-308-124-700-865;;023-173-801-208-849;;037-230-075-698-623;;047-360-148-496-677;;127-805-672-908-534;;005-279-713-790-659;;015-730-844-944-036;;045-171-698-135-82X;;016-171-978-858-692;;166-555-805-340-029;;054-488-247-087-541;;033-616-791-081-284;;019-691-355-788-075;;022-313-131-002-600;;101-176-387-365-494;;071-884-889-810-923;;093-644-165-171-316;;024-896-536-081-888;;062-062-357-731-897;;030-518-488-585-14X;;117-727-978-770-992;;018-538-384-825-51X;;136-740-729-110-737;;042-458-353-182-603;;087-460-061-778-670;;103-675-344-034-942;;012-508-370-118-261;;048-496-862-378-271;;057-524-635-047-941;;087-689-520-976-322;;014-055-151-986-708;;009-967-950-291-84X;;026-258-064-344-956;;108-841-138-394-210;;052-507-092-115-672;;073-579-333-616-852;;069-634-607-125-845;;073-957-137-341-99X;;016-857-056-204-779;;006-965-348-959-327;;069-201-580-559-411;;044-986-423-610-506;;009-804-034-362-036;;056-447-493-020-483;;006-094-893-306-822;;068-297-576-912-836;;075-446-171-092-446;;045-087-390-059-179;;092-118-862-731-992;;003-273-587-266-097;;039-796-353-798-401;;075-630-552-888-747;;007-439-820-967-512;;106-386-562-055-571;;000-697-321-429-645;;016-190-545-942-040;;077-528-432-594-48X;;009-624-738-787-819;;073-207-123-392-582;;014-216-752-035-849;;031-118-187-392-620;;069-756-981-474-282;;147-362-666-707-029;;036-583-381-962-32X;;035-323-175-823-719;;039-790-799-566-253;;173-216-758-750-312;;039-330-535-028-278;;107-408-321-102-833;;008-152-329-341-999;;015-723-513-532-306;;072-815-085-423-546;;135-929-415-919-181;;050-196-602-601-032;;024-159-223-922-842;;018-449-444-179-579;;072-672-534-953-687;;090-476-747-411-405;;008-963-463-995-669,pmc45644;;10.1073/pnas.90.1.282;;8419933;;10218996;;10.1210/en.140.5.2415;;10.1210/endo.140.5.6682;;10.1172/jci3265;;9927498;;pmc407892;;pmc38054;;8876132;;10.1073/pnas.93.21.11313;;7489990;;10.1002/hep.1840220627;;10.1016/0270-9139(95)90207-4;;8806697;;10.1126/science.274.5286.373;;8832876;;7954393;;7584098;;pmc47282;;10.1073/pnas.90.17.8033;;8396259;;10.1073/pnas.90.15.7024;;8346212;;pmc47068;;10.1073/pnas.92.5.1411;;pmc42529;;7877992;;10.1038/nbt0598-444;;9592392;;10.1073/pnas.91.8.3054;;8159705;;pmc43513;;pmc185987;;8675647;;10.1172/jci118347;;7834628;;8640822;;1314384;;pmc48847;;10.1073/pnas.89.8.3266;;pmc40642;;7479831;;10.1073/pnas.92.23.10516;;9624219;;10.1016/s1055-3207(18)30262-x;;10.1128/jvi.73.9.7556-7564.1999;;10438845;;pmc104282;;10.1016/s1055-3207(18)30260-6;;9624217;;10.1126/science.282.5392.1332;;9812900;;10.1038/sj.onc.1200826;;9010226;;9433649;;10.1023/a:1005980418533;;8750009;;10.1093/clinchem/40.4.510;;8149602;;9406237;;9270005;;7552983;;1655012;;10.1073/pnas.93.7.2909;;pmc39733;;8610141;;8607030;;9650617;;10.1089/hum.1998.9.9-1323;;9111301;;10.1021/jm960794l;;1323709;;10.1128/jvi.66.9.5509-5515.1992;;pmc289109;;10.1128/mcb.18.9.5208;;pmc109106;;9710605;;10.1146/annurev.mi.49.100195.003331;;8561476;;10.1146/annurev.micro.49.1.675;;8162589;;2824847;;pmc250519;;10.1128/jvi.62.1.196-205.1988;;10.1128/jvi.62.8.2970-2977.1988;;2839713;;pmc253735;;10079100;;10.1172/jci6017;;pmc408151;;10.1089/10430349950017725;;10428217;;8011700;;10.1097/00001622-199403000-00016;;8607025;;9694816;;10.1074/jbc.273.33.20737;;pmc413467;;8099545;;10.1002/j.1460-2075.1993.tb05891.x;;10400723;;10.1128/jvi.73.8.6319-6326.1999;;pmc112710;;pmc190890;;8892941;;10.1128/jvi.70.11.8138-8141.1996;;10.1038/11320;;10426310;;10.1126/science.271.5252.1079;;8599082;;10.1089/hum.1998.9.18-2653;;9874263;;1373198;;10.1128/jvi.66.5.2952-2965.1992;;pmc241054;;10361126;;10.1182/blood.v93.12.4284;;7474937;;10428757;;10.1096/fasebj.13.11.1325;;9414254;;10.1089/hum.1997.8.17-2057;;10.1016/0378-1119(95)00184-8;;7642110;;9331089;;2680389;;10.3109/03602538909103550;;8040891;;10.1093/jnci/86.16.1228;;10.1128/mcb.16.3.1047;;8622649;;pmc231087;;2472789;;10.1016/0006-291x(89)91362-4;;7711114;;10.1615/critrevoncog.v5.i4.30;;8789801;;1326612;;10.3171/jns.1992.77.4.0590;;pmc191798;;9188630;;10.1128/jvi.71.7.5560-5569.1997;;1851332;;10.1126/science.1851332;;10749560;;10.1172/jci9744;;pmc382984;;9499088;;10.1128/jvi.72.3.2289-2296.1998;;pmc109527;;10.1099/0022-1317-64-5-997;;6302217;;7781922;;10.1096/fasebj.9.2.7781922;;10.1089/hum.1997.8.7-803;;9143906;;8033122;;7585221;;10.1038/nm0995-938;;9188579;;10.1128/jvi.71.7.5124-5132.1997;;pmc191747;;8887567;;pmc452208;;10.1002/j.1460-2075.1996.tb00853.x;;10.1093/jnci/82.4.297;;2299679;;7543006;;8137255;;10.1074/jbc.274.9.5588;;10026175;;10397242;;10.3892/ijo.2.5.731;;21573617;;7568227;;pmc40896;;10.1073/pnas.92.21.9829;;8620485;;10.1089/hum.1993.4.1-39;;8384892;;10.1016/0169-5002(95)99039-k;;10.1128/jvi.69.5.3033-3041.1995;;7707530;;pmc189003;;8035495;;10.1128/jvi.68.8.4963-4972.1994;;pmc236437;;10.1089/hum.1997.8.5-533;;9095405;;8729908;;9650611;;10.1089/hum.1998.9.9-1261;;9396605;;10.1038/nm1297-1354;;10.1006/jsre.1999.5642;;10357920;;9205053;;10.1126/science.2994215;;2994215;;10.1089/10430340050015536;;10779168,"Abe, M. and Kufe, D., ""Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene,"" Proc. Natl. Acad. Sci. USA 90:282-286, The National Academy of Sciences (1993).;;Albarracin, C.T., et al., ""The Gonadotropin-Releasing Hormone Receptor Gene Promoter Directs Pituitary-Specific Oncogene Expression in Transgenic Mice,"" Endocrinology 140:2415-2421, The Endocrine Society (May 1999).;;Amizuka, N., et al., ""Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage,"" J. Clin. Invest. 103:373-381, American Society for Clinical Investigation (Feb. 1999).;;Andreansky, S.S., et al., The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors, Proc. Natl. Acad. Sci. USA 93:11313-11318, The National Academy of Sciences (1996).;;Arbuthnot P., et al., ""Hepatoma Cell-Specific Expression of a Retrovirally Transferred Gene is achieved by alpha-Fetoprotein but not Insulin-like Growth Factor II Regulatory Sequences,"" Hepatology 22:1788-1796, John Wiley & Sons, Inc. (1995).;;Bennett, J.D., et al., ""E2F binding is required but not sufficient for repression of B-myb transcription in quiescent fibroblasts,"" Oncogene 13:1073-1082, Stockton Press (1996).;;Bischoff, J.R., et al., ""An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells,"" Science 274:373-376, American Association for the Advancement of Science (1996).;;Boviatsis, E.J., et al., ""Long-Term Survival Rats Harboring Brain Neoplasms Treated with Ganciclovir and a Herpes Simplex Virus Vector That Retains an Intact Thymidine Kinase Gene,"" Cancer Res. 54:5745-5751, The American Association for Cancer Research, Inc. (1994).;;Boviatsis, E.J., et al., ""Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase,"" Gene Ther. 1:323-331, Macmillan Press (1994).;;Burns, J.C., et al., Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells, Proc. Natl. Acad. Sci. USA 90:8033-8037, The National Academy of Sciences (1993).;;Caruso, M., et al., ""Regression of established macroscopic liver metastases after in situ transduction of a suicide gene,"" Proc. Natl. Acad. Sci. USA 90:7024-7028, The National Academy of Sciences (1993).;;Chambers, R., et al., ""Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma,"" Proc. Natl. Acad. Sci. USA 92:1411-1415, The National Academy of Sciences (1995).;;Chase, M., et al., ""An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,"" Nature Biotechnol. 16:444-448, Nature Publishing Group (May 1998).;;Chen, S.-H., et al., ""Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo,"" Proc. Natl. Acad. Sci. USA 91:3054-3057, The National Academy of Sciences (1994).;;Chen, L., et al., ""Breast Cancer Selective Gene Expression and Therapy Mediated by Recombinant Adenoviruses Containing the DF3/MUC1 Promoter,"" J. Clin. Invest. 96:2772-2782, American Society for Clinical Investigation (1995).;;Chen, L. and Waxman, D.J., ""Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy,"" Cancer Res. 55:581-589, The American Association for Cancer Research, Inc. (1995).;;Chen, L., et al., ""Sensitization of Human Breast Cancer Cells to Cyclophosphamide and Ifosfamide by Transfer of Liver Cytochrome P450 Gene,"" Cancer Res. 56:1331-1340, The American Association for Cancer Research, Inc. (1996).;;Chou, J. and Roizman, B., ""The gamma1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells,"" Proc. Natl. Acad. Sci. USA 89: 3266-3270, The National Academy of Sciences (1992).;;Chou, J., et al., ""Association of a Mr 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2alpha and premature shutoff of protein synthesis after infection with gamma134.5- mutants of herpes simplex virus 1,"" Proc. Natl. Acad. Sci. USA 92:10516-10520, The National Academy of Sciences (1995).;;Chung, R.Y. and Chiocca, E.A., ""Gene Therapy for Tumors of the Central Nervous System,"" Surg. Oncol. Clin. N. Am. 7:589-602, W.B. Saunders Company (Jul. 1998).;;Chung, R.Y., et al., B-myb Promoter Retargeting of Herpes Simplex Virus gamma34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells, J. Virol. 73:7556-7564, American Society for Microbiology (Sep. 1999).;;Clary, B.M., et al., ""Transcriptional Targeting for Cancer Gene Therapy,"" Surg. Oncol. Clin. N. Am. 7:565:574,W.B. Saunders Company (Jul. 1998).;;Coffey, M.C., et al., ""Reovirus Therapy of Tumors with Activated Ras Pathway,"" Science 282:1332-1334, American Association for the Advancement of Science (Nov. 1998).;;Coll-Fresno, P.M., et al, Cytotoxic activity of a diptheria Toxin/FGF6 mitotoxin on human tumour cell lines, Oncogene 14:243-247, Stockton Press (1997).;;Colombo, M.P., et al., ""Imunotherapy I: Cytokine gene transfer strategies,"" Cancer Metastasis Rev. 16:421-432, Kluwer Academic Publishers (1997).;;Connors, T.A., ""The choice of prodrugs for gene directed enzyme prodrug therapy of cancer,"" Gene Ther. 2:702-709, Stockton Press (1995).;;Culver, K.W., ""Clinical Applications of Gene Therapy for Cancer,"" Clin. Chem. 40:510-512, American Association for Clinical Chemistry (1994).;;Dachs, G.U., et al., ""Targeting Gene Therapy to Cancer: A Review,"" Oncol. Res. 9:313-325, Cognizant Comm. Corp. (1997).;;Dehal, S.S. and Kupfer, D., ""CYP2D6 Catalyzes Tamoxifen 4-Hydroxylation in Human Liver,"" Cancer Res. 57:3402-3406, The American Association for Cancer Research, Inc. (1997).;;Deonarain, M.P., et al., ""Genetic delivery of enzymes for cancer therapy,"" Gene Therapy 2:235-244, Stockton Press (1995).;;Ezzeddine, Z.D., et al, ""Selective Killing of Glioma Cells in Culture and In Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase Gene,"" New Biol. 3:608-614, W.B. Saunders (1991).;;Fakhrai, H., et al., ""Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy,"" Proc. Natl. Acad. Sci. USA 93:2909-2914, The National Academy of Sciences (1996).;;Freeman, S. M., et al., ""In Situ Use of Suicide Genes for Cancer Therapy,"" Semin. Oncol. 23:31-45, W.B. Saunders Company (1996).;;Freytag, S.O., et al., ""A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy,"" Hum. Gene Ther. 9:1323-1333, Mary Ann Liebert, Inc. (Jun. 1998).;;Friedlos, F., et al., ""Mustard Prodrugs for Activation by Escherichia coli Nitroreductase in Gene-Directed Enzyme Prodrug Therapy,"" J. Med. Chem. 40:1270-1275, American Chemical Society (1997).;;Gage, P.J., et al., ""A Cell-Free Recombination System for Site-Specific Integration of Multigenic Shuttle Plasmids Into the Herpes Simplex Virus Type 1 Genome,"" J. Virol. 66:5509-5515, American Society for Microbiology (1992).;;Gale, Jr., M., et al., ""Control of PKR Protein Kinase by Hepatitis C Virus Nonstructural 5A Protein: Molecular Mechanisms of Kinase Regulation,"" Mol. Cell. Biol. 18:5208-5218, American Society for Microbiology. (Sep. 1998).;;Glorioso, J.C., et al., ""Herpes simplex virus-based vectors,"" Sem. Virol. 3:265-276, Academic Press Ltd. (1992).;;Glorioso, J.C., et al., ""Development and Application of Herpes Simplex Virus Vectors for Human Gene Therapy,"" Annu. Rev. Microbiol. 49:675-710, Annual Reviews, Inc. (1995).;;Goeptar, A.R., et al., ""Cytotoxicity of Mitomycin C and Adriamycin in Freshly Isolated Rat Hepatocytes: The Role of Cytochrome P450,"" Cancer Res. 54:2411-2418, The American Association for Cancer Research, Inc. (1994).;;Goldstein, D.J. and Weller, S.K., ""Herpes Simplex Virus Type 1-Induced Ribonucleotide Reductase Activity Is Dispensable for Virus Growth and DNA Synthesis: Isolation and Characterization of an ICP6 lacZ Insertion Mutant,"" J. Virol. 62:196-205, American Society for Microbiology (1988).;;Goldstein, D.J. and Weller, S.K., ""An ICP6:: lacZ Insertional Mutagen Is Used To Demonstrate that the UL52 Gene of Herpes Simplex Virus Type 1 Is Required for Virus Growth and DNA Synthesis,"" J. Virol. 62:2970-2977, American Society for Microbiology (1988).;;Guillot, P.V., et al., ""A vascular bed-specific pathway regulates cardiac expression of endothelial nitric oxide synthase,"" J. Clin. Invest. 103:799-805, American Society for Clinical Investigation (Mar. 1999).;;Hallenbeck, P.L., et al., ""A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma,"" Hum. Gene Ther. 10:1721-1733, Mary Ann Liebert, Inc (Jul. 1999).;;Hart, I.R. and Vile, R.G. ""Targeted therapy for malignant melanoma,"" Curr. Opin. Oncol. 6:221-225, Current Science ISBN (1994).;;Hart, I.R., et al., ""Tissue Specific Promoters in Targeting Systemically Delivered Gene Therapy,"" Semin. Oncol. 23:154-158, W.B. Saunders Company (1996).;;He, B., et al., ""The gamma134.5 Protein of Herpes Simplex Virus 1 Has the Structural and Functional Attributes of a Protein Phosphatase 1 Regulatory Subunit and Is Present in a High Molecular Weight Complex with the Enzyme in Infected Cells,"" J. Biol. Chem. 273:20737-20743, The American Society for Biochemistry and Molecular Biology, Inc. (Aug. 1998).;;Hollywood, D. and Hurst, H., ""A novel transcription factor, 0B2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines,"" EMBO J. 12:2369-2375, Oxford University Press (1993).;;Hunter, W.D., et al., ""Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates,"" J. Virol. 73:6319-6326, American Society for Microbiology (Aug. 1999).;;Hwang, J.J., et al., ""Novel Retroviral Vector Transferring a Suicide Gene and a Selectable Marker Gene with Enhanced Gene Expression by Using a Tetracycline-Responsive Expression System,"" J. Virol. 70:8138-8141, American Society for Microbiology (1996).;;Ikeda, K., et al., ""Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses,"" Nat. Med. 5:881-887, Nature Publishing Group (Aug. 1999).;;Jain, R.K., et al., ""Delivery of Molecular Medicine to Solid Tumors,"" Science 271:1079-1080, American Association for the Advancement of Science (1996).;;Jérôme, V. and Müller, R., ""Tissue-Specific, Cell Cycle-Regulated Chimeric Transcription Factors for the Targeting of Gene Expression to Tumor Cells,"" Hum. Gene Ther. 9:2653-2659, Mary Ann Liebert, Inc. (Dec. 1998).;;Johnson, P.A., et al., ""Cytotoxicity of a Replication-Defective Mutant of Herpes Simplex Virus Type 1,"" J. Virol. 66:2952-2965, American Society for Microbiology (1992).;;Kappel, A., et al., ""Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promoter/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice,"" Blood 93:4284-4292, The American Society of Hematology (Jun. 1999).;;Kesari, S., et al., ""Therapy of Experimental Human Brain Tumors Using a Neuroattenuated Herpes Simplex Virus Mutant,"" Lab. Invest. 73:636-648, Nature Publishing Group (1995).;;Kooby, D.A., et al., ""Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207),"" FASEB J. 13:1325-1334, The Federation of American Societies for Experimental Biology (Aug. 1999).;;Kramm, C.M., et al., ""Therapeutic Efficiency and Safety of a Second-Generation Replication-Conditional HSV1 Vector for Brain Tumor Gene Therapy,"" Hum. Gene. Ther. 8:2057-2068, Mary Ann Liebert, Inc. (1997).;;Lam, E.W.-F., et al., ""Cell-cycle regulation of human B-myb transcription,"" Gene 160:277-281, Elsevier Science B.V. (1995).;;Lan., K-H., et al., ""In Vivo Selective Gene Expression and Therapy Mediated by Adenoviral Vectors for Human Carcinoembryonic Antigen-producing Gastric Carcinoma,"" Cancer Res. 57:4279-4284, The American Assocation for Cancer Research (1997).;;LeBlanc, G.A. and Waxman, D.J., ""Interaction of Anticancer Drugs with Hepatic Monooxygenase Enzymes,"" Drug Metab. Rev. 20:395-439, Marcel Dekker, Inc. (1989).;;Lorence, R.M., et al., ""Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy,"" J. Natl. Cancer Inst. 86:1228-1233, Oxford University Press (1994).;;Lukas, J., et al., ""Deregulated Expression of E2F Family Members Induces S-phase Entry and Overcomes p16INK4A-Mediated Growth Suppression,"" Mol. Cell. Biol. 16:1047-1057, American Society for Microbiology (1996).;;Lundwall, A., ""Characterization of the Gene for Prostate-Specific Antigen, a Human Glandular Kallikrein,"" Biochem. Biophys. Res. Commun. 161:1151-1159, Academic Press, Inc. (1989).;;Lyon, J., et al., ""The Role of Myb Proteins in Normal and Neoplastic Cell Proliferation,"" Crit. Rev. Oncogenesis 5:373-388, Begell House, Inc. (1994).;;Manome, Y., et al., ""Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide,"" Gene Therapy 3:513-520, Stockton Press (1996).;;Markert, J.M., et al, ""Expanded spectrum of viral therapy in the treatment of nervous system tumors,"" J. Neurosurg. 77:590-594, American Association of Neurological Surgeons (1992).;;Markovitz, N.S., et al., ""The Range and Distribution of Murine Central Nervous System Cells Infectd with the gamma134.5- Mutant of Herpes Simplex Virus 1,"" J. Virol. 71:5560-5569, American Society for Microbiology (1997).;;Martuza, R.L., et al., ""Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant,"" Science 252:854-856, American Association for the Advancement of Science (1991).;;Martuza, R.L., et al., ""Conditionally replicating herpes vectors for cancer therapy,"" J. Clin. Invest. 105:841-846, The American Society of Clinical Investigation, Inc. (Apr. 2000).;;Massie, B., et al., ""Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Regulatable Expression Cassette,"" J. Virol. 72:2289-2296, American Society for Microbiology (Mar. 1998).;;McLaughlan, J. and Clements, J.B., ""Organization of the Herpes Simplex Virus Type 1 Transcription Unit Encoding Two Early Proteins with Molecular Weights of 140000 and 40000,"" J. Gen. Virol. 64:997-1006, Society for General Microbiology (1983).;;Miller, N. and Vile, R., ""Targeted vectors for gene therapy,"" FASEB J. 9:190-199, The Federation of American Societies for Experimental Biology (1995).;;Miller, N. and Whelan, J., ""Progress in Transcriptionally Targeted and Regulatable Vectors for Genetic Therapy,"" Hum. Gene Ther. 8:803-815, Mary Ann Liebert, Inc. (1997).;;Mineta, T., et al., ""Treatment of Malignant Gliomas Using Ganciclovir-hypersensitive, Ribonucloetide Reductase-deficient Herpes Simplex Viral Mutant,"" Cancer Res. 54:3963-3966, The American Association for Cancer Research (1994).;;Mineta, T., et al., ""Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas,"" Nature Med. 1:938-943, Nature Publishing Group(1995).;;Miyatake, S., et al., ""Transcriptional Targeting of Herpes Simplex Virus for Cell-Specific Replication,"" J. Virol. 71:5124-5132, American Society for Microbiology (1997).;;Mohr, I. and Gluzman, Y., ""A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function,"" EMBO J. 15:4759-4766, Oxford University Press (1996).;;Moolten, F.L. and Wells, J.M., ""Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors,"" J. Natl. Cancer Inst. 82:297-300, Oxford University Press (1990).;;Moolten, F.L., et al., ""Drug sensitivity (""suicide"") genes for selective cancer chemotherapy,"" Cancer Gene Ther. 1:279-287, Appleton and Lange (1994).;;Mullen, C.A., et al., ""Tumors Expressing the Cytosine Deaminase Suicide Gene Can Be Eliminated in Vivo with 5-Fluorocytosine and Induce Protective Immunity to Wild Type Tumor,"" Cancer Res. 54:1503-1506, The American Association for Cancer Research (1994).;;Munaut, C., et al., ""Murine Matrix Metalloproteinase 9 Gene,"" J. Biol. Chem. 274:5588-5596, The American Society for Biochemistry and Molecular Biology, Inc. (Feb. 1999).;;Nagayama, Y., et al., ""Enhanced Efficacy of Transcriptionally Targeted Suicide Gene/Prodrug Therapy for Thyroid Carcinoma with the Cre-loxP System,"" Cancer Res. 59:3049-3052, The American Association for Cancer Research, Inc. (Jul. 1999).;;Nakamura, H., et al., ""Oncolysis of Colon Carcinoma Liver Metastasis in Genetically Engineered HSV-1 Vector MTB34.5,""presented at the 91st Annual Meeting of the American Association for Cancer Research, Apr. 1-5, 2000, San Francisco, CA, Proc. Am. Assoc. Cancer Res . . . 41:466 , Abstract No. 2970 (Mar. 2000).;;Ng, S.F. and Waxman, D.J., ""Activation of thio-TEPA cytotoxicity toward human breast cancer cells by hepatic cytochrome P450,"" Intl. J. Oncology 2:731-738, Laboratory of Clinical Virology, University of Crete Faculty of Medicine (1993).;;Nilaver, G., et al., ""Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption,"" Proc. Natl. Acad. Sci. USA 92:9829-9833, The National Academy of Sciences (1995).;;O'Malley, B.W., Jr., et al., ""Combination Gene Therapy for Oral Cancer in a Murine Model,"" Cancer Res. 56:1737-1741, The American Association for Cancer Research, Inc. (1996).;;Oldfield, E., et al., ""Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous Ganciclovir,"" Hum. Gene Ther. 4:39-69, Mary Ann Liebert, Inc. (1993).;;Osaki, T., et al., ""Gene Therapy for Carcinoembryonic Antigen-Producing Human Lung Cancer Cells by Cell Type-Specific Expression of Herpes Simplex Virus Thymidine Kinase Gene,"" Cancer Res. 54:5258-5261, The American Association for Cancer Research, Inc. (1994).;;Perng, G.-C., et al., ""An Avirulent ICP34.5 Deletion Mutant of Herpes Simplex Virus Type 1 Is Capable of In Vivo Spontaneous Reactivation."" J. Virol. 69:3033-3041, American Society for Microbiology (1995).;;Pyles, R.B. and Thompson, R.I., ""Evidence that the Herpes Simplex Virus Type 1 Uracil DNA Glycosylase Is Required for Efficient Viral Replication and Latency in the Murine Nervous System,"" J. Virol. 68:4963-4972, American Society for Microbiology (1994).;;Pyles, R.B., et al., ""A Novel Multiply-Mutated HSV-1 Strain for the Treatment of Human Brain Tumors,"" Hum. Gene Ther. 8:533-544, Mary Ann Liebert, Inc. (1997).;;Rainov, N.G., et al., ""Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm,"" Cancer Gene Ther. 3:99-106, Nature Publishing Group (1996).;;Rainov, N.G., et al., ""New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-Aminoanthracene/4-Ipomeanol,"" Hum. Gene Ther. 9:1261-1273, Mary Ann Liebert, Inc. (1998).;;Ram, Z., et al., ""Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells,"" Nature Med. 3:1354-1361, Nature Publishing Group (1997).;;Ray, M.K., et al., ""Beta Cell-Specific Ablation of Target Gene Using Cre-loxP System in Transgenic Mice,"" J. Surg. Res. 84:199-203, Academic Press (Jun. 1999).;;Rodriguez, R., et al., ""Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-Specific Antigen-Positive Prostate Cancer Cells,"" Cancer Res. 57:2559-2563, The American Association for Cancer Research, Inc. (1997).;;Roizman, B. and Jenkins, F.J., ""Genetic Engineering of Novel Genomes of Large DNA Viruses,"" Science 229:1208-1214, American Association for the Advancement of Science (1985).;;Rosenberg, S.A., et al., ""Human Gene Marker/Therapy Clinical Protocols,"" Hum. Gene Ther. 11:919-979, Mary Ann Liebert, inc. (Apr. 2000).",EXPIRED
26,AU,A,AU 2000/034774 A,093-637-149-430-335,2001-03-26,2001,AU 2000/034774 A,2000-02-02,US 15162199 P;;US 0002409 W,1999-08-31,Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression,,MASSACHUSETTS GEN HOSPITAL,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/093-637-149-430-335,Patent Application,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
27,ZA,B,ZA 200202413 B,005-321-729-613-522,2003-06-25,2003,ZA 200202413 A,2002-03-26,US 15162199 P,1999-08-31,Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/005-321-729-613-522,Granted Patent,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,A61K31/675;;A61K35/76;;A61K45/00;;C12N15/09;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
28,AU,B2,AU 781219 B2,033-077-472-847-625,2005-05-12,2005,AU 2000/034774 A,2000-02-02,US 15162199 P;;US 0002409 W,1999-08-31,Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/033-077-472-847-625,Granted Patent,no,1,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
29,CA,A1,CA 2383372 A1,041-395-140-652-702,2001-03-08,2001,CA 2383372 A,2000-02-02,US 15162199 P;;US 0002409 W,1999-08-31,CELL-SPECIFIC AND/OR TUMOR-SPECIFIC PROMOTER RETARGETING OF HERPES GAMMA 34.5 GENE EXPRESSION,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populatio ns of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes .gamma.34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/041-395-140-652-702,Patent Application,no,0,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,0,0,,,,EXPIRED
30,EP,B1,EP 1212428 B1,139-706-959-044-499,2004-12-01,2004,EP 00913305 A,2000-02-02,US 0002409 W;;US 15162199 P,1999-08-31,CELL-SPECIFIC AND/OR TUMOR-SPECIFIC PROMOTER RETARGETING OF HERPES GAMMA 34.5 GENE EXPRESSION,The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of the herpes gamma 34.5 gene.,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/139-706-959-044-499,Granted Patent,yes,4,0,21,24,0,A61K48/00;;A61K2039/525;;A61K2039/5256;;C07K14/005;;C12N7/00;;C12N15/86;;C12N2710/16043;;C12N2710/16622;;C12N2710/16643;;C12N2830/00;;A61P35/00;;A61P43/00;;C12N7/04,C12N15/09;;A61K31/675;;A61K35/76;;A61K45/00;;A61K48/00;;A61P35/00;;A61P43/00;;C07K14/035;;C12N7/00;;C12N7/02;;C12N15/38;;C12N15/869;;C12R1/93,,6,0,,,"C.M. KRAMM ET AL.: ""Therapeutic and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy"" HUMAN GENE THERAPY, vol. 8, no. 17, 20 November 1997 (1997-11-20), pages 2057-2068, XP000929872 MARY ANN LIEBERT, INC. PUBLISHERS, NEW YORK, US cited in the application;;CHAMBERS R ET AL: ""Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma"" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 92, no. 5, 28 February 1995 (1995-02-28), pages 1411-1415, XP002090032 ISSN: 0027-8424 cited in the application;;PERNG ET AL: ""AN AVIRULENT ICP34.5 DELETION MUTANT OF HERPES SIMPLEX VIRUS TYPE 1 IS CAPABLE OF IN VIVO SPONTANEOUS REACTIVATION"" JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 69, no. 5, 1 May 1995 (1995-05-01), pages 3033-3041, XP002090031 ISSN: 0022-538X;;LAM E W -F ET AL: ""Cell-cycle regulation of human B-myb transcription"" GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 160, no. 2, 28 July 1995 (1995-07-28), pages 277-281, XP004042159 ISSN: 0378-1119;;CHUNG R Y ET AL: ""B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells."" JOURNAL OF VIROLOGY, (1999 SEP) 73 (9) 7556-64. JOURNAL CODE: KCV. , XP002144570;;NAKAMURA HIDEO ET AL: ""Oncolysis of colon carcinoma liver metastasis in genetically-engineered HSV-1 vector Myb34.5."" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03), page 466 XP002144571 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000 ISSN: 0197-016X",EXPIRED
31,DK,T3,DK 1212428 T3,141-340-530-291-268,2005-03-21,2005,DK 00913305 T,2000-02-02,US 0002409 W,2000-02-02,Ændring af målretning af Herpes-gamma 34.5-genekspression med cellespecifik og/eller tumorspecifik promotor,,GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;CHUNG RICHARD Y,,https://lens.org/141-340-530-291-268,Granted Patent,no,0,0,1,1,0,,A61K48/00;;C07K14/035;;C12N7/04;;C12N15/38;;C12N15/86,,0,0,,,,EXPIRED
32,EP,A2,EP 2086555 A2,152-436-666-350-103,2009-08-12,2009,EP 07867326 A,2007-10-31,US 2007/0023001 W;;US 85549406 P,2006-10-31,METHODS AND COMPOSITIONS FOR INHIBITING GSK-3 IN GLIAL CELL RELATED DISORDERS,,UNIV OHIO STATE RES FOUND,LAWLER SEAN E;;NOWICKI MICHAL OSKAR;;CHIOCCA ANTONIO E,,https://lens.org/152-436-666-350-103,Patent Application,yes,0,0,6,6,0,A61K31/4015;;A61K31/426;;A61K33/14;;C12Q1/485;;G01N33/57407;;G01N2333/912;;G01N2500/00;;A61P35/00;;A61K33/14;;G01N2500/00;;G01N2333/912;;C12Q1/485;;A61K31/426;;A61K31/4015;;G01N33/57407,A61K39/395;;A61K31/00;;A61P35/00;;C12Q1/70;;G01N33/50,,0,0,,,,DISCONTINUED
33,WO,A3,WO 2008/054786 A3,117-914-235-975-026,2008-11-06,2008,US 2007/0023001 W,2007-10-31,US 85549406 P,2006-10-31,METHODS AND COMPOSITIONS FOR INHIBITING GSK-3 IN GLIAL CELL RELATED DISORDERS,A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 α or β inactivation.,UNIV OHIO STATE RES FOUND;;LAWLER SEAN E;;NOWICKI MICHAL OSKAR;;CHIOCCA ANTONIO E,LAWLER SEAN E;;NOWICKI MICHAL OSKAR;;CHIOCCA ANTONIO E,,https://lens.org/117-914-235-975-026,Search Report,yes,2,0,6,6,0,A61K31/4015;;A61K31/426;;A61K33/14;;C12Q1/485;;G01N33/57407;;G01N2333/912;;G01N2500/00;;A61P35/00;;A61K33/14;;G01N2500/00;;G01N2333/912;;C12Q1/485;;A61K31/426;;A61K31/4015;;G01N33/57407,A61K31/00;;A61K39/395;;C12Q1/70,,0,0,,,,PENDING
34,US,A1,US 2010/0143500 A1,185-158-769-046-833,2010-06-10,2010,US 44781107 A,2007-10-31,US 44781107 A;;US 85549406 P;;US 2007/0023001 W,2006-10-31,Methods and Compositions for Inhibiting GSK-3 In Glial Cell Related Disorders,A method of treating a glial cell related disorder in a mammalian subject includes administering a drug which enhances or prolongs GSK-3 α or β inactivation.,UNIV OHIO STATE RES FOUND,LAWLER SEAN E;;NOWICKI MICHAL OSKAR;;CHIOCCA E ANTONIO,THE OHIO STATE UNIVERSITY (2009-12-21),https://lens.org/185-158-769-046-833,Patent Application,yes,6,2,6,6,0,A61K31/4015;;A61K31/426;;A61K33/14;;C12Q1/485;;G01N33/57407;;G01N2333/912;;G01N2500/00;;A61P35/00;;A61K33/14;;G01N2500/00;;G01N2333/912;;C12Q1/485;;A61K31/426;;A61K31/4015;;G01N33/57407,A61K33/14;;A61K31/4015;;A61K31/426;;A61P35/00;;C01D15/04;;C07D207/24;;C07D277/38;;C12N9/12;;C12Q1/48,424/677;;514/425;;514/371;;435/15;;435/194;;548/544;;548/192;;423/499.3,0,0,,,,DISCONTINUED
35,EP,A4,EP 2086555 A4,010-877-241-385-356,2009-12-23,2009,EP 07867326 A,2007-10-31,US 2007/0023001 W;;US 85549406 P,2006-10-31,METHODS AND COMPOSITIONS FOR INHIBITING GSK-3 IN GLIAL CELL RELATED DISORDERS,,UNIV OHIO STATE RES FOUND,LAWLER SEAN E;;NOWICKI MICHAL OSKAR;;CHIOCCA ANTONIO E,,https://lens.org/010-877-241-385-356,Search Report,no,5,0,6,6,0,A61K31/4015;;A61K31/426;;A61K33/14;;C12Q1/485;;G01N33/57407;;G01N2333/912;;G01N2500/00;;A61P35/00;;A61K33/14;;G01N2500/00;;G01N2333/912;;C12Q1/485;;A61K31/426;;A61K31/4015;;G01N33/57407,A61K39/395;;A61K31/00;;A61P35/00;;C12Q1/70;;G01N33/50,,1,1,007-041-767-922-824,pmc2604845;;10.1152/jn.90722.2008;;18715894,"OHARA PETER T ET AL: ""Evidence for a Role of Connexin 43 in Trigeminal Pain Using RNA Interference In Vivo"", JOURNAL OF NEUROPHYSIOLOGY (BETHESDA), vol. 100, no. 6, December 2008 (2008-12-01), pages 3064 - 3073, ISSN: 0022-3077",DISCONTINUED
36,US,B2,US 7214515 B2,049-599-660-504-936,2007-05-08,2007,US 3521602 A,2002-01-04,US 3521602 A;;US 25969701 P;;US 28740401 P;;US 29425401 P;;US 33051101 P,2001-01-05,Viral delivery system for infectious transfer of large genomic DNA inserts,"The present invention relates to HSV-based amplicon vectors carrying a genomic DNA fragment, and methods of constructing and using the same. Included within the present invention is a method of converting any large capacity DNA cloning vector, such as a BAC or PAC, into an HSV amplicon or hybrid HSV amplicon using site-specific, or other types of recombination, so that genomic DNA inserts within the BAC or PAC clone can be delivered by infection to a cell, and efficiently expressed. The present invention also relates to a system for the rapid creation of viral vectors carrying transgenes of interest. This aspect of the invention is accomplished through recombination between: (a) a large-capacity cloning vector carrying a viral genome, and (b) a transfer vector containing the transgene of interest. Finally, an expression-ready genomic DNA library is disclosed.",GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;WADE-MARTINS RICHARD,GENERAL HOSPITAL CORPORATION THE (2002-01-02),https://lens.org/049-599-660-504-936,Granted Patent,yes,32,1,3,3,0,A61K38/177;;A61K38/45;;A61K48/00;;C12N7/00;;C12N15/86;;C12N2710/10343;;C12N2710/16643;;C12N2800/108;;C12N2800/204;;C12N2800/206;;C12N2800/30;;C12N7/00;;C12N2800/30;;C12N2710/16643;;C12N2800/204;;A61K38/45;;C12N2800/206;;A61K38/177;;C12N15/86;;A61K48/00;;C12N2710/10343;;C12N2800/108,C12N15/64;;A61K35/76;;A61K38/17;;A61K38/45;;A61K48/00;;C12N15/70;;C12N15/79;;C12N15/861;;C12N15/869,435/91.41;;435/91.4;;435/320.1,105,102,108-350-527-415-058;;087-772-374-828-926;;047-218-825-724-079;;091-974-420-276-457;;048-946-157-905-289;;012-895-982-899-17X;;057-907-536-885-737;;003-801-029-263-031;;027-273-945-178-603;;025-226-585-864-700;;011-596-321-144-013;;021-466-072-115-955;;044-135-659-393-274;;038-957-195-669-548;;000-532-578-248-270;;015-585-302-194-72X;;067-299-297-315-177;;071-442-638-420-64X;;081-259-220-811-595;;086-409-425-521-658;;016-742-447-932-634;;000-033-151-883-738;;036-778-002-919-330;;067-488-534-167-28X;;071-547-378-265-25X;;127-348-232-397-557;;029-114-817-824-206;;108-718-229-730-968;;110-408-278-056-613;;034-362-991-825-187;;096-826-527-607-030;;048-802-949-100-822;;002-512-736-644-602;;071-034-900-585-923;;027-200-766-946-788;;108-448-445-113-510;;092-067-236-045-728;;000-302-849-709-734;;154-704-594-641-040;;106-802-599-287-763;;012-659-596-980-119;;036-493-208-662-084;;068-535-317-120-413;;108-350-527-415-058;;062-825-278-526-054;;060-440-545-500-845;;059-172-711-641-317;;047-218-825-724-079;;000-362-547-589-786;;129-236-633-688-941;;038-993-273-741-436;;018-212-988-910-723;;059-917-365-206-753;;001-146-799-922-450;;086-587-143-781-330;;011-530-925-868-58X;;035-792-138-687-350;;005-727-659-161-961;;117-012-020-789-100;;080-787-242-731-417;;055-037-767-329-851;;030-952-514-166-654;;032-789-200-339-116;;016-951-944-561-353;;020-654-753-299-413;;031-042-320-042-892;;091-032-822-161-40X;;091-974-420-276-457;;061-175-736-700-104;;041-689-592-143-013;;058-139-996-726-603;;046-103-492-718-925;;147-237-287-123-813;;024-533-020-155-927;;016-140-577-556-587;;006-178-237-948-016;;000-581-994-047-145;;082-139-264-011-549;;125-082-407-097-073;;019-684-250-470-866;;058-349-675-570-594;;009-662-306-508-916;;096-118-605-940-529;;025-904-317-675-989;;026-711-813-145-35X;;161-269-679-102-273;;100-049-792-255-151;;166-022-850-729-381;;048-946-157-905-289;;028-010-312-336-917;;040-775-351-136-108;;018-149-842-551-597;;118-752-949-246-084;;043-789-288-360-743;;055-464-936-380-401;;086-808-737-760-162;;021-839-856-024-866;;102-127-079-827-998;;022-760-388-186-892;;038-338-201-467-238;;083-200-999-470-558;;117-216-763-616-862,9048203;;10.1089/hum.1997.8.3-359;;10.1002/0470842385.ch8;;pmc310707;;9548976;;10.1101/gr.8.4.404;;9874276;;10.1089/hum.1998.9.18-2787;;pmc190931;;8970963;;10.1128/jvi.70.12.8422-8430.1996;;10954601;;pmc110714;;10.1093/nar/28.17.3323;;10.1097/00001756-199712010-00029;;9427374;;11017062;;10.1038/79839;;9160756;;pmc3764491;;10.1016/s0092-8674(00)80246-9;;10.1038/nm1295-1303;;7489413;;9240964;;10.1096/fasebj.11.8.9240964;;9679020;;10.1126/science.281.5373.60;;10.1073/pnas.91.6.2076;;pmc43312;;8134351;;10827452;;10.1016/s0168-9525(00)02015-1;;10.1016/0092-8674(79)90182-x;;24511574;;369702;;pmc3933433;;10.1038/nbt0598-444;;9592392;;11021599;;10.1038/sj.gt.3301280;;10.1006/viro.1993.1572;;8212547;;2018042;;pmc1683055;;8387378;;10.1038/ng0393-219;;pmc20961;;9653172;;10.1073/pnas.95.14.8245;;7671105;;7669103;;10.1126/science.266.5189.1399;;pmc2638002;;10.1016/0378-1119(89)90088-7;;2777090;;9306401;;10.1038/nbt0997-866;;7584109;;8794366;;10.1128/jvi.70.10.7190-7197.1996;;pmc190772;;10.1007/bf03401718;;pmc2230287;;9440115;;10.1007/978-1-59259-478-8_4;;pmc255605;;6321792;;10.1128/jvi.50.1.248-254.1984;;2843986;;10.1126/science.2843986;;pmc2581874;;10.1126/science.241.4873.1667;;2174168;;pmc55078;;10.1073/pnas.87.22.8950;;10.1016/b978-012397570-6/50003-4;;10.1016/0092-8674(88)90028-1;;2846181;;10.1038/340393a0;;2547164;;10.1038/ng0497-345;;9090378;;9176490;;10.1038/nm0697-639;;10.1038/326292a0;;3821905;;10.1038/79876;;11017071;;10505118;;10.1038/sj.gt.3300887;;10.1242/jcs.63.1.77;;6313714;;10.1038/ng0194-84;;8136839;;10.1038/sj.gt.3300578;;9472550;;9048203;;10.1089/hum.1997.8.3-359;;7842013;;10.1038/ng1094-148;;8122308;;10.1016/0168-9525(93)90104-p;;10.1006/geno.1996.0268;;8661051;;pmc310707;;9548976;;10.1101/gr.8.4.404;;8974620;;10.1111/j.1750-3639.1995.tb00615.x;;7866875;;10.1007/bf02824809;;8382374;;10.1126/science.8382374;;10.1016/s0168-9525(99)01780-1;;10498936;;8679207;;10.2144/19962003460;;10.1006/viro.1999.0108;;10648187;;10.1128/jvi.67.8.4566-4579.1993;;pmc237841;;8392598;;9049635;;10.1101/gr.7.2.179;;9405686;;pmc25110;;10.1073/pnas.94.26.14759;;7765076;;10.1016/0167-7799(94)90140-6;;10.1152/ajpregu.1994.266.1.r292;;8304553;;10.1615/critrevtherdrugcarriersyst.v12.i4.10;;9501965;;10954612;;pmc110716;;10.1093/nar/28.17.e79;;10645956;;pmc310499;;pmc47951;;10.1073/pnas.90.23.11207;;8248229;;pmc353115;;10.1128/jvi.29.1.275-284.1979;;219222;;9470229;;10.1016/s0167-7799(97)01137-2;;10.1038/ng0196-6;;8528253;;7585128;;10.1038/nm0695-592;;9874276;;10.1089/hum.1998.9.18-2787;;10.1006/mthe.2001.0294;;11319922;;10.1016/0958-1669(94)90068-x;;7765467;;10.1038/ng0298-180;;9462752;;10899823;;10.1006/mthe.2000.0096;;8607026;;pmc50007;;1528894;;10.1073/pnas.89.18.8794;;9306392;;10.1038/nbt0997-839;;1309283;;10.1016/0042-6822(92)90062-t;;10.1016/s0171-2985(11)80121-x;;10781094;;10.1073/pnas.080502497;;pmc18325;;10.1016/0092-8674(82)90035-6;;6290080;;2983310;;10.1073/pnas.82.3.694;;pmc397112;;10.1016/0168-9525(90)90117-o;;10.1038/ng0994-33;;7987390;;8986434;;9359107;;10.1038/nbt1197-1257;;10.1016/s0959-437x(98)80093-2;;9691004;;10075999;;10.1093/nar/27.7.1674;;pmc148371;;10.1038/82444;;11101814;;11689853;;10.1038/nbt1101-1067;;10.2172/573257;;pmc190931;;8970963;;10.1128/jvi.70.12.8422-8430.1996;;10.1038/sj.gt.3300523;;9425435;;10.2144/00281st05;;10649778;;9741425;;10.1089/hum.1998.9.13-1863;;9020933;;8789800;;10.1159/000150293;;8407248;;pmc188865;;10.1128/jvi.69.4.2004-2015.1995;;7884845;;9306400;;10.1038/nbt0997-859;;10431235;;10.1038/11896;;10.1038/313812a0;;2983224;;2439408;;10.1016/0378-1119(87)90096-5;;10.1007/bf00046349;;9034598;;10.1038/2417;;9771703,"Johnston et al. HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells. Hum Gene Ther. Feb. 10, 1997;8(3):359-70.;;Ebersole et al. (""Mammalian Artificial Chromosomes: Prospects for Gene Therapy"" in Gene Therapy Technologies, Applications and Regulations (Meager, A., Ed.) (C) 1999, John Wiley & Sons Ltd, pp. 165-178.;;Kim et al. Modification of bacterial artificial chromosome clones using Cre recombinase: introduction of selectable markers for expression in eukaryotic cells, Genome Res. Apr. 1998;8(4):404-12.;;Saeki et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther. Dec. 10, 1998;9(18):2787-94.;;Wang et al. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol. Dec. 1996;70(12):8422-30.;;Woodfield et al. Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3'-para-nitrophenyl phosphate ester. Nucleic Acids Res. Sep. 1, 2000;28(17):3323-31.;;Aboody-Guterman, K.S., et al., ""Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo,"" Neuroreport 8:3801-3808, Rapid Science Publishers (1997).;;Altshuler, D., et al., ""Guilt by association,"" Nat. Genet. 26:135-137, Nature Publishing Co. (Oct. 2000).;;Antoch, M.P., et al., ""Functional Identification of the Mouse Circadian Clock Gene by Transgenic BAC Rescue,"" Cell 89:655-667, Cell Press (1997).;;Banerjee, S., et al., ""Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus,"" Nat. Med. 1:1303-1308, Nature Publishing Co. (1995).;;Bilbao, G., et al., ""Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo,"" FASEB J. 11:624-634, Federation of American Societies for Experimental Biology (1997).;;Blackwood, E.M. and Kadonaga, J.T., ""Going the Distance: A Current View of Enhancer Action,"" Science 281:60-63, American Association for the Advancement of Science (1998).;;Bobo, R.H., et al., ""Convection-enhanced delivery of macromolecules in the brain,"" Proc. Natl. Acad. Sci. 91:2076-2080, National Academy of Sciences (1994).;;Breakfield, X.O., et al., ""4. Herpes Simplex Virus Vectors for Tumor Therapy,"" in: The Internet Book of Gene Therapy: Cancer Therapeutics, Sobol, R.E. and Scanlon, K.J., eds., Appleton and Lange, Stamford, Connecticut, pp. 41-56 (1995).;;Brune, W., et al., ""Forward with BACs new tools for herpesvirus genomics,"" Trends Genet. 16:254-259, Elsevier Trends Journals (Jun. 2000).;;Caskey, C.T. and Kruh, G.D., ""The HPRT Locus,"" Cell 16:1-9, Massachusetts Institute of Technology (1979).;;Chase, M., et al., ""An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,"" Nat. Biotechnol. 16:444-448, Nature Publishing Co. (1998).;;Compton, S.H., et al., ""Stable integration of large (>100kb) PAC constructs in HaCaT keratinocytes using an integrin-targeting peptide delivery system,"" Gene Ther. 7:1600-1605, Macmillan Publishers Ltd. (Sep. 2000).;;Cunningham, C. and Davidson, A.J., ""A Cosmid-Based System for Constructing Mutants of Herpes Simplex Virus Type 1,"" Virology 197:116-124, Academic Press, Inc. (1993).;;Davidson, B.L., et al., ""Identification of 17 Independent Mutations Responsible for Human Hypoxanthine-Guanine Phosphoribosyltransferase (HPRT) Deficiency,"" Am. J. Hum. Genet. 48:951-958, University of Chicago Press (1991).;;Davidson, B.L., et al., ""A model system for in vivo gene transfer into the central nervous system using an adenoviral vector,"" Nat. Genet. 3:219-223, Nature Publishing Co. (1993).;;Delecluse, H.-J., et al., ""Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells,"" Proc. Natl. Acad. Sci. USA 95:8245-8250, National Academy of Sciences (1998).;;Dornburg, R., ""Reticuloendotheliosis viruses and derived vectors,"" Gene. Ther. 2:301-310, Stockton Press (1995).;;During, M.J., et al., ""Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase,"" Science 266:1399-1403, American Association for the Advancement of Science (1994).;;Evans, G.A., et al., ""High efficiency vectors for cosmid microcloning and genomic analysis,"" Gene 79:9-20, Elsevier Science B.V. (1989).;;Feng, M., et al., ""Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector,"" Nat. Biotechnol. 15:866-870, Nature Publishing Co. (1997).;;Flotte, T.R. and Carter, B.J., ""Adeno-associated virus vectors for gene therapy,"" Gene Ther. 2:357-362, Stockton Press (1995).;;Fraefel, C., et al., ""Helper Virus-Free Transfer of Herpes Simplex Virus Type 1 Plasmid Vectors into Neural Cells,"" J. Virol. 70:7190-7197, American Society for Microbiology (1996).;;Fraefel, C., et al., ""Gene Transfer into Hepatocytes Mediated by Helper Virus-Free HSV/AAV Hybrid Vectors,"" Mol. Med. 3:813-825, Springer (1997).;;Fraefel, C., et al., ""4. HSV-1 Amplicon,"" in: Gene Therapy for Neurological Disorders and Brain Tumors, Chiocca, E.A. and Breakefield, X.O., eds., Humana Press, Totowa, New Jersey, pp. 63-82 (1998).;;Gardella, T., et al., ""Detection of Circular and Linear Herpesvirus DNA Molecules in Mammalian Cells by Gel Electrophoresis,"" J. Virol. 50:248-254, American Society for Microbiology (1984).;;Geller, A.I. and Breakefield, X.O., ""A Defective HSV-1 Vector Expresses Escherichia coli beta-Galactosidase in Cultured Peripheral Neurons,"" Science 241:1667-1669, American Association for the Advancement of Science (1988).;;Geller, A.I., et al., ""An efficient deletion mutant packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology,"" Proc. Natl. Acad. Sci. USA 87:8950-8954, National Academy of Sciences (1990).;;Glorioso, J.C., et al., ""Chapter 1. Herpes Simplex Virus as a Gene-Delivery Vector for the Central Nervous System,"" in: Viral Vectors: Gene Therapy and Neuroscience Applications, Kaplitt, M.G. and Loewy, A.D., eds. Academic Press, Inc., New York, New York, pp. 1-23, (1995).;;Hammerschmidt, W. and Sugden, B., ""Identification and Characterization of oriLyt, a Lytic Origin of DNA Replication of Epstein-Barr Virus,""Cell 55:427-433, Cell Press (1988).;;Hammerschmidt, W. and Sugden, B., ""Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes"" Nature 340:393-397, Macmillan Journals Ltd. (1989).;;Harrington, J.J., et al., ""Formation of de novo centromeres and construction of first-generation human artificial microchromosomes,"" Nat, Genet. 15:345-355, Nature Publishing Co. (1997).;;Heise, C., et al., ""ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents,"" Nat. Med. 3:639-645, Nature Publishing Co. (1997).;;Hooper, M., et al., ""HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells,"" Nature 326:292-295, Macmillan Journals Ltd. (1987).;;Horikawa, Y., et al., ""Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus,"" Nat. Genet. 26:163-175 Nature Publishing Co. (Oct. 2000).;;Horsburgh, B.C., et al., ""Allele replacement: an application that permits rapid manipulation of herpes simplex virus type 1 genomes,"" Gene Ther. 6:922-930, Stockton Press (1999).;;Huschtscha, L.I. and Holliday, R., ""Limited and Unlimited Growth of SV40- Transformed Cells from Human Diploid MRC-5 Fibroblasts,"" J. Cell. Sci. 63:77-99, The Company of Biologist Limited (1983).;;Ioannou, P.A., et al., ""A new bacteriophage P1-derived vector for the propagation of large human DNA fragments,"" Nat. Genet. 6;84-89 Nature Publishing Co. (1994).;;Jacoby, D.R., et al., ""Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes,"" Gene Ther. 4:1281-1283, Stockton Press (1997).;;Johnston, K.M., et al., ""HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma Cells,"" Hum. Gene Ther. 8:359-370, Mary Ann Liebert, Inc. (1997).;;Kaplitt, M.G., et al., ""Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain,"" Nat. Genet. 8:148-154, Nature Publishing Co. (1994).;;Kilby, N.J., et al., ""Site-specific recombinases: tools for genome engineering,"" Trends Genet. 9:413-421, Elsevier Science Publishers Ltd. (1993).;;Kim, U.-J., et al., ""Construction and Characterization of a Human Bacterial Artificial Chromosome Library,"" Genomics 34:213-218, Academic Press, Inc. (1996).;;Kim, S.Y., et al., ""Modification of Bacterial Artificial Chromosome Clones Using Cre Recombinase: Introduction of Selectable Markers for Expression in Eukaryotic Cells,"" Genome Res. 8:404-412, Cold Spring Harbor Laboratory Press (1998).;;Kramm, C.M., et al., ""Gene Therapy for Brain Tumors,"" Brain Pathol. 5:345-381, International Society of Neuropathology (1995).;;Latchman, D.S., et al., ""Herpes Simplex Virus Vectors for Gene Therapy,"" Mol. Biotechnol. 2:179-195, Humana Press (1994).;;La Gal La Salle, G., et al., ""An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain,"" Science 259:988-990, American Association for the Advancement of Science (1993).;;Li, Q., et al., ""Locus control regions coming of age at a decade plus,"" Trends Genet. 15:403-408, Elsevier Science Ltd. (1999).;;Lim, F., et al., ""Generation of High-Titer Defective HSV-1 Vectors Using and IE 2 Deletion Mutant and Quantitative Study of Expression in Cultured Cortical Cells,"" BioTechniques 20:460-469, Eaton Publishing Co. (1996).;;Logvinoff, C. and Epstein, A.L., ""Genetic Engineering of Herpes Simplex Virus and Vector and Vector Genomes Carrying loxP Sites in Cells Expressing Cre Recombinase,"" Virology 267:102-110, Academic Press, Inc. (Feb. 2000).;;Luckow, V.A., et al., ""Efficient Generation of Infectious Recombinant Baculoviruses by Site-Specific Transposon-Mediated Insertion of Foreign Genes into a Baculovirus Geome Propagated in Escherichia coli,"" J. Virol. 67:4566-4579, American Society fro Microbiology (1993).;;Mejfa, J.E. and Monaco, A.P., ""Retrofitting Vectors for Escherichia coli-Based Artificial Chromosomes (PACs and BACs) with Markers for Transfection Studies,"" Genome Res. 7:179-186, Cold Spring Harbor Laboratory Press (1997).;;Messerle, M., et al., ""Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome,"" Proc. Natl. Acad. Sci. USA 94:14759-14763, National Academy of Sciences (1997).;;Monaco, A.P. and Larin, Z., ""YACs, BACs, PACs and MACs: artificial chromosomes as research tools,"" Trends Biotech. 12:280-286, Elsevier Science Ltd. (1994).;;Morrison, P.F., et al., ""High-flow microinfusion: tissue penetration and pharmacodynamics,"" Am. J. Physiol. 266:R292-R305, American Physiological Society (1994).;;Nakanishi, M., ""Gene Introduction Into Animal Tissues,"" Crit. Rev. Ther. Drug Carr. Sys. 12:263-310, Begell House, Inc. (1995).;;Nefedov, M., et al., ""Insertion of disease-causing mutations in BACs by homologous recombination in Escherichia coli,"" Nucl. Acids Res. 28:e79i-e79iv, Oxford University Press (Sep. 2000).;;Osoegawa, K., et al., ""Bacterial Articicial Chromosome Libraries for Mouse Sequencing and Functional Analysis,"" Genome Res. 10:116-128, Cold Spring Laboratiory Press (Jan. 2000).;;Pellegrino, L.J. and Cushman, A.J., ""Chapter 3. Use of the Stereotaxic Technique,"" in: Methods in Psychobiology, Myers, R.D., ed., Academic Press, New York, New York, pp. 67-90 (1990).;;Peterson, K.R., et al., ""Use of yeast artificial chromosomes (YACs) for studying control of gene expression: Correct regulation of the genes of a human beta-globin locus YAC following transfer to mouse erythroleukemia cell lines,"" Proc. Natl. Acad. Sci. USA 90:11207-11211, National Academy of Sciences (1993).;;Preston, C.M., ""Control of herpes Simplex Virus Type 1 mRNA Synthesis in Cells Infected with Wild-Type Virus or the Temperature-Sensitive Mutant tsK,"" J. Virol. 29:275-284, American Society for Microbiology (1979).;;Robbins, P.D., et al., ""Viral vectors for gene therapy,"" Trends Biotechnol. 16:35-40, Elsevier Trends Journals (1998).;;Roder, J. and Hickey, W. F., ""Mouse models, immunology, multiple sclerosis and myelination,"" Nat. Genet. 12:6-8, Nature Publishing Co. (1996).;;Rossant, J. and Nagy, A., ""Genome engineering: the new mouse genetics,"" Nat. Med. 1:592-594, Nature Publishing Co. (1995).;;Saeki, Y., et al., ""Herpes Simplex Virus Type 1 DNA Amplified as Bacterial Artificial Chromosome in Escherichia coli: Rescue of Replication-Competent Virus Progeny and Packaging of Amplicon Vectors,"" Hum. Gen. Ther. 9:2787-2794, Mary Ann Liebert, Inc. (1998).;;Saeki, Y., et al., ""Improved Helper Virus-Free Packaging System for HSV Amplicon Vectors Using an ICP27 Deleted, Oversized HSV-1 DNA in a Bacterial Artificial Chromosome,"" Mol. Ther. 3:591-601, Academic Press, Inc. (Apr. 2001).;;Sauer, B., ""Site-specific recombination: developments and applications,"" Curr. Opin. Biotechnol. 5:521-527, Current Biology Ltd. (1994).;;Schiedner, G., et al., ""Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity,"" Nat. Genet. 18:180-183 Nature Publishing Co. (1998).;;Sena-Esteves, M., et al., ""HSV-1 Amplicon Vectors- Simplicity and Versatility,"" Mol. Ther. 2:9-15, Academic Press, Inc. (Jul. 2000).;;Shaughnessy, E., et al., ""Parvoviral Vectors for the Gene Therapy of Cancer,"" Semin. Oncol. 23:159-171, W.B. Saunders Co. (1996).;;Shizuya, H., et al., ""Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector,"" Proc. Natl. Acad. Sci. USA 89:8794-8797, National Academy of sciences (1992).;;Simon, M.I., ""Dysfunctional genomics: BACs to the rescue,"" Nat. Biotechnol. 15:839, Nature Publishing Co. (1997).;;Smith, I.L., et al., ""Evidence that The Herpes Simplex Virus Immediate Early Protein ICP27 Acts Post-Transcriptionally during Infection to Regulate Gene Expression,"" Virology 186:74-86, Academic Press, Inc. (1992).;;Smith, G.A. and Enquist, L.W.,""A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis,"" Proc. Natl. Acad. Sci. USA 97:4873-4878, National Academy of sciences (Apr. 2000).;;Spaete, R.R. and Frenkel, N., ""The Herpes Simplex Virus Amplicon: A New Eucaryotic Defective-Virus Cloning-Amplifying Vector,"" Cell 30:295-304, Massachusetts Institute of Technology (1982).;;Spaete, R.R. and Frenkel, N., ""The herpes simplex virus amplicon: Analyses of cis-acting replication functions,"" Proc. Natl. Acad. Sci. USA 82:694-698, National Academy of Sciences (1985).;;Sternberg, N., ""Bacteriophage P1 cloning system for the isolation, amplification, and recovery of DNA fragments as large as 100 kilobase pairs,"" Proc. Natl. Acad. Sci. USA 87:103-107, National Academy of Sciences (1990).;;Sun, T.-Q., et al., ""Human artificial episomal chromosomes for cloning large DNA fragments in human cells,"" Nat. Genet. 8:33-41, Nature Publishing Co. (1994).;;Sun, T.-Q., et al., ""Engineering a mini-herpesvirus as a general strategy to transduce up to 180 kb of functional self-replicating human mini-chromosomes,"" Gene Ther. 3:1081-1088, Stockton Press (1996).;;Vos, J.-M.H., ""The simplicity of complex MACs,"" Nat. Biotechnol. 15:1257-1259, Nature Publishing Co. (1997).;;Vos, J.-M.H., ""Mammalian artificial chromosomes as tools for gene therapy,"" Curr. Opin. Genet. Dev. 8:351-359, Current Biology Ltd. (1998).;;Wade-Martins, R., et al., ""Long-term stability of large insert genomic DNA episomal shuttle vectors in human cells,"" Nucl. Acids Res. 27:1674-1682, Oxford University Press (1999).;;Wade-Martins, R., et al., ""Stable correction of a genetic deficiency in human cells by an episome carrying a 115 kb genomic transgene,"" Nat. Biotechnol. 18:1311-1314, Nature Publishing Co. (Dec. 2000).;;Wade-Martins, R., et al., ""An Infectious transfer and expression system for genomic DNA loci in human and mouse cells,"" Nat. Biotechnol. 19:1067-1070, Nature Publishing Co. (Nov. 2001).;;Wang, M., et al., ""Human Artificial Episomal Chromosomes (HAECS) for Building Large Genomic Libraries,"" in: Human Genome Program, U.S. Department of Energy, Human Genome Program Report, Part 2, 1996 Research Abstracts, Human Genome Management Information System, Oak Ridge National Laboratory, Oak Ridge, Tennessee, p. 30 (1997).;;Wang, S. and Vos, J.-M., ""A Hybrid Herpesvirus Infectious Vector Based on Epstein-Barr Virus and Herpes Simplex Virus Type 1 for Gene Transfer into Human Cells In Vitro and In Vivo,"" J. Virol. 70:8422-8430, American Society for Microbiology (1996).;;Wang, S., et al., ""A novel herpesvirus amplicon system for in vivo gene delivery,"" Gene Ther. 4:1132-1141, Stockton Press (1997).;;Wang, X., et al., ""Fifty-One Kilobase HSV-1 Plasmid Vector Can Be Packaged Using a Helper Virus-Free System and Supports Expression in the Rat Brain,"" BioTechniques 28:102-107, Eaton Publishing Co. (Jan. 2000).;;Watson, J.D., et al., ""Working toward Human Gene Therapy,"" in: Recombinant DNA, 2nd Ed. Chapter 28, Watson, J.D., et al., eds. Scientific American Books, New York, New York, pp. 567-581 (1992).;;Westphal, E.M., et al., ""A System for Shuttling 200-kb BAC/PAC Clones into Human Cells: Stable Extrachromosomal Persistence and Long-Term Ectopic Gene Activation,"" Hum. Gene Ther. 9:1863-1873, Mary Ann Liebert, Inc. (1998).;;Wilson, J.M., ""Vectors- shuttle vehicles for gene therapy,"" Clin. Exp. Immunol. 107 (Suppl. 1):31-32, Blackwell Science Ltd. (1997).;;Wohlgemuth, J.G., et al., ""Long-term gene expression from autonomously replicating vectors in mammalian cells,"" Gene Ther. 3:503-512, Stockton Press (1996).;;Wolf, H., et al., ""Epstein-Barr Virus and Its Interaction with the Host,"" Intervirology 35:26-39, S. Karger (1993).;;Yang, Y., et al., ""Cellular and Humoral Immune Response to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses,""J. Virol. 69:2004-2015, American Society for Microbiology (1995).;;Yang, X.W., et al., ""Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome,"" Biotechnol. 15:859-865, Nature Publishing Co. (1997).;;Yang, X.W., et al., ""BAC-mediated gene-dosage analysis reveals a role for Zirprol (Ru49/Zfp38) in progenitor cell proliferation in cerebellum and skin,"" Nat. Genet. 22:327-335, Nature Publishing Co. (1999).;;Yates, J.L., et al., ""Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells,"" Nature 313:812-815, Macmillan Journals Ltd. (1985).;;Yee, J.K., et al., ""Epitope insertion into the human hypoxanthine phosphoribosyltransferase protein and detection of the mutant protein by an anti-peptide antibody,"" Gene 53:97-104, Elsevier Science B.V. (1987).;;Zhang, J. and Russell, S.J., ""Vectors for cancer gene therapy,"" Canc. Metast. Rev. 15:385-401, Kluwer Academic Publishers (1996).;;Zhang, Y., et al., ""A new logic for DNA engineering using recombination in Escherichia coli,"" Nat. Genet. 20:123-128, Nature Publishing Co. (1998).",EXPIRED
37,AU,A,AU 2000/019151 A,115-152-315-867-921,2000-06-05,2000,AU 2000/019151 A,1999-11-17,US 10888198 P;;US 9927206 W,1998-11-17,A method of genetic vector delivery,,GEN HOSPITAL CORP;;ALKERMES INC,CHIOCCA E ANTONIO;;IKEDA KEIRO;;BARTUS RAYMOND T,,https://lens.org/115-152-315-867-921,Patent Application,no,0,0,3,3,0,A61K48/00;;A61P35/00,A61K48/00;;A61P35/00,,0,0,,,,DISCONTINUED
38,WO,A3,WO 2000/029033 A3,017-889-297-555-783,2000-10-05,2000,US 9927206 W,1999-11-17,US 10888198 P,1998-11-17,A METHOD OF GENETIC VECTOR DELIVERY,The invention relates to a method of administering a genetic vector to a target cell in a patient by immunosuppressing the patient and administering the genetic vector. The invention also relates to a method of administering a genetic vector to a target cell in a patient by administering a complement inhibitor and the genetic vector. The invention also relates to further administering a blood-organ barrier modifier.,GEN HOSPITAL CORP;;ALKERMES INC;;CHIOCCA E ANTONIO;;IKEDA KEIRO;;BARTUS RAYMOND T,CHIOCCA E ANTONIO;;IKEDA KEIRO;;BARTUS RAYMOND T,,https://lens.org/017-889-297-555-783,Search Report,yes,2,0,3,3,0,A61K48/00;;A61P35/00,A61K48/00;;A61P35/00,,7,6,011-123-942-708-168;;012-626-606-258-365;;043-489-467-510-132;;058-527-916-576-292;;039-790-799-566-253;;009-967-950-291-84X,10.1038/sj.gt.3300564;;9578838;;10.1016/s0165-2478(97)00049-7;;9232420;;10.1038/sj.gt.3300607;;9614578;;10.1006/exnr.1996.0156;;8812155;;7568227;;pmc40896;;10.1073/pnas.92.21.9829;;10.1038/11320;;10426310,"BOUVET M ET AL: ""Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide."", GENE THERAPY FEB., 1998, vol. 5, no. 2, February 1998 (1998-02-01), pages 189 - 195, XP000907596, ISSN: 0969-7128;;CHRIST MARIELLE ET AL: ""Gene therapy with recombinant adenovirus vectors: Evaluation of the host immune response."", IMMUNOLOGY LETTERS 1997, vol. 57, no. 1-3, 1997, pages 19 - 25, XP000907595, ISSN: 0165-2478;;ROLLINS SCOTT A ET AL: ""Protection of retroviral vector particles via complement inhibition: A novel strategy for in vivo gene therapy."", KEYSTONE SYMPOSIUM ON GENE THERAPY AND MOLECULAR MEDICINE;STEAMBOAT SPRINGS, COLORADO, USA; MARCH 26-APRIL 1, 1995, no. 21A, 1995, Journal of Cellular Biochemistry Supplement 1995, pages 413, XP002139447, ISSN: 0733-1959;;HOFMANN C ET AL: ""Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system."", GENE THERAPY APRIL, 1998, vol. 5, no. 4, April 1998 (1998-04-01), pages 531 - 536, XP000914540, ISSN: 0969-7128;;ELLIOTT PETER J ET AL: ""Unlocking the blood-brain barrier: A role for RMP-7 in brain tumor therapy."", EXPERIMENTAL NEUROLOGY 1996, vol. 141, no. 2, 1996, pages 214 - 224, XP000907588, ISSN: 0014-4886;;NILAVER: ""delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption"", PROC. NATL. ACAD SCI, vol. 92, 1995, pages 9829 - 9833, XP002139449;;IKEDA KEIRO ET AL: ""Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses."", NATURE MEDICINE AUG., 1999, vol. 5, no. 8, August 1999 (1999-08-01), pages 881 - 887, XP002139450, ISSN: 1078-8956",PENDING
39,US,A1,US 2002/0110543 A1,175-280-116-413-006,2002-08-15,2002,US 3521602 A,2002-01-04,US 3521602 A;;US 25969701 P;;US 28740401 P;;US 29425401 P;;US 33051101 P,2001-01-05,Viral delivery system for infectious transfer of large genomic DNA inserts,"
   The present invention relates to HSV-based amplicon vectors carrying a genomic DNA fragment, and methods of constructing and using the same. Included within the present invention is a method of converting any large capacity DNA cloning vector, such as a BAC or PAC, into an HSV amplicon or hybrid HSV amplicon using site-specific, or other types of recombination, so that genomic DNA inserts within the BAC or PAC clone can be delivered by infection to a cell, and efficiently expressed. The present invention also relates to a system for the rapid creation of viral vectors carrying transgenes of interest. This aspect of the invention is accomplished through recombination between: (a) a large-capacity cloning vector carrying a viral genome, and (b) a transfer vector containing the transgene of interest. Finally, an expression-ready genomic DNA library is disclosed. 
",GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;WADE-MARTINS RICHARD,GENERAL HOSPITAL CORPORATION THE (2002-01-02),https://lens.org/175-280-116-413-006,Patent Application,yes,20,19,3,3,0,A61K38/177;;A61K38/45;;A61K48/00;;C12N7/00;;C12N15/86;;C12N2710/10343;;C12N2710/16643;;C12N2800/108;;C12N2800/204;;C12N2800/206;;C12N2800/30;;C12N7/00;;C12N2800/30;;C12N2710/16643;;C12N2800/204;;A61K38/45;;C12N2800/206;;A61K38/177;;C12N15/86;;A61K48/00;;C12N2710/10343;;C12N2800/108,A61K35/76;;A61K38/17;;A61K38/45;;A61K48/00;;C12N15/861;;C12N15/869,424/93.2;;435/456,0,0,,,,EXPIRED
40,WO,A1,WO 2002/053576 A1,120-932-876-695-056,2002-07-11,2002,US 0200097 W,2002-01-04,US 25969701 P;;US 28740401 P;;US 29425401 P;;US 33051101 P,2001-01-05,VIRAL DELIVERY SYSTEM FOR INFECTIOUS TRANSFER OF LARGE GENOMIC DNA INSERTS,"The present invention relates to HSV-based amplicon vectors carrying a genomic DNA fragment, and methods of constructing and using the same. Included within the present invention is a method of converting any large capacity DNA cloning vector, such as a BAC or PAC, into an HSV amplicon or hybrid HSV amplicon using site-specific, or other types of recombination, so that genomic DNA inserts within the BAC or PAC clone can be delivered by infection to a cell, and efficiently expressed. The present invention also relates to a system for the rapid creation of viral vectors carrying transgenes of interest. This aspect of the invention is accomplished through recombination between: (a) a large-capacity cloning vector carrying a viral genome, and (b) a transfer vector containing the transgene of interest. Finally, an expression-ready genomic DNA library is disclosed.",GEN HOSPITAL CORP,CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;WADE-MARTINS RICHARD,,https://lens.org/120-932-876-695-056,Patent Application,yes,1,0,3,3,0,A61K38/177;;A61K38/45;;A61K48/00;;C12N7/00;;C12N15/86;;C12N2710/10343;;C12N2710/16643;;C12N2800/108;;C12N2800/204;;C12N2800/206;;C12N2800/30;;C12N7/00;;C12N2800/30;;C12N2710/16643;;C12N2800/204;;A61K38/45;;C12N2800/206;;A61K38/177;;C12N15/86;;A61K48/00;;C12N2710/10343;;C12N2800/108,A61K35/76;;A61K38/17;;A61K38/45;;A61K48/00;;C12N15/861;;C12N15/869,,3,3,079-869-700-012-027;;035-792-138-687-350;;012-119-157-251-611,10.1128/jvi.72.9.7137-7143.1998;;9696807;;pmc109935;;9405686;;pmc25110;;10.1073/pnas.94.26.14759;;10535985;;10.1073/pnas.96.22.12697;;pmc23055,"STAVROPOULOS, T.A. ET AL.: ""An enhanced packaging system for helper-dependent herpes simplex virus vectors"", J. VIROL., vol. 72, no. 9, September 1998 (1998-09-01), pages 7137 - 7143, XP002142149;;MESSERLE, M. ET AL.: ""Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome"", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 26, December 1997 (1997-12-01), pages 14759 - 14763, XP002086655;;SUTER, M. ET AL.: ""BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1"", PROC. NATL. ACAD. SCI. USA, vol. 92, no. 22, 26 October 1999 (1999-10-26), pages 12697 - 12702, XP002156799",PENDING
41,WO,A2,WO 2000/029033 A2,159-845-985-095-172,2000-05-25,2000,US 9927206 W,1999-11-17,US 10888198 P,1998-11-17,A METHOD OF GENETIC VECTOR DELIVERY,The invention relates to a method of administering a genetic vector to a target cell in a patient by immunosuppressing the patient and administering the genetic vector. The invention also relates to a method of administering a genetic vector to a target cell in a patient by administering a complement inhibitor and the genetic vector. The invention also relates to further administering a blood-organ barrier modifier.,GEN HOSPITAL CORP;;ALKERMES INC;;CHIOCCA E ANTONIO;;IKEDA KEIRO;;BARTUS RAYMOND T,CHIOCCA E ANTONIO;;IKEDA KEIRO;;BARTUS RAYMOND T,,https://lens.org/159-845-985-095-172,Patent Application,yes,0,13,3,3,0,A61K48/00;;A61P35/00,A61K48/00;;A61P35/00,,0,0,,,,PENDING
42,US,A1,US 2001/0031480 A1,161-079-087-197-021,2001-10-18,2001,US 75864401 A,2001-01-11,US 75864401 A;;US 17561600 P,2000-01-11,Three-dimensional cell growth assay,"
   The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics. 
",DEISBOECK THOMAS S.;;WRIGHT JOHN D.;;CHIOCCA E. ANTONIO,DEISBOECK THOMAS S;;WRIGHT JOHN D;;CHIOCCA E ANTONIO,GENERAL HOSPITAL CORPORATION THE (2001-05-01),https://lens.org/161-079-087-197-021,Patent Application,yes,5,7,4,4,0,C12M41/36;;C12M41/36;;C12M23/34;;C12M23/34,C12M1/12;;C12M1/34,435/40.5;;435/287.1,0,0,,,,EXPIRED
43,US,A1,US 2004/0029209 A1,034-017-747-998-417,2004-02-12,2004,US 36567703 A,2003-02-12,US 36567703 A;;US 75864401 A;;US 17561600 P,2000-01-11,Three-dimensional cell growth assay,"
   The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics. 
",GEN HOSPITAL CORP,DEISBOECK THOMAS S;;CHIOCCA E ANTONIO;;WRIGHT JOHN D,,https://lens.org/034-017-747-998-417,Patent Application,yes,20,1,4,4,0,C12M41/36;;C12M41/36;;C12M23/34;;C12M23/34,C12M1/12;;C12M1/34,435/29;;435/32,0,0,,,,EXPIRED
44,US,B2,US 6849424 B2,098-304-925-635-816,2005-02-01,2005,US 36567703 A,2003-02-12,US 36567703 A;;US 75864401 A;;US 17561600 P,2000-01-11,Three-dimensional cell growth assay,"The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics.",GEN HOSPITAL CORP,DEISBOECK THOMAS S;;CHIOCCA E ANTONIO;;WRIGHT JOHN D,,https://lens.org/098-304-925-635-816,Granted Patent,yes,5,0,4,4,0,C12M41/36;;C12M41/36;;C12M23/34;;C12M23/34,C12M1/12;;C12M1/34,435/29;;435/32,4,4,031-103-876-474-558;;015-628-130-754-918;;124-967-532-932-068;;026-995-240-553-547,903181;;10.1002/ijc.2910200120;;10.1097/00006123-199508000-00015;;10.1227/00006123-199508000-00015;;7477782;;10.1023/a:1005758626348;;9540052;;2722434,"Jörgen Carlsson, ""A Proliferation Gradient in Three-Dimensional Colonies of Cultured Human Glioma Cells,"" Int. J. Cancer, 20:129-136, 1977.;;Giese et al., ""Substrates for Astrocytoma Invasion,"" Neurosurgery, 37(2):294-302, 1995.;;Khoshyomn et al., ""Four-dimensional analysis of human brain tumor spheroid invasion into fetal rat brain aggregates using confocal scanning laser microscopy,"" J. of Neuro-Oncology, 38:1-10, 1998.;;Lillian A. Repesh, ""A New in vitro Assay for Quantitating Tumor Cell Invasion,"" Invasion Metatasis, 9:192-208, 1989.",EXPIRED
45,US,B2,US 6602701 B2,098-178-021-611-710,2003-08-05,2003,US 75864401 A,2001-01-11,US 75864401 A;;US 17561600 P,2000-01-11,Three-dimensional cell growth assay,"
    The invention relates to devices and methods for growing cells in vitro in an enclosed device that allows for a three-dimensional measurement over time of both their proliferative and/or invasive properties. By growing the cells in an enclosed matrix that resembles the environment that the cells confront in vivo, the cells can divide, invade, and form branched networks as they do in living tissue, e.g., in an individual. The devices of the invention include a test chamber in which cells, e.g., tumor cells, are placed and permitted to divide and/or invade. Cells can be placed within an insert within a chamber of the device. A delivery chamber that connects to the test chamber enables the delivery of agents that can be studied, e.g., for their therapeutic potential. The assay devices of the invention can be used as model systems to study cancer biology and to evaluate the efficacy of anti-cancer therapeutics. 
",GEN HOSPITAL CORP,DEISBOECK THOMAS S;;CHIOCCA E ANTONIO;;WRIGHT JOHN D,GENERAL HOSPITAL CORPORATION THE (2001-05-01),https://lens.org/098-178-021-611-710,Granted Patent,yes,5,9,4,4,0,C12M41/36;;C12M41/36;;C12M23/34;;C12M23/34,C12M1/12;;C12M1/34,435/288.2;;435/304.2;;422/102,4,4,031-103-876-474-558;;015-628-130-754-918;;124-967-532-932-068;;026-995-240-553-547,903181;;10.1002/ijc.2910200120;;10.1097/00006123-199508000-00015;;10.1227/00006123-199508000-00015;;7477782;;10.1023/a:1005758626348;;9540052;;2722434,"Jörgen Carlsson, ""A Proliferation Gradient in Three-Dimensional Colonies of Cultured Human Glioma Cells,"" Int. J. Cancer, 20:129-136, 1977.;;Giese et al., ""Substrates for Astrocytoma Invasion,"" Neurosurgery, 37(2):294-302, 1995.;;Khoshyomn et al., ""Four-dimensional analysis of human brain tumor spheroid invasion into fetal rat brain aggregates using confocal scanning laser microscopy,"" J. of Neuro-Oncology, 38:1-10, 1998.;;Lillian A. Repesh, ""A New in vitro Assay for Quantitating Tumor Cell Invasion,"" Invasion Metastasis, 9:192-208, 1989.",EXPIRED
46,US,B1,US 6544781 B1,140-110-720-797-032,2003-04-08,2003,US 61780000 A,2000-07-17,US 61780000 A;;US 14402199 P,1999-07-15,Non-defective Epstein-Barr viral vector,"
    The present invention relates to a viral vector system derived from Epstein-Barr Virus (EBV), where the transgene is effectively inserted into the EBV major internal repeat region (IR1) without adverse affect on EBV latent or lytic function. The vector of the invention can target and stably transform B-lymphocyte cells, both in culture and in vivo. 
",GEN HOSPITAL CORP,JIANG XIAOQUN;;CHIOCCA E ANTONIO;;KIEFF ELLIOTT;;WANG FRED;;HOCHBERG FRED,THE BRIGHAM & WOMEN'S HOSPITAL INC (1999-10-10);;THE GENERAL HOSPITAL CORPORATION (1999-08-18),https://lens.org/140-110-720-797-032,Granted Patent,yes,8,3,2,2,0,A61K48/00;;A61K48/00;;C12N15/86;;C12N15/86;;C12N2710/16243;;C12N2710/16243,A61K48/00;;C12N15/869,435/320.1;;435/325;;435/455;;514/44,40,40,019-810-335-711-889;;063-168-275-838-641;;009-416-320-508-847;;061-781-143-638-27X;;025-226-585-864-700;;083-366-647-068-936;;067-497-557-188-192;;015-585-302-194-72X;;049-870-597-924-772;;065-518-065-428-417;;016-742-447-932-634;;019-691-355-788-075;;029-114-817-824-206;;101-176-387-365-494;;002-512-736-644-602;;068-535-317-120-413;;082-543-948-205-314;;035-302-769-653-988;;105-535-664-850-074;;086-587-143-781-330;;020-514-470-353-526;;035-792-138-687-350;;069-756-981-474-282;;080-787-242-731-417;;031-284-697-047-425;;052-064-371-488-359;;020-654-753-299-413;;011-454-156-456-457;;091-974-420-276-457;;031-219-847-005-829;;115-548-282-815-500;;011-410-477-229-242;;024-533-020-155-927;;031-421-786-559-471;;139-442-068-301-221;;017-573-834-592-440;;046-494-293-077-046;;018-149-842-551-597;;118-752-949-246-084;;083-200-999-470-558,9579858;;8953314;;10.1089/hum.1996.7.18-2235;;9305836;;10.1038/38410;;10894261;;10.1002/(sici)1521-2254(200005/06)2:3<148::aid-jgm105>3.0.co;2-q;;10.1038/nm1295-1303;;7489413;;7954393;;8396947;;10.1038/nbt0598-444;;9592392;;7834628;;10.1128/jvi.44.1.286-294.1982;;pmc256264;;6292491;;pmc20961;;9653172;;10.1073/pnas.95.14.8245;;1655012;;8794366;;10.1128/jvi.70.10.7190-7197.1996;;pmc190772;;8607030;;10.1016/b978-012397570-6/50003-4;;10.1038/sj.gt.3300578;;9472550;;10.1007/978-1-4615-5357-1_16;;10026857;;9625252;;10.1089/hum.1998.9.8-1131;;9156804;;10.1128/jvi.67.8.4566-4579.1993;;pmc237841;;8392598;;2417242;;10.1073/pnas.83.2.399;;pmc322866;;9405686;;pmc25110;;10.1073/pnas.94.26.14759;;8137255;;10.1615/critrevtherdrugcarriersyst.v12.i4.10;;9501965;;10.1126/science.2660262;;2660262;;10.1089/hum.1998.9.8-1119;;9625250;;9470229;;10.1016/s0167-7799(97)01137-2;;8876136;;pmc38058;;10.1073/pnas.93.21.11334;;9874276;;10.1089/hum.1998.9.18-2787;;3460083;;pmc323897;;10.1073/pnas.83.14.5096;;9821275;;10.1016/s0958-1669(98)80032-3;;8794379;;10.1128/jvi.70.10.7260-7263.1996;;pmc190785;;pmc50007;;1528894;;10.1073/pnas.89.18.8794;;pmc387125;;3025831;;10.1073/pnas.83.24.9298;;10.1016/0006-2952(93)90310-s;;8484807;;10.1089/hum.1994.5.8-969;;7948146;;9930345;;10.1038/sj.gt.3300736;;9741425;;10.1089/hum.1998.9.13-1863;;9020933;;10.1007/bf00046349;;9034598,"Anderson, W.F., ""Human gene therapy,"" Nature 392:25-30, Nature Publishing Group (1998).;;Rogers, R.P. et al., ""Killing Epstein-Barr Virus-Positive B Lymphocytes by Gene Therapy: Comparing the Efficacy of Cytosine Deaminase and Herpes Simplex Virus Thymidine Kinase,"" Hum. Gene Ther. 7:2235-2245, Mary Ann Liebert, Inc. (1996).;;Verma, I.M. and Somia, N., ""Gene therapy-promises, problems, and prospects,"" Nature 389:239-242, Nature Publishing Group (1997).;;Aghi, M. et al., ""Prodrug activation enzymes in cancer gene therapy,"" J. Gene Med. 2:148-164 (2000).;;Banerjee, S. et al., ""Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein-Barr virus,"" Nature Med. 1:1303-1308 (1995).;;Boviatsis, E.J. et al., ""Long-Term Survival of Rats Harboring Brain Neoplasms Treated with Ganciclovir and a Herpes Simplex Virus Vector that Retains an Intact Thymidine Kinase Gene,"" Cancer Res. 54:5475-5751 (1994).;;Cachianes, G. et al., ""Epstein-Barr Virus-Derived Vectors for Transient and Stable Expression of Recombinant Proteins,"" BioTechniques 15:255-259 (1993).;;Chase, M. et al., ""An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,"" Nature Biotechnol. 16:444-448 (1998).;;Chen, L. and D.J. Waxman, ""Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphosphorines following Cytochrome P-450 Gene Transfer: Development of a Combined Chemotherapy/Cancer Gene Therapy Strategy,"" Cancer Res. 55:581-589 (1995).;;Cheung, A. and E. Kieff, ""Long Internal Direct Repeat in Epstein-Barr Virus DNA,"" J. Virology 44:286-294 (1982).;;Delecluse, H.-J. et al., ""Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells,"" Proc. Natl. Acad. Sci. USA 95:8245-8250 (Jul. 1998).;;Ezzeddine, Z.D. et al., ""Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase gene,"" New Biol. 3:608-614 (1991).;;Fraefel, C. et al., ""Helper Virus-Free Transfer of Herpes Simplex Virus Type 1 Plasmid Vectors into Neural Cells,"" J. Virology 70:7190-7197 (1996).;;Freeman, S.M. et al., ""In Situ Use of Suicide Genes for Cancer Therapy,"" Semin. Oncology 23:31-45 (1996).;;Glorioso, J.C. et al., ""Herpes Simplex Virus as a Gene-Delivery Vector for the Central Nervous System,"" in Viral Vectors, Gene Therapy and Neuroscience Applications, Kaplitt, M.G. and A.D. Loewy, eds., Academic Press, San Diege, CA, pp. 1-23 (1995).;;Jacoby, D.R. et al., ""Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes,"" Gene Ther. 4:1281-1283 (1997).;;Karle, P. et al., ""Intratumoral Injection of Encapsulated Cells Producing an Oxazaphosphorine Activating Cytochrome P450 for Targeted Chemotherapy,"" in Gene Therapy of Cancer, Walden et al., eds., Plenum Press, NY, pp. 97-106 (1998).;;Kenney, S. et al., ""Gene Therapy Strategies for Treating Epstein-Barr Virus-Associated Lymphomas: Comparison of Two Different Epstein-Barr Virus-Based Vectors,"" Human Gene Ther. 9:1131-1141 (May 1998).;;Lei, D.C. et al., ""Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells,"" Gene Ther. 3:427-436 (1996).;;Luckow, V.A. et al., ""Efficient Generation of Infectious Recombinant Baculoviruses by Site-Specific Transposon-Mediated Insertion of Foreign Genes into a Baculovirus Genome Propagated in Escherichia coli,"" J. Virology 67:4566-4579 (1993).;;McGarry, T.J. et al., ""Inhibition of heat shock protein synthesis by heat-inducible antisense RNA,"" Proc. Natl. Acad. Sci. USA 83:399-403 (1986).;;Messerle, M. et al., ""Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome,"" Proc. Natl. Acad. Sci. USA 94:14759-14763 (1997).;;Mullen, C.A. et al., ""Tumors Expressing the Cytosine Deaminase Suicide Gene Can Be Eliminated in Vivo with 5-Fluorocytosine and Induce Protective Immunity to Wild Type Tumor,"" Cancer Res. 54:1503-1506 (1994).;;Nakanishi, M. et al., ""Gene Introduction Into Animal Tissues,"" Crit. Rev. Therapeut. Drug Carrier Systems 12:263-310 (1995).;;O'Connor, M. et al., ""Construction of Large DNA Segments in Escherichia coli,"" Science 244:1307-1312 (1989).;;Paillard, F., ""Epstein-Barr Virus Vectors for the Treatment of Epstein-Barr Virus-Associated Cancers,"" Human Gene Ther. 9:1119-1120 (May 1998).;;Robbins, P.D. et al., ""Viral vectors for gene therapy,"" TIBTECH 16:35-40 (Jan. 1998).;;Robertson, E.S. et al., ""Epstein-Barr virus vectors for gene delivery to B lymphocytes,"" Proc. Natl. Acad. Sci. USA 93:11334-11340 (1996).;;Saeki, Y. et al., ""Herpes Simplex Virus Type 1 DNA Amplified as Bacterial Artificial Chromosome in Escherichia coli: Rescue of Replication-Competent Virus Progeny and Packaging of Amplicon Vectors,"" Hum. Gene Ther. 9:2787-2794 (Dec. 1998).;;Sample, J. et al., ""Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: A probable transcriptional initiation site,"" Proc. Natl. Acad. Sci. USA 83:5096-5100 (1986).;;Sclimenti, C.R. and M.P. Calos, ""Epstein-Barr virus vectors for gene expression and transfer,"" Curr. Opin. Biotechnol. 9:476-479 (Oct. 1998).;;Shimizu, N. et al., ""Clonal Propagation of Epstein-Barr Virus (EBV) Recombinants in EBV-Negative Akata Cells,"" J. Virology 70:7260-7263 (1996).;;Shizuya, H. et al., ""Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using a F-factor-based vector,"" Proc. Natl. Acad. Sci. USA 89:8794-8797 (1992).;;Speck, S.H. et al., ""An Epstein-Barr virus transcript from a latently infected, growth-transformed B-cell line encodes a highly repetitive polypeptide,"" Proc. Natl. Acad. Sci. USA 83:9298-9302 (1986).;;Weber, G.F. and D.J. Waxman, ""Activation of the Anti-Cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes,"" Biochem. Pharmacol. 45:1685-1694 (1993).;;Wei, M.X. et al., ""Experimental Tumor Therapy in mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene,"" Hum. Gene Ther. 5:969-978 (1994).;;Wendelburg, B.J. and J.-M.H. Vos, ""An enhanced EBNA1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells,"" Gene Therapy 5:1389-1399 (1998).;;Westphal, E.M. et al., ""A System for Shuttling 200-kb BAC/PAC Clones into Human Cells: Stable Extrachromosomal Persistence and Long-Term Ectopic Gene Activation,"" Human Gene Therapy 9:1863-1873 (Sep. 1998).;;Wilson, J.M., ""Vectors-shuttle vehicles for gene therapy,"" Clin. Exp. Immunol. 107(suppl):31-32 (1997).;;Zhang, J. and S.J. Russell, ""Vectors for cancer gene therapy,"" Cancer & Metastasis Rev. 15:385-401 (1996).",EXPIRED
47,WO,A1,WO 2001/005229 A1,192-301-716-737-481,2001-01-25,2001,US 0019306 W,2000-07-17,US 14402199 P,1999-07-15,NON-DEFECTIVE EPSTEIN-BARR VIRAL VECTOR,"The present invention relates to a viral vector system derived from Epstein-Barr Virus (EBV), where the transgene is effectively inserted into the EBV major internal repeat region (IR1) without adverse affect on EBV latent or lytic function. The vector of the invention can target and stably transform B-lymphocyte cells, both in culture and in vivo.",GEN HOSPITAL CORP;;BRIGHAM & WOMENS HOSPITAL;;JIANG XIAOQUN;;CHIOCCA E ANTONIO;;KIEFF ELLIOTT;;WANG FRED;;HOCHBERG FRED,JIANG XIAOQUN;;CHIOCCA E ANTONIO;;KIEFF ELLIOTT;;WANG FRED;;HOCHBERG FRED,,https://lens.org/192-301-716-737-481,Patent Application,yes,1,17,2,2,0,A61K48/00;;A61K48/00;;C12N15/86;;C12N15/86;;C12N2710/16243;;C12N2710/16243,A61K48/00;;C12N15/869,,4,4,082-543-948-205-314;;035-302-769-653-988;;046-494-293-077-046;;018-149-842-551-597,10.1007/978-1-4615-5357-1_16;;10026857;;9625252;;10.1089/hum.1998.9.8-1131;;9930345;;10.1038/sj.gt.3300736;;9741425;;10.1089/hum.1998.9.13-1863,"KARLE ET AL.: ""Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating P450 for targeted chemotherapy"", GENE THERAPY OF CANCER,, vol. 451, 1998, pages 97 - 106, XP002931317;;KENNEY ET AL.: ""Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-barr virus-based vectors"", HUMAN GENE THERAPY,, vol. 9, 20 May 1998 (1998-05-20), pages 1131 - 1141, XP002931316;;WENDELBURG ET AL.: ""An enhanced EBNA1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells"", GENE THERAPY,, vol. 5, 1998, pages 1389 - 1399, XP002931315;;WESTPHAL ET AL.: ""A system for shuttling 200-kb BAC/PAC clones into human cells: stable extrachromosomal persistence and long-term ectopic gene activation"", HUMAN GENE THERAPY,, vol. 9, 1 September 1998 (1998-09-01), pages 1863 - 1873, XP002931314",PENDING
48,DE,T3,DE 69532994 T3,071-112-225-721-506,2008-02-07,2008,DE 69532994 T,1995-08-15,US 29150094 A;;US 33052394 A;;US 9510365 W,1994-08-17,"VERWENDUNG EINES VON EINEM VIRALEN VEKTOR KODIERTEN CYTOCHROM P450 GENS, IN KOMBINATION MIT EINEM CHEMOTHERAPEUTISCHEN MITTEL, ZUR SELEKTIVEN ZERSTÖRUNG NEOPLASTISCHER ZELLEN","A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/071-112-225-721-506,Amended Patent,no,0,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N9/02;;C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N15/52;;C12N15/63;;C12N15/86,,0,0,,,,EXPIRED
49,DE,T2,DE 69532994 T2,001-719-638-623-658,2005-05-25,2005,DE 69532994 T,1995-08-15,US 29150094 A;;US 33052394 A;;US 9510365 W,1994-08-17,"VERWENDUNG EINES VON EINEM VIRALEN VEKTOR KODIERTEN CYTOCHROM P450 GENS, IN KOMBINATION MIT EINEM CHEMOTHERAPEUTISCHEN MITTEL, ZUR SELEKTIVEN ZERSTÖRUNG NEOPLASTISCHER ZELLEN","A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;BOSTON UNIVERSITY BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/001-719-638-623-658,Granted Patent,no,0,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02,,0,0,,,,EXPIRED
50,WO,A1,WO 1996/004789 A1,083-383-421-961-988,1996-02-22,1996,US 9510365 W,1995-08-15,US 29150094 A;;US 33052394 A,1994-08-17,A METHOD OF SELECTIVELY DESTROYING NEOPLASTIC CELLS,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/083-383-421-961-988,Patent Application,yes,0,14,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02;;C12N15/09,,5,5,073-685-885-892-301;;164-851-805-098-969;;080-476-437-936-318;;139-442-068-301-221;;009-272-992-175-141,1347590;;10.1016/0140-6736(92)90606-4;;10.1002/1097-0142(19920915)70:4+<1810::aid-cncr2820701624>3.0.co;2-3;;10.1126/science.1317968;;1317968;;10.1016/0006-2952(93)90310-s;;8484807;;7923173,"THE LANCET, Volume 339, issued 21 March 1992, GUTIERREZ et al., ""Gene Therapy for Cancer"", pages 715-721.;;CANCER (Supplement), Volume 70, Number 6, issued 15 September 1992, FRIEDMANN et al., ""Gene Therapy of Cancer Through Restoration of Tumor Suppressor Functions"", pages 1810-1818.;;SCIENCE, Volume 256, issued 12 June 1992, CULVER et al., ""In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors"", pages 1550-1552.;;BIOCHEMICAL PHARMACOLOGY, Volume 45, issued 1993, WEBER et al., ""Activation of the Anti-Cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes"", pages 1685-1694.;;CANCER RESEARCH, Volume 54, issued 15 October 1994, MANOME et al., ""Enhancer Sequences of the DF3 Gene Regulate Expression of the Herpes Simplex Virus Thymidine Kinase Gene and Confer Sensitivity of Human Breast Cancer Cells to Ganciclovir"", pages 5408-5413.",PATENTED
51,AT,T1,AT E266092 T1,096-616-556-498-835,2004-05-15,2004,AT 95929543 T,1995-08-15,US 29150094 A;;US 33052394 A;;US 9510365 W,1994-08-17,"VERWENDUNG EINES VON EINEM VIRALEN VEKTOR KODIERTEN CYTOCHROM P450 GENS, IN KOMBINATION MIT EINEM CHEMOTHERAPEUTISCHEN MITTEL, ZUR SELEKTIVEN ZERSTÖRUNG NEOPLASTISCHER ZELLEN","A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/096-616-556-498-835,Granted Patent,no,0,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02,,0,0,,,,PENDING
52,EP,A4,EP 0776161 A4,041-113-298-124-83X,1999-04-07,1999,EP 95929543 A,1995-08-15,US 9510365 W;;US 29150094 A;;US 33052394 A,1994-08-17,A METHOD OF SELECTIVELY DESTROYING NEOPLASTIC CELLS,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/041-113-298-124-83X,Search Report,no,2,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02,,2,2,017-573-834-592-440;;033-280-578-049-414,10.1089/hum.1994.5.8-969;;7948146;;8330360;;10.1093/carcin/14.7.1421,"WEI M X ET AL: ""EXPERIMENTAL TUMOR THERAPY IN MICE USING THE CYCLOPHOSPHAMIDE-ACTIVATING CYTOCHROME P450 2B1 GENE"", HUMAN GENE THERAPY, vol. 5, no. 8, August 1994 (1994-08-01), pages 969 - 978, XP002040463;;TIANO H F ET AL: ""RETROVRIAL MEDIATED EXPRESSION OF HUMAN CYTOCHROME P450 2A6 IN C3H/10T1/2 CELLS CONFERS TRANSFORMABILITY BY 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK)"", CARCINOGENESIS, vol. 14, no. 7, July 1993 (1993-07-01), pages 1421 - 1427, XP002040462",EXPIRED
53,US,A,US 5688773 A,169-301-167-539-496,1997-11-18,1997,US 33052394 A,1994-10-28,US 33052394 A;;US 29150094 A,1994-08-17,Method of selectively destroying neoplastic cells,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,BOSTON UNIVERSITY (1995-06-06);;GENERAL HOSPITAL CORPORATION THE (1995-01-31);;DANA-FARBER CANCER INSTITUTE (1995-06-06),https://lens.org/169-301-167-539-496,Granted Patent,yes,0,76,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;C12N15/09;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02,514/44;;424/93.1;;424/93.21;;435/172.3;;435/240.1;;435/240.2;;435/240.25;;435/320.1,99,85,048-530-059-021-552;;020-911-768-583-956;;106-386-562-055-571;;092-815-793-011-724;;073-685-885-892-301;;164-851-805-098-969;;080-476-437-936-318;;139-442-068-301-221;;009-272-992-175-141;;069-143-556-543-556;;044-417-500-326-42X;;077-592-655-457-833;;133-556-877-605-214;;017-148-816-748-803;;067-259-000-991-62X;;085-158-968-415-237;;030-794-145-737-923;;030-920-168-136-252;;055-953-481-364-727;;008-931-252-597-648;;006-337-451-089-406;;021-612-736-655-480;;040-261-462-285-781;;015-032-663-524-878;;067-860-940-124-777;;009-824-145-561-618;;098-557-060-207-307;;027-435-622-442-317;;013-964-801-683-699;;069-981-066-527-898;;045-962-320-146-915;;057-820-800-008-37X;;037-401-867-644-969;;023-885-708-943-06X;;006-736-105-492-604;;079-914-030-799-675;;081-388-049-836-987;;005-875-631-950-867;;034-830-908-616-814;;018-024-066-836-75X;;057-490-251-759-365;;087-982-142-180-097;;007-762-686-010-84X;;150-226-324-388-605;;014-107-916-561-843;;140-325-954-606-161;;142-077-331-209-912;;080-476-437-936-318;;000-230-315-925-387;;020-179-506-154-209;;094-454-444-717-667;;049-839-122-312-830;;091-751-031-967-731;;087-879-787-031-413;;121-624-233-852-021;;009-797-632-957-766;;019-691-355-788-075;;084-231-315-309-498;;046-748-437-273-335;;053-869-135-364-674;;062-802-698-341-513;;113-651-591-024-609;;097-031-033-739-268;;021-123-645-824-632;;083-786-091-950-747;;011-625-718-457-157;;131-010-333-758-346;;041-604-753-881-477;;096-826-527-607-030;;048-286-798-016-050;;031-818-712-694-764;;161-592-702-535-465;;015-368-624-035-157;;011-150-739-719-041;;020-823-192-972-19X;;011-382-405-870-481;;066-683-018-891-703;;023-959-787-852-017;;046-903-338-865-084;;096-670-534-321-307;;098-483-195-240-041;;073-307-121-263-419;;040-630-404-484-177;;054-483-590-622-262;;079-943-516-872-898,7652552;;10.1126/science.7652552;;10.1016/0168-9525(94)90095-7;;8036720;;7781922;;10.1096/fasebj.9.2.7781922;;10.1016/s0140-6736(95)92467-1;;7490986;;1347590;;10.1016/0140-6736(92)90606-4;;10.1002/1097-0142(19920915)70:4+<1810::aid-cncr2820701624>3.0.co;2-3;;10.1126/science.1317968;;1317968;;10.1016/0006-2952(93)90310-s;;8484807;;7923173;;10.1016/0014-4827(74)90142-6;;4857160;;10.1016/0378-1119(90)90006-d;;2197186;;3664493;;10.1016/s0065-230x(08)60900-8;;92181;;2144057;;10.1126/science.2144057;;pmc43782;;10.1073/pnas.91.10.4348;;8183911;;10.1016/0378-1119(90)90292-y;;2323577;;4703128;;10.1001/jama.1912.04260050113010;;10.1126/science.161.3839.370;;4873531;;4323142;;10.3171/jns.1971.34.3.0310;;10.1007/bf00199936;;3164257;;2699511;;4559710;;10.1016/0006-8993(72)90398-8;;10.1111/j.1601-5223.1984.tb00455.x;;6490389;;3335011;;2733785;;10.1038/339538a0;;10.1089/hum.1994.5.2-183;;8186298;;10.1007/bf02935741;;10.1007/978-1-4612-4604-6_12;;3077063;;10.3171/jns.1994.80.2.0283;;8283268;;6294260;;10.3171/jns.1983.58.2.0159;;pmc47282;;10.1073/pnas.90.17.8033;;8396259;;10.1016/0168-9525(89)90029-2;;2660363;;10.1073/pnas.90.15.7024;;8346212;;pmc47068;;10.1146/annurev.neuro.12.1.47;;10.1146/annurev.ne.12.030189.000403;;2648957;;10.1385/0-89603-140-3:177;;8495410;;8242617;;10.1006/abbi.1994.1259;;8203907;;2938288;;10.1016/0090-3019(86)90080-7;;2706622;;10.1126/science.3018926;;3018926;;2543985;;pmc287348;;10.1073/pnas.86.12.4736;;7049370;;pmc391921;;6093098;;10.1073/pnas.81.20.6349;;3005858;;10.1056/nejm198603133141105;;3005859;;10.1056/nejm198603203141205;;10.1016/0006-2952(79)90222-3;;475846;;10.1126/science.1317968;;1317968;;10.1073/pnas.85.17.6460;;3413107;;pmc281992;;10.1016/0006-8993(70)90026-0;;5433105;;10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t;;3179928;;2272335;;pmc1568032;;10.1289/ehp.908863;;3137560;;pmc281846;;10.1073/pnas.85.16.5769;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;pmc298021;;10.1073/pnas.86.18.7186;;2571151;;10.1093/jac/12.suppl_b.9;;6313600;;1655012;;10.1016/0896-6273(88)90175-4;;2856096;;8221662;;3698009;;2317829;;10.1126/science.2660259;;2660259;;2306744;;214430;;10.1016/s0021-9258(17)34236-9;;10.1016/0306-4522(87)90159-x;;3325854;;2200845;;10.1099/00221287-136-6-1125;;2123742;;10.1093/nar/16.12.5690;;2838826;;pmc336797;;2843986;;10.1126/science.2843986;;pmc2581874;;10.1126/science.241.4873.1667;;2153970;;pmc53428;;10.1073/pnas.87.3.1149;;2245487;;10.1007/bf00689268;;3551938;;pmc7161754;;10.1002/bies.950050605;;10.1016/0360-3016(85)90152-x;;3882642;;pmc282185;;3174639;;10.1073/pnas.85.19.7356;;10.1021/tx00022a001;;1912325;;7260917;;10.3171/jns.1987.67.6.0864;;3316532;;2555447;;10.1002/jmv.1890290103;;2352944;;pmc54184;;10.1073/pnas.87.12.4697;;10.1073/pnas.86.8.2698;;2539597;;pmc286985;;8487757;;10.1007/bf00926090;;3028054;;10.1016/0065-2571(86)90010-5;;1673381;;12106111;;10.1111/j.1460-9568.1990.tb00389.x;;10.1126/science.3201247;;3201247,"Marshall, Science 269:1050 1055, 1995.;;Culver et al., Trends Genetics, 10(5):174 178, 1994.;;Miller et al., FASEB Journal, 9;190 199, 1995.;;Hodgson et al., Exp. Opin. Ther. Pat. 5(5):459 468, 1995.;;Orkin et al. Report and Recommendations . . . Dec. 7, 1995, 1 40.;;LaFont et al., Lancet 346:1442 1443, 1995.;;Gutierrez et al, Gene Therapy for Cancer, The Lancet, vol. 339: Mar. 21, 1992 pp. 715 721.;;Friedmann, T., Gene Therapy of Cancer Through Restoration of Tumor Suppressor Functions, Cancer, vol. (6) 70, Sep. 15, 1992.;;Culver et al, Science, vol. 256, 12, Jun. 1992 pp. 1550 1552.;;Weber et al, Biochemical Pharmacology, vol. 45, 1993 pp. 1685 1694.;;Manome et al, Cancer Research, 54, 5408 5413 Oct. 15, 1994.;;Amano et al., High Activity of Choline Acetyltransferase Induced in Neuroblastoma x Glia Hybrid Cells, Exp. Cell Res. 85:399 408 (1974).;;Angier, N. Tumor Treatment Showing Promise, N.Y. Times, National Edition, p. B11 (Sep. 8, 1993).;;Araki et al., The Essential Region for Assembly and Particle Formation in Hepatitis B Virus Surface Antigen Produced in Yeast Cells, Gene 89:195 201 (1990).;;Arndt et al., Intrathecal Administration of 4 Hydroperoxycyclophosphamide in Rhesus Monkeys, Cancer Res. 47:5932 5934 (1987).;;Austin, F.C. and Boone, C.W., Virus Augmentation of the Antigenicity of Tumor Cell Extracts, Adv. Cancer Res. 30:301 345 (1979).;;Baker et al., Suppression of Human Colorectal Carcinoma Cell Growth by Wild Type p53, Science 249:912 915 (1990).;;Barba et al., Development of anti tumor immunity following thymididine kinase mediated killing of experimental brain tumors, PNAS USA 91:4348 4352 (1994).;;Barker et al., Cloning and Sequence Analysis of the Human Gene Encoding Eosinophil Major Basic Protein, Gene 86:285 289 (1990).;;Barker et al., Development of an Animal Brain Tumor Model and Its Response to Therapy with 1,3 Bis(2 chlorethyl 1 nitrosourea, Cancer Res. 33:976 983 (1973).;;Beerman, W.F., Meningeal Carcinomatosis, JAMA 58(19):1437 1439 (1912).;;Benda et al., Differentiated Rat Glial Cell Strain in Tissue Culture, Science 161:370 371 (1968).;;Benda et al., Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture, J. Neurosurg. 34:310 323 (1971).;;Bennett, J.E., Antimicrobial Agents: Antifungal Agents, in: Goodman and Gilman s The Pharmacological Basis of Therapeutics, Gilman et al., eds., vol. 8, Pergamon Press: NY, NY, pp. 1165 1181 (1990).;;Berends et al., The Detection of Virally Induced Tumors by 131 I and 125 I Labeled Syngeneic Monoclonal Antibodies, Cancer Immunol. Immunother. 26:243 249 (1988).;;Bernstein, A. and Breitman, M., Genetic Ablation in Transgenic Mice, Mol. Biol. Med. 6:523 530 (1989).;;Bignami et al., Localization of the Glial Fibrillary Acidic Protein in Astrocytes by Immunofluorescence, Brain Res. 43:429 435 (1972).;;Bigner et al. Patterns of the Early, Gross Chromosomal Changes in Malignant Human Gliomas, Hereditas 101:103 113 (1984).;;Bigner et al., Specific Chromosomal Abnormalities in Malignant Human Gliomas, Cancer Res. 88:405 411 (1988).;;Borrelli et al., Transgenic Mice with Inducible Dwarfism, Nature 339:538 541 (1989).;;Boviatsis et al., Gene Transfer into Experimental Brain Tumors Mediated by Adenovirus, Herpes Simplex Virus, and Retrovirus Vectors, Human Gene Ther. 5:183 191 (1994).;;Breakefield, X.O. and Geller, A.I., Gene Transfer into the Nervous System, Molec. Neurobiol. 1:339 371 (1987).;;Brem et al., Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain, J. Neurosurg. 80:283 290 (1994).;;Burger et al., Computerized tomographic and pathologic studies of the untreated quiescent, and recurrent glioblastoma multiforme, J. Neurosurg. 58:159 169 (1983).;;Burns et al., Vesicular Stomatitis Virus G Glycoprotein Pseudotyped Retroviral Vectors: Concentration to Very High Titer and Efficient Gene Transfer Into Mammalian and Nonmammalian Cells, PNAS USA 90:8033 8037 (1993).;;Capecchi, M.R., The New Mouse Genetics: Altering the Genome by Gene Targeting, TIG 5(3):70 76 (1989).;;Caruso et al., Regression of Established Macroscopic Liver Metastases After In Situ Transduction of a Suicide Gene, PNAS USA 90:7024 7028 (1993).;;Cepko, C., Immortalization of Neural Cells via Retrovirus Mediated Oncogene Transduction, Ann. Rev. Neurosci. 12:47 65 (1989).;;Cepko, C., Lineage Analysis and Immortalization of Neural Cells via Retrovirus Vectors, in: Neuromethods, vol. 16, Molecular Neurobiological Techniques, Bolton et al., eds., Clifton, NJ, Humana, pp. 177 219 (1989).;;Cepko et al., Preparation of a Specific Retrovirus Producer Cell Line, in: Current Protocols in Molec. Biol., Ausubel et al., eds., Wiley and Sons, NY, pp. 9.11.1 9.11.12 (1992).;;Chana, T.K.H. and Waxman, D.J., Cyclophosphamide Modulates Rat Hepatic Cytochrome P450 2C11 and Steroid 5 Reductase Activity and Messenger RNA Levels through the Combined Action of Acrolein and Phosphoramide Mustard, Cancer Res. 53:2490 2497 (1993).;;Chang et al., Differential Activation of Cyclophosphamide and Ifosphamide by Cytochromes P 450 2B and 3A in Human Liver Microsomes, Cancer Res. 53:5629 5637 (1993).;;Chang et al., Evaluation of Triacetyloleandomycin, Naphthoflavone and Diethyldithiocarbamate as Selective Chemical Probes for Inhibition of Human Cytochromes P450, Arch. Biochem. Biophys. 311(2):437 442 (1994).;;Cheng et al., Photoradiation Therapy: Current Status and Applications in the Treatment of Brain Tumors, Surg. Neurol. 25:423 435 (1986).;;Chiocca et al., Virus Mediated Genetic Treatment of Rodent Gliomas, in: Gene Therapeutics, Wolff, J.A., ed., Birkhauser Publ., Boston, MA, pp. 245 262 (1994).;;Clarke, L. and Waxman, D.J., Oxidative Metabolism of Cyclophosphamide: Identification of the Hepatic Monooxygenase Catalysts of Drug Activation, Cancer Res. 49:2344 2350 (1989).;;Coen et al., A Genetic Approach to Promoter Recognition During trans Induction of Viral Gene Expression, Science 234:53 59 (1986).;;Coen et al., Thymidine Kinase Negative Herpes Simplex Virus Mutants Establish Latency in Mouse Trigeminal Ganglia but do not Reactivate, PNAS USA 86:4736 4740 (1989).;;Colvin, M., Alkylating Agents and Platinum Antitumor Compounds, in: Cancer Medicine, Holland et al., eds., Lea and Febiger, Philadelphia, PA, pp. 733 754 (1993).;;Colvin, M. and Hilton, J. Pharmacology of Cyclophosphamide and Metabolites, Cancer Treat. Rep. 65 (Suppl. 3):89 95 (1981).;;Cone, R.D. and Mulligan, R.C., High efficiency gene transfer into mammalian cells: Generation of helper free recombinant retrovirus with broad mammalian host range, PNAS USA 81:6349 6353 (1984).;;Corey et al., Infections With Herpes Simplex Viruses, Part I, New Engl. J. Med. 314(11):686 691 (1986).;;Corey et, al., Infections With Herpes Simplex Viruses, Part II, New Engl. J. Med. 314(12):749 757 (1986).;;Cox, P.J., Cyclophosphamide Cystitis Identification of Acrolein as the Causative Agent, Biochem. Pharmacol. 28:2045 2049 (1979).;;Culver et al., In Vivo Gene Transfer with Retroviral Vector Producer Cells for Treatment of Experimental Brain Tumors, Science 256:1550 1552 (1992).;;Danos, O. and Mulligan, R.C., Safe and Efficient Generation of Recombinant Retroviruses with Amphotropic and Ecotropic Host Ranges, PNAS USA 85:6460 6464 (1988).;;Das, G.D. and Altman, J., Postnatal neurogenesis in the caudate nucleus and nucleus accumbens septi in the rat, Brain Res. 21:122 127 (1970).;;Daumas DuDort et al. Grading of Astrocytomas, A Simple and Reproducible Method, Cancer 62(10):2152 2165 (1988).;;Doehmer et al., Genetically Engineered V79 Chinese Hamster Cells Metabolically Activate the Cytostatic Drugs Cyclophosphamide and Ifosfamide, Environ. Health Perspectives 88:63 65 (1990).;;Doehmer et al., Stable expression of rat cytochrome P 450IIB1 cDNA in Chinese hamster cells (V79) and metabolic activation of aflotoxin B 1 , PNAS USA 85:5769 5773 (1988).;;Dranoff et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte macrophage colony stimulating factor stimulates potent, specific, and long lasting anti tumor immunity, PNAS USA 90:3539 3543 (1993).;;El Azouzi et al., Loss of Distinct Regions on the Short Arm of Chromosome 17 Associated with Tumorigenesis of Human Astrocytomas, PNAS USA 86:7186 7190 (1989).;;Elion, G.B., The biochemistry and mechanism of action of acyclovir, J. Antimicrob. Chemother. 12, Suppl. B:9 17 (1983).;;Ezzedine et al., Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase Gene, New Biologist 3(6):608 614 (1991).;;Ezzedine et al., Selective Killing of Rat C6 Glioma Cells Following Retrovirus Mediated Transfer of the Herpes Simplex Virus Thymidine Kinase Gene, Soc. Neurosci. Abstr. 16:Part 1, Abstract 189.3 (1990).;;Frederiksen et al., Immortalization of Precursor Cells from the Mammalian CNS, Neuron 1:439 448 (1988).;;Freeman et al., The Bystander Effect : Tumor Regression When a Fraction of the Tumor Mass Is Genetically Modified, Cancer Res. 53:5274 5283 (1993).;;Freeman et al., Tumor Regression when a Fraction of the Tumor Mass Contains the HSV TK Gene, J Cell Biochem. 16F:47 Abstract No. V 209 (1992).;;Friedman et al., Experimental Chemotherapy of Human Medulloblastoma with Classical Alkylators, Cancer Res. 46:2827 2833 (1986).;;Friedman et al., Glutathione Protects Cardiac and Skeletal Muscle from Cyclophospamide induced Toxicity, Cancer Res. 50:2455 2462 (1990).;;Friedman et al., Phase I trial of intrathecal 4 hydroperoxycyclophosphamide for neoplastic meningitis, Proc. Amer. Assoc. Cancer Res. 34:269 Abstract No. 1598 (1993).;;Friedmann, T., Progress Toward Human Gene Therapy, Science 244:1275 1281 (1989).;;Fuchs et al., Activity of Intrathecal 4 Hydroperoxycyclophosphamide in a Nude Rat Model of Human Neoplastic Meningitis, Cancer Res. 50:1954 1959 (1990).;;Fyfe et al., Thymidine Kinase from Herpes Simplex Virus Phosphorylates the New Antiviral Compound, 9 (2 Hydroxyethoxymethyl)guanine, J. Biol. Chem. 253(24):8721 8727 (1978).;;Gage et al., Grafting Genetically Modified Cells to the Brain: Possibilities for the Future, Neuroscience 23(3):795 807 (1987).;;Gannon, V.P.J., Molecular Cloning and Nucleotide Sequence of Another Variant of the Escherichia coli Shiga like Toxin II Family, J. General Microbiol. 136:1125 1135 (1990).;;Gansbacher et al., Retroviral Vector mediated Interferon Gene Transfer into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity, Cancer Res. 50:7820 7825 (1990).;;Geller, A.I., A New Method to Propagate Defective HSV 1 Vectors, Nucl. Acids Res. 16(12):5690 (1988).;;Geller, A.I. and Breakefield, X.O., A Defective HSV 1 Vector Expresses Escherichia coli Galactosidase in Cultured Peripheral Neurons, Science 241:1667 1669 (1988).;;Geller, A.I. and Freese, A., Infection of Cultured Central Nervous System Neurons with a Defective Herpes Simplex Virus 1 Vector Results in Stable Expression of Escherichia coli Galactosidase, PNAS USA 87:1149 1153 (1990).;;Genka et al., Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat, Cancer Chemother. Pharmacol. 27:1 7 (1990).;;Gilboa. E., Retroviral Gene Transfer: Applications to Human Therapy, in: Biology of Hematopoiesis, Wiley Liss, Inc., pp. 301 311 (1990).;;Gilboa, E., Retrovirus Vectors and their Uses in Molecular Biology, BioEssays 5(6):252 257 (1987).;;Gilboa et al., Transfer and Expression of Cloned Genes Using Retroviral Vectors, Biotechniques 4(6):504 512 (1986).;;Glatstein et al., The Imaging Revolution and Radiation Oncology: Use of CT, Ultrasound, and NMR for Localization, Treatment Planning and Treatment Delivery, Intl. J. Radiation Oncology Biol. Phys. 11(2):299 314 (1985).;;Gray et al., Radial Arrangement of Clonally Related Cells in the Chicken Optic Tectum: Lineage Analysis with a Recombinant Retrovirus, PNAS USA 85:7356 7360 (1988).;;Guengerich, F.P., Oxidation of Toxic and Carcinogenic Chemicals by Human Cytochrome P 450 Enzymes, Chem. Res. Toxicol. 4(4):391 407 (1991).;;Gurtoo et al., Role of Glutathione in the Metabolism dependent Toxicity and Chemotherapy of Cyclophosphamide, Cancer Res. 41:3584 3591 (1981).;;Gutin et al., Recurrent Malignant Gliomas: Survival Following Interstitial Brachytherapy with High Activity Iodine 125 Sources, J. Neurosurg. 67:864 873 (1987).;;Hanada et al., Combined Effects of Acyclovir and Human Interferon on Herpes Simplex Virus Replication in Cultured Neural Cells, J. Med. Virol. 29:7 12 (1989).;;Hatton, J.D., Migration of Grafted Neonatal Astrocytes in Neonatal and Adult Hosts, Soc. Neurosci. Abstr. 15(2):1369 Abstract No. 539.8 (1989).;;Heimbrook et al., Transforming Growth Factor Pseudomonas Exotoxin Fusion Protein Prolongs Survival of Nude Mice Bearing Tumor Xenografts, PNAS USA 87:4697 4701 (1990).;;Henson, J.W. and Posner, J.B., Neurological Complications, in: Cancer Medicine, Holland et al., eds., Lea and Febiger, Philadelphia, PA, pp. 2268 2286 (1993).;;Heyman et al., Thymidine kinase obliteration: Creation of transgenic mice with controlled immune deficiency, PNAS USA 86:2698 2702 (1989).;;Hodgson et al., Expression analysis of the mixed function oxidase system in rat brain by the polymerase chain reaction, Mol. Cell Biochem. 120:171 179 (1993).;;Hohorst et al., The Enzymatic Basis of Cyclophosphamide Specificity, Adv. Enzyme Regul. 25:99 122 (1986).;;Hong et al., Pharmacokinetics of 4 Hydroxycyclophosphamide and Metabolites in the Rat, Drug Metab. Dispos. 19(1): 1 7 (1991).;;Horellou et al., Behavioural Effect of Engineered Cells that Synthesize L DOPA or Dopamine after Grafting into the Rat Neostriatum, Eur. J. Neurosci. 2:116 119 (1990).;;Huang et al., Suppression of the Neoplastic Phenotype by Replacement of the RB Gene in Human Cancer Cells, Science 242:1563 1566 (1988).",EXPIRED
54,CA,C,CA 2197677 C,109-209-337-432-870,2009-03-10,2009,CA 2197677 A,1995-08-15,US 29150094 A;;US 33052394 A;;US 9510365 W,1994-08-17,A METHOD OF SELECTIVELY DESTROYING NEOPLASTIC CELLS,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targe ts the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",DANA FARBER CANCER INST INC;;GEN HOSPITAL CORP;;UNIV BOSTON,WAXMAN DAVID J;;CHEN LING;;WEI MING X;;BREAKEFIELD XANDRA O;;CHIOCCA E ANTONIO,,https://lens.org/109-209-337-432-870,Granted Patent,no,0,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,A61K48/00;;C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N7/01;;C12N9/02;;C12N15/86,,0,0,,,,EXPIRED
55,EP,B1,EP 0776161 B1,157-686-908-002-958,2004-05-06,2004,EP 95929543 A,1995-08-15,US 9510365 W;;US 29150094 A;;US 33052394 A,1994-08-17,USE OF A VIRAL VECTOR ENCODING A CYTOCHROME P450 GENE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR SELECTIVELY DESTROYING NEOPLASTIC CELLS,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/157-686-908-002-958,Granted Patent,yes,2,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02,,7,0,,,"WEI M X ET AL: ""EXPERIMENTAL TUMOR THERAPY IN MICE USING THE CYCLOPHOSPHAMIDE-ACTIVATING CYTOCHROME P450 2B1 GENE"" HUMAN GENE THERAPY, vol. 5, no. 8, August 1994, pages 969-978, XP002040463;;TIANO H F ET AL: ""RETROVRIAL MEDIATED EXPRESSION OF HUMAN CYTOCHROME P450 2A6 IN C3H/10T1/2 CELLS CONFERS TRANSFORMABILITY BY 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTA NONE (NNK)"" CARCINOGENESIS, vol. 14, no. 7, July 1993, pages 1421-1427, XP002040462;;THE LANCET, Volume 339, issued 21 March 1992, GUTIERREZ et al., ""Gene Therapy for Cancer"", pages 715-721.;;CANCER (Supplement), Volume 70, Number 6, issued 15 September 1992, FRIEDMANN et al., ""Gene Therapy of Cancer Through Restoration of Tumor Suppressor Functions"", pages 1810-1818.;;SCIENCE, Volume 256, issued 12 June 1992, CULVER et al., ""In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors"", pages 1550-1552.;;BIOCHEMICAL PHARMACOLOGY, Volume 45, issued 1993, WEBER et al., ""Activation of the Anti-Cancer Drug Ifosphamide by Rat Liver Microsomal P450 Enzymes"", pages 1685-1694.;;CANCER RESEARCH, Volume 54, issued 15 October 1994, MANOME et al., ""Enhancer Sequences of the DF3 Gene Regulate Expression of the Herpes Simplex Virus Thymidine Kinase Gene and Confer Sensitivity of Human Breast Cancer Cells to Ganciclovir"", pages 5408-5413.",EXPIRED
56,CA,A1,CA 2197677 A1,002-712-726-399-961,1996-02-22,1996,CA 2197677 A,1995-08-15,US 29150094 A;;US 33052394 A;;US 9510365 W,1994-08-17,A METHOD OF SELECTIVELY DESTROYING NEOPLASTIC CELLS,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/002-712-726-399-961,Patent Application,no,0,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02,,0,0,,,,EXPIRED
57,EP,B2,EP 0776161 B2,150-535-600-777-455,2007-09-12,2007,EP 95929543 A,1995-08-15,US 9510365 W;;US 29150094 A;;US 33052394 A,1994-08-17,USE OF A VIRAL VECTOR ENCODING A CYTOCHROME P450 GENE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR SELECTIVELY DESTROYING NEOPLASTIC CELLS,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/150-535-600-777-455,Granted Patent,yes,1,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N9/02;;C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N15/52;;C12N15/63;;C12N15/86,,16,8,012-814-814-668-025;;001-822-263-537-686;;033-280-578-049-414;;068-130-872-335-901;;020-911-768-583-956;;031-118-187-392-620;;049-870-597-924-772;;055-507-394-428-526,5061308;;1654555;;10.1073/pnas.88.18.8039;;pmc52441;;8330360;;10.1093/carcin/14.7.1421;;7654455;;10.1016/0959-8049(94)90482-0;;10.1016/0168-9525(94)90095-7;;8036720;;7543006;;7834628;;2473464;;10.1016/1043-6618(89)90235-1,"Sladek, Cancer Research, 32 (1972), pp. 535-542;;Huber, Proc. Natl. Acad. Sci. USA, 88 (1991), pp. 8039-8043;;Tiano, Carcinogenesis, 14(7) (1993), pp. 1421-1427;;Blaese, European Journal of Cancer, 30A, 8 (1994), pp. 1190-1193;;Culver, TIG, 10, 5 (May, 1994), pp. 174-178;;Wei, Human Gene Therapy, 5, abstract, PubMed Meline, August 1, 1994;;Wei, Conference Abstract, Gene Therapy, Cold Spring Harbour, New York, September 21-25, 1994;;Chen, Ernst Schering Research Foundation Workshop, 13, Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research, pp. 57-80, October, 1994;;Moolten, Cancer Gene Therapy, 1, 4, pp. 279-287; December, 1994;;Chen, Cancer Research, 55, pp. 581-589; February 1, 1995;;PubMed help manual;;PubMed Abstracts (1994 to 1997);;Library of Congress online catalogue;;Strobel et al., Pharmacol Res., 1989 Mar-Apr; 21(2):169-75;;E-mails to Bernstein (publisher);;Chen, Ernst Schering Research Foundation Workshop, 13, Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research; Preface, Table of Contents, List of contrubutors, Index, pp. i-xv; October, 1994",EXPIRED
58,US,A1,US 2021/0369837 A1,006-083-760-071-923,2021-12-02,2021,US 201716336207 A,2017-09-26,US 201716336207 A;;US 201662399976 P;;US 2017/0053496 W,2016-09-26,METHODS OF TREATING TIM-3 ELEVATION,The present disclosure provides formulations and therapies for treating subjects with elevated levels of TIM-3 using gene-based cytotoxic immunostimulant therapy alone or with other immunotherapies.,ADVANTAGENE INC;;CANDEL THERAPEUTICS INC,AGUILAR-CORDOVA ESTUARDO;;AGUILAR LAURA KAYE;;CHIOCCA ANTONIO E;;GUZIK BRIAN;;LAWLER SEAN;;SPERANZA MARIA CARMELLA,CANDEL THERAPEUTICS INC (2021-02-01);;THE BRIGHAM AND WOMEN'S HOSPITAL INC (2021-01-28),https://lens.org/006-083-760-071-923,Patent Application,yes,0,0,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K39/245;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/19;;A61K38/20;;A61K38/21;;A61K39/39;;A61K39/395;;A61P35/00,,0,0,,,,DISCONTINUED
59,EP,A1,EP 3515486 A1,008-516-616-075-253,2019-07-31,2019,EP 17854134 A,2017-09-26,US 201662399976 P;;US 2017/0053496 W,2016-09-26,METHODS OF TREATING TIM-3 ELEVATION,,ADVANTAGENE INC,AGUILAR-CORDOVA ESTUARDO;;GUZIK BRIAN;;AGUILAR LAURA KAYE;;CHIOCCA ANTONIO E;;LAWLER SEAN;;SPERANZA MARIA CARMELLA,"CANDEL THERAPEUTICS, INC. (2021-08-04)",https://lens.org/008-516-616-075-253,Patent Application,yes,0,0,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K39/39;;A61K39/395;;A61P35/00,,0,0,,,,DISCONTINUED
60,CN,A,CN 109937051 A,023-666-874-844-796,2019-06-25,2019,CN 201780069200 A,2017-09-26,US 201662399976 P;;US 2017/0053496 W,2016-09-26,METHODS OF TREATING TIM-3 ELEVATION,The present disclosure provides formulations and therapies for treating subjects with elevated levels of TIM-3 using gene -based cytotoxic immunostimulant therapy alone or with other immunotherapies.,ADVANTAGENE INC,AGUILAR-CORDOVA ESTUARDO;;GUZIK BRIAN;;AGUILAR LAURA KAYE;;CHIOCCA ANTONIO E;;LAWLER SEAN;;SPERANZA MARIA CARMELLA,,https://lens.org/023-666-874-844-796,Patent Application,no,5,0,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K39/39;;A61K39/395;;A61P35/00,,0,0,,,,DISCONTINUED
61,KR,A,KR 20190059304 A,152-588-738-843-12X,2019-05-30,2019,KR 20197011865 A,2017-09-26,US 201662399976 P;;US 2017/0053496 W,2016-09-26,TIM-3 상승을 치료하는 방법,본 개시내용은 유전자-기반 세포독성 면역자극 요법을 단독으로 또는 다른 면역요법과 함께 사용하여 TIM-3의 상승된 수준을 갖는 대상체를 치료하는 제제 및 요법을 제공한다.,ADVANTAGENE INC,AGUILAR CORDOVA ESTUARDO;;GUZIK BRIAN;;AGUILAR LAURA KAYE;;CHIOCCA ANTONIO E;;LAWLER SEAN;;SPERANZA MARIA CARMELLA,,https://lens.org/152-588-738-843-12X,Patent Application,no,0,0,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K48/00;;A61K39/00;;A61K39/39;;A61K39/395;;A61K45/06;;A61P35/00,,0,0,,,,DISCONTINUED
62,EP,A4,EP 3515486 A4,131-896-005-339-893,2020-05-20,2020,EP 17854134 A,2017-09-26,US 201662399976 P;;US 2017/0053496 W,2016-09-26,METHODS OF TREATING TIM-3 ELEVATION,,ADVANTAGENE INC,AGUILAR-CORDOVA ESTUARDO;;GUZIK BRIAN;;AGUILAR LAURA KAYE;;CHIOCCA ANTONIO E;;LAWLER SEAN;;SPERANZA MARIA CARMELLA,"CANDEL THERAPEUTICS, INC. (2021-08-04)",https://lens.org/131-896-005-339-893,Search Report,no,0,0,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K39/39;;A61K39/395;;A61P35/00,,6,5,017-417-445-255-649;;029-727-284-355-241;;004-852-463-741-290;;016-435-266-803-470;;009-754-875-423-064,10.1177/095632020101200305;;12959326;;9759929;;10.1089/hum.1998.9.14-2019;;10495430;;10.1002/(sici)1097-0215(19991029)83:3<374::aid-ijc13>3.0.co;2-;;10.1002/(sici)1097-0215(19991029)83:3<374::aid-ijc13>3.0.co;2-#;;27249715;;10.1200/edbk_159084;;10.14694/edbk_159084;;10.1038/sj.cgt.7700215;;10917212,"SHAW M M ET AL: ""Ganciclovir and penciclovir, but not acyclovir, induce apoptosis in herpes simplex virus thymidine kinase-transformed baby hamster kidney cells"", ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, INTERNATIONAL MEDICAL PRESS, GB, vol. 12, no. 3, 1 May 2001 (2001-05-01), pages 175 - 186, XP009112694, ISSN: 0956-3202;;MULLEN C A ET AL: ""GANCICLOVIR CHEMOABLATION OF HERPES THYMIDINE KINASE SUICIDE GENE-MODIFIED TUMORS PRODUCES TUMOR NECROSIS AND INDUCES SYSTEMIC IMMUNE RESPONSES"", HUMAN GENE THERAPY, MARY ANN LIEBERT, INC. PUBLISHERS, GB, vol. 9, 20 September 1998 (1998-09-20), pages 2019 - 2030, XP002906363, ISSN: 1043-0342;;SHIGEKI KURIYAMA ET AL: ""Cancer gene therapy with HSV-tk/GCV system depends on t-cell-mediated immune responses and causes apoptotic death of tumor cellsIn vivo"", INTERNATIONAL JOURNAL OF CANCER, vol. 83, no. 3, 29 October 1999 (1999-10-29), US, pages 374 - 380, XP055683373, ISSN: 0020-7136, DOI: 10.1002/(SICI)1097-0215(19991029)83:3<374::AID-IJC13>3.0.CO;2-#;;""Educational Book"", vol. 36, 1 May 2016, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, ISSN: 1548-8748, article MICHAEL LIM ET AL: ""Current State of Immune-Based Therapies for Glioblastoma"", pages: e132 - e139, XP055683168, DOI: 10.14694/EDBK_159084;;MAJUMDAR A S ET AL: ""EFFICACY OF HERPES SIMPLEX VIRUS THYMIDINE KINASE IN COMBINATION WITH CYTOKINE GENE THERAPY IN AN EXPERIMENTAL METASTATIC BREAST CANCER MODEL"", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 7, no. 7, 1 July 2000 (2000-07-01), pages 1086 - 1099, XP001088082, ISSN: 0929-1903, DOI: 10.1038/SJ.CGT.7700215;;See also references of WO 2018058123A1",DISCONTINUED
63,MX,A,MX 2019003314 A,104-644-895-639-459,2020-01-30,2020,MX 2019003314 A,2017-09-26,US 201662399976 P;;US 2017/0053496 W,2016-09-26,METHODS OF TREATING TIM-3 ELEVATION.,The present disclosure provides formulations and therapies for treating subjects with elevated levels of TIM- 3 using gene -based cytotoxic immunostimulant therapy alone or with other immunotherapies.,ADVANTAGENE INC,ESTUARDO AGUILAR-CORDVA;;BRIAN GUZIK;;LAURA KAYE AGUILAR;;ANTONIO E CHIOCCA;;SEAN LAWLER;;MARIA CARMELLA SPERANZA,AMVAC HONG KONG LIMITED (2021-07-15),https://lens.org/104-644-895-639-459,Patent Application,no,0,0,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K39/39;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
64,CA,A1,CA 3037253 A1,112-308-121-582-089,2018-03-29,2018,CA 3037253 A,2017-09-26,US 201662399976 P;;US 2017/0053496 W,2016-09-26,METHODS OF TREATING TIM-3 ELEVATION,The present disclosure provides formulations and therapies for treating subjects with elevated levels of TIM- 3 using gene -based cytotoxic immunostimulant therapy alone or with other immunotherapies.,ADVANTAGENE INC,AGUILAR-CORDOVA ESTUARDO;;GUZIK BRIAN;;AGUILAR LAURA KAYE;;CHIOCCA ANTONIO E;;LAWLER SEAN;;SPERANZA MARIA CARMELLA,,https://lens.org/112-308-121-582-089,Patent Application,no,0,0,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K39/39;;A61K39/395;;A61P35/00,,0,0,,,,PENDING
65,WO,A1,WO 2018/058123 A1,022-708-548-568-489,2018-03-29,2018,US 2017/0053496 W,2017-09-26,US 201662399976 P,2016-09-26,METHODS OF TREATING TIM-3 ELEVATION,The present disclosure provides formulations and therapies for treating subjects with elevated levels of TIM- 3 using gene -based cytotoxic immunostimulant therapy alone or with other immunotherapies.,ADVANTAGENE INC,AGUILAR-CORDOVA ESTUARDO;;GUZIK BRIAN;;AGUILAR LAURA KAYE;;CHIOCCA ANTONIO E;;LAWLER SEAN;;SPERANZA MARIA CARMELLA,,https://lens.org/022-708-548-568-489,Patent Application,yes,3,6,10,10,0,A61K39/39;;A61K39/39541;;A61K48/00;;A61K31/522;;C07K16/2818;;A61K2039/505;;C07K2317/76;;A61P35/00;;A61K39/0011;;A61K2039/545;;A61K2039/55561;;A01K2207/12;;A01K2227/105;;A01K2267/0393;;C12N2710/10041;;A61K31/52;;A61K45/06;;A61P35/00;;A61K31/522;;A61K39/0011;;A61K39/39;;A61K39/3955;;A61K39/39558;;A61K45/06;;A61K48/00;;A61K2300/00;;A61K2039/545;;A61K2039/55561;;A61K2039/505;;C12N2710/10041;;A61P35/00;;A61K31/52;;A61K31/522;;A61K35/76;;A61K35/761;;A61K35/763;;A61K38/193;;A61K38/20;;A61K38/2013;;A61K38/2046;;A61K38/208;;A61K38/2086;;A61K38/21;;A61K39/245;;A61K39/39;;A61K39/3955;;A61K2039/55561;;A61K2039/55572,A61K39/39;;A61K39/395;;A61P35/00,,4,3,032-798-610-749-999;;051-197-074-773-471;;090-276-024-473-614,10.1200/jco.2015.33.15_suppl.2010;;pmc5500167;;10.1016/s1470-2045(15)00544-6;;26858122;;10655437;;10.1093/jnci/92.3.205,"AGUILAR ET AL.: ""Phase II multicenter study of gene mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma"", J CLINICAL ONCOLOGY, 2015, XP055483874, Retrieved from the Internet <URL:http://ascopubs.org/doilabs/10.1200/jco.2015.33.15-suppl.2010> [retrieved on 20171128];;ANTONIA ET AL.: ""Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study"", LANCET ONCOL., vol. 17, no. 3, March 2016 (2016-03-01), pages 299 - 308, XP029444691;;THERASSE ET AL., J. NATL. CANCER INST., vol. 92, no. 3, 2000, pages 205 - 216;;See also references of EP 3515486A4",PENDING
66,EP,A1,EP 2422003 A1,026-373-599-039-935,2012-02-29,2012,EP 10767837 A,2010-04-23,US 2010/0032234 W;;US 18294809 P;;US 17229409 P,2009-04-24,INTERACTIVE MICROENVIRONMENT SYSTEM,,UNIV OHIO STATE,LANUTTI JOHN J;;JOHNSON JED K;;CHIOCCA E ANTONIO;;FISCHER SARA NICOLE;;LAWLER SEAN E;;LIN YOUNG C;;MARSH CLAY B,,https://lens.org/026-373-599-039-935,Patent Application,yes,0,8,5,5,0,C12M23/12;;C12M23/12;;C12M23/34;;C12M23/34;;C12M25/04;;C12M25/04;;C12M35/04;;C12M35/04;;C12M35/08;;C12M35/08;;C12N5/0068;;C12N5/0068;;C12N2533/40;;C12N2533/40;;D01D5/003;;D01D5/003;;D01F6/625;;D01F6/625,D02G3/00;;C12M1/00;;C12N5/00,,0,0,,,,DISCONTINUED
67,EP,A1,EP 0776161 A1,104-911-703-646-640,1997-06-04,1997,EP 95929543 A,1995-08-15,US 9510365 W;;US 29150094 A;;US 33052394 A,1994-08-17,USE OF A VIRAL VECTOR ENCODING A CYTOCHROME P450 GENE IN COMBINATION WITH A CHEMOTHERAPEUTIC AGENT FOR SELECTIVELY DESTROYING NEOPLASTIC CELLS,"A method for selectively killing nervous system and peripheral neoplastic cells is provided. Viral vectors are used to selectively express a cytochrome P450 gene in neoplastic cells, whose gene product targets the cells for selective killing, by rendering the cells sensitive to a chemotherapeutic agent.",GEN HOSPITAL CORP;;UNIV BOSTON;;DANA FARBER CANCER INST INC,CHIOCCA E ANTONIO;;WAXMAN DAVID J;;WEI MING X CNRS ERS -CER VI;;BREAKEFIELD XANDRA O;;CHEN LING,,https://lens.org/104-911-703-646-640,Patent Application,yes,0,0,14,14,0,A61K38/00;;A61K48/00;;C12N9/0079;;C12N2799/027;;A61P25/00;;A61P35/00;;A61K2300/00;;C12N9/0079;;A61K38/00;;A61K48/00;;C12N2799/027,C12N15/09;;A61K31/675;;A61K35/76;;A61K38/00;;A61K48/00;;A61P25/00;;A61P35/00;;C12N5/10;;C12N9/02,,0,0,,,,EXPIRED
68,WO,A1,WO 2010/124207 A1,095-871-330-006-481,2010-10-28,2010,US 2010/0032234 W,2010-04-23,US 18294809 P;;US 17229409 P,2009-04-24,INTERACTIVE MICROENVIRONMENT SYSTEM,"A culture cell for growing animal cells in vitro has sides and a bottom forming a volume. The volume contains a layer of nanofiber upon which animal cells can be cultured. The layer of nanofiber can be oriented or non-oriented. Multiple layers can be placed in the volume, where the layers have different composition and/or different porosity. The nanofiber can be, for example, surface treated or of a core-shell construction.",UNIV OHIO STATE,LANUTTI JOHN J;;JOHNSON JED K;;CHIOCCA E ANTONIO;;FISCHER SARA NICOLE;;LAWLER SEAN E;;LIN YOUNG C;;MARSH CLAY B,,https://lens.org/095-871-330-006-481,Patent Application,yes,2,24,5,5,0,C12M23/12;;C12M23/12;;C12M23/34;;C12M23/34;;C12M25/04;;C12M25/04;;C12M35/04;;C12M35/04;;C12M35/08;;C12M35/08;;C12N5/0068;;C12N5/0068;;C12N2533/40;;C12N2533/40;;D01D5/003;;D01D5/003;;D01F6/625;;D01F6/625,D02G3/00,,1,0,,,See also references of EP 2422003A4,PENDING
69,EP,A4,EP 2422003 A4,007-954-191-485-305,2012-10-31,2012,EP 10767837 A,2010-04-23,US 2010/0032234 W;;US 18294809 P;;US 17229409 P,2009-04-24,INTERACTIVE MICROENVIRONMENT SYSTEM,,UNIV OHIO STATE,LANUTTI JOHN J;;JOHNSON JED K;;CHIOCCA E ANTONIO;;FISCHER SARA NICOLE;;LAWLER SEAN E;;LIN YOUNG C;;MARSH CLAY B,,https://lens.org/007-954-191-485-305,Search Report,no,2,0,5,5,0,C12M23/12;;C12M23/12;;C12M23/34;;C12M23/34;;C12M25/04;;C12M25/04;;C12M35/04;;C12M35/04;;C12M35/08;;C12M35/08;;C12N5/0068;;C12N5/0068;;C12N2533/40;;C12N2533/40;;D01D5/003;;D01D5/003;;D01F6/625;;D01F6/625,D02G3/00;;C12M1/00;;C12N5/00,,1,0,,,See also references of WO 2010124207A1,DISCONTINUED
70,US,A1,US 2010/0273258 A1,184-440-572-257-269,2010-10-28,2010,US 76632810 A,2010-04-23,US 76632810 A;;US 17229409 P;;US 18294809 P,2009-04-24,Interactive Microenvironment System,"A culture cell for growing animal cells in vitro has sides and a bottom forming a volume. The volume contains a layer of nanofiber upon which animal cells can be cultured. The layer of nanofiber can be oriented or non-oriented. Multiple layers can be placed in the volume, where the layers have different composition and/or different porosity. The nanofiber can be, for example, surface treated or of a core-shell construction.",UNIV OHIO STATE,LANNUTTI JOHN J;;JOHNSON JED K;;CHIOCCA E ANTONIO;;FISCHER SARA NICOLE;;LAWLER SEAN E;;LIN YOUNG C;;MARSH CLAY B,THE OHIO STATE UNIVERSITY (2010-04-22),https://lens.org/184-440-572-257-269,Patent Application,no,3,76,5,5,0,C12M23/12;;C12M23/12;;C12M23/34;;C12M23/34;;C12M25/04;;C12M25/04;;C12M35/04;;C12M35/04;;C12M35/08;;C12M35/08;;C12N5/0068;;C12N5/0068;;C12N2533/40;;C12N2533/40;;D01D5/003;;D01D5/003;;D01F6/625;;D01F6/625,C12N5/071;;C12M3/00,435/366;;435/289.1,0,0,,,,DISCONTINUED
71,WO,A2,WO 2000/034497 A2,064-230-049-094-593,2000-06-15,2000,US 9929120 W,1999-12-09,US 11163098 P;;US 16137499 P,1998-12-09,ENHANCED PACKAGING OF HERPES VIRUS AMPLICONS AND GENERATION OF RECOMBINANT VIRUS VECTORS,"The present invention relates to an enhanced and simplified herpes virus amplicon packaging system and method of generating recombinant herpes virus vectors by 'pac rescue'. In one embodiment of this packaging system, the HSW-1 genome is cloned and maintained as a single-copy, F-plasmid-based BAC in E.coli. Such a plasmid, containing the HSV-1 genome deleted for the pac signals, did not generate replication-competent progeny virus upon transfection into mammalian cells, but rather, supported the packaging of co-transfected amplicon DNA which contained a functional pac signal. In another embodiment, the HSV genome cloned in BAC has an intact pac signal, however, the helper HSV genome is made packaging defective by increasing or decreasing the size of the BAC. This method involves the co-introduction of DNA fragments containing a pac site flanked by homologous HSV sequences and pac-deleted helper virus genome to permissive cells. In another embodiment, any kind of modification can be introduced into the viral genome through homologous recombination in bacteria.",BREAKEFIELD XANDRA O;;CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;FRAEFEL CORNEL;;TOBLER KURT;;ACKERMANN MATHIAS;;SUTER MARK;;ADEMA GOSSE J;;SHORTMAN KEN,BREAKEFIELD XANDRA O;;CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;FRAEFEL CORNEL;;TOBLER KURT;;ACKERMANN MATHIAS;;SUTER MARK;;ADEMA GOSSE J;;SHORTMAN KEN,,https://lens.org/064-230-049-094-593,Patent Application,yes,0,8,4,4,2,A61K39/00;;A61K39/245;;A61K48/00;;A61K2039/5256;;A61K2039/53;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C12N2800/204;;A61K2039/545;;A61K39/12;;C12N15/86;;C12N2800/204;;C12N2710/16634;;C12N2710/16643;;A61K39/245;;A61K48/00;;A61K39/00;;A61K2039/5256;;A61K2039/53;;A61K2039/545;;A61K39/12,A61K39/00;;A61K39/245;;A61K48/00;;C12N15/33;;C12N15/38;;C12N15/869,,0,0,,,,PENDING
72,US,B1,US 6573090 B1,164-380-958-506-929,2003-06-03,2003,US 45806899 A,1999-12-09,US 45806899 A;;US 16137499 P;;US 11163098 P,1998-12-09,Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors,"
    The present invention relates to an enhanced and simplified herpes virus amplicon packaging system. The packaging system comprises a herpes virus amplicon vector and a packaging vector. In one embodiment, the packaging vector comprises a bacterial artificial chromosome (BAC) containing the HSV-1 genome. The packaging vector contains an intact pac site but is otherwise rendered packaging defective. The packaging vector can be rendered packaging defective by inserting nucleotides into the pac site, or by otherwise interfering with the capsid's ability to close, for example, by increasing the size of the DNA fragment upon which the herpes virus genome is cloned. This system can be used to package a wide range of nucleotide sequences (e.g., a therapeutic or antigenic gene) into an empty herpes virus particle taking advantage of the large transgene capacity of herpes viruses. This system can also be used as a vaccine to induce protective immunity against HSV-1, or other complex pathogens. 
",GEN HOSPITAL CORP;;UNIV MEDICAL CT ST RADBOUD OF;;UNIV ZUERICH;;INST MEDICAL W & E HALL,BREAKEFIELD XANDRA O;;CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;FRAEFEL CORNEL;;TOBLER KURT;;ACKERMANN MATHIAS;;SUTER MARK;;ADEMA GOSSE J;;SHORTMAN KEN,GENERAL HOSPITAL CORPORATION THE (2000-04-07);;WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH THE (2000-02-25);;UNIVERSITY MEDICAL CENTER ST. RADBOUD OF THE UNIVERSITY OF NIJMEGEN (2000-02-20);;ZURICH UNIVERSITY OF (2000-02-21),https://lens.org/164-380-958-506-929,Granted Patent,yes,16,43,4,4,2,A61K39/00;;A61K39/245;;A61K48/00;;A61K2039/5256;;A61K2039/53;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C12N2800/204;;A61K2039/545;;A61K39/12;;C12N15/86;;C12N2800/204;;C12N2710/16634;;C12N2710/16643;;A61K39/245;;A61K48/00;;A61K39/00;;A61K2039/5256;;A61K2039/53;;A61K2039/545;;A61K39/12,A61K39/00;;A61K39/245;;A61K48/00;;C12N15/33;;C12N15/38;;C12N15/869,435/320.1;;435/69.1;;435/6;;435/455.1;;435/375.1;;435/235.1;;435/239;;536/23.1;;514/44;;424/199.1;;424/201.1;;424/202.1;;424/203.1;;424/229.1;;424/234.1;;424/93.1,64,59,009-416-320-508-847;;057-907-536-885-737;;046-941-920-735-995;;075-248-118-035-197;;011-596-321-144-013;;015-585-302-194-72X;;059-068-942-380-417;;049-165-631-221-007;;021-497-633-872-529;;029-250-644-782-533;;071-442-638-420-64X;;016-742-447-932-634;;000-033-151-883-738;;067-488-534-167-28X;;002-875-896-938-872;;127-348-232-397-557;;077-800-503-184-833;;029-114-817-824-206;;108-718-229-730-968;;110-408-278-056-613;;057-454-491-246-27X;;048-802-949-100-822;;002-512-736-644-602;;036-493-208-662-084;;050-738-349-969-573;;108-350-527-415-058;;016-232-000-040-461;;060-440-545-500-845;;009-618-196-138-468;;000-362-547-589-786;;129-236-633-688-941;;059-917-365-206-753;;086-587-143-781-330;;027-374-789-634-250;;067-343-526-327-020;;035-792-138-687-350;;080-787-242-731-417;;031-284-697-047-425;;026-392-563-631-578;;008-004-805-248-070;;021-914-429-320-027;;020-654-753-299-413;;000-193-460-055-664;;091-974-420-276-457;;086-745-584-060-521;;147-237-287-123-813;;024-533-020-155-927;;038-765-735-585-016;;038-042-482-349-453;;082-547-839-909-388;;082-139-264-011-549;;079-869-700-012-027;;012-119-157-251-611;;019-179-062-355-804;;070-557-043-082-884;;067-212-489-735-972;;021-839-856-024-866;;083-200-999-470-558;;117-216-763-616-862,9305836;;10.1038/38410;;10.1097/00001756-199712010-00029;;9427374;;pmc250644;;10.1128/jvi.63.5.2260-2269.1989;;2539517;;10.1073/pnas.90.13.6165;;pmc46888;;8392189;;9240964;;10.1096/fasebj.11.8.9240964;;10.1038/nbt0598-444;;9592392;;pmc189458;;7543591;;10.1128/jvi.69.9.5849-5852.1995;;10.1002/eji.1830270927;;9341774;;10.1099/0022-1317-74-3-387;;8383174;;10.1099/0022-1317-73-2-303;;1311359;;10.1006/viro.1993.1572;;8212547;;pmc20961;;9653172;;10.1073/pnas.95.14.8245;;7671105;;10.1016/0378-1119(89)90088-7;;2777090;;1962209;;10.1126/science.1962209;;7584109;;3746946;;10.1002/jnr.490160114;;8794366;;10.1128/jvi.70.10.7190-7197.1996;;pmc190772;;10.1007/bf03401718;;pmc2230287;;9440115;;10.1007/978-1-59259-478-8_4;;10.1002/0471142301.ns0414s06;;2174168;;pmc55078;;10.1073/pnas.87.22.8950;;10.1016/b978-012397570-6/50003-4;;10.1038/ng0194-84;;8136839;;10.1016/0008-8749(91)90194-g;;1671342;;9048203;;10.1089/hum.1997.8.3-359;;10.1093/intimm/9.9.1319;;9310835;;8122308;;10.1016/0168-9525(93)90104-p;;pmc7117511;;1441196;;10.1016/0378-1135(92)90100-8;;8974620;;10.1111/j.1750-3639.1995.tb00615.x;;7866875;;10.1007/bf02824809;;8679207;;10.2144/19962003460;;10.1128/jvi.67.8.4566-4579.1993;;pmc237841;;8392598;;10.1099/0022-1317-69-7-1531;;2839594;;10.1016/0042-6822(88)90417-5;;2827384;;9405686;;pmc25110;;10.1073/pnas.94.26.14759;;10.1615/critrevtherdrugcarriersyst.v12.i4.10;;9501965;;10.1126/science.2660262;;2660262;;10.1016/0264-410x(95)00069-d;;8578820;;9546773;;10.1038/nm0498-381;;10.1128/jvi.67.12.7149-7160.1993;;8230437;;pmc238177;;9470229;;10.1016/s0167-7799(97)01137-2;;1662844;;10.1016/0168-1702(91)90076-8;;9874276;;10.1089/hum.1998.9.18-2787;;pmc188685;;7529328;;10.1128/jvi.69.2.1122-1131.1995;;8607026;;pmc50007;;1528894;;10.1073/pnas.89.18.8794;;10.1016/s0264-410x(98)00111-x;;9711791;;7912023;;10.1006/viro.1994.1324;;9109503;;10.1046/j.1471-4159.1997.68051792.x;;10.1016/0092-8674(82)90035-6;;6290080;;10.1128/jvi.72.9.7137-7143.1998;;9696807;;pmc109935;;10535985;;10.1073/pnas.96.22.12697;;pmc23055;;10.1128/jvi.66.12.7336-7345.1992;;pmc240438;;1331523;;8095512;;10.1038/ng0892-379;;1338772;;9306400;;10.1038/nbt0997-859;;10.1007/bf00046349;;9034598;;10.1038/2417;;9771703,"Verma et al. Nature 1997, vol. 389, pp. 239-242.*;;Orkin et al. 1996 Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy.*;;Aboody-Guterman, K. S., et al., ""Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo,"" NeuroReport 8:3801-3808 (Dec. 1997).;;Ace, C. I., et al., ""Construction and Characterization of a Herpes Simplex Virus Type 1 Mutant Unable to Transinduce Immediate-Early Gene Expression,"" J. Virol. 63:2260-2269 (1989).;;Bergold, P. J., et al., ""Transsynaptic neuronal loss induced in hippocampal slice cultures by a herpes simplex virus vector expressing the GluR6 subunit of the kainate receptor,"" Proc. Natl. Acad. Sci. USA 90:6165-6169 (1993).;;Bilbao, G., et al., ""Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo,"" FASEB J. 11:624-634 (Jul. 1997).;;Breakfield, X. O., et al., ""Herpes Simplex Virus Vectors for Tumor Therapy,"" in The Internet Book of Gene Therapy, Cancer Therapeutics, Sobel, R. E. and Scanlon, K. J., eds., Appleton & Lange, Stanford, CT, pp. 41-56 (1995).;;Chase, M., et al., ""An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy,"" Nature Biotechnol. 16:444-448 (May 1998).;;Cose, S. C., et al., ""Characterization of a Diverse Primary Herpes Simplex Virus Type 1 gB-Specific Cytotoxic T-Cell Response Showing a Preferential Vbeta Bias,"" J. Virol. 69:5849-5852 (1995).;;Cose, S. C., et al., ""Antigen-specific CD8+ T cell subset distribution in lymph nodes draining the site of herpes simplex virus infection,"" Eur. J. Immunol. 27:2310-2316 (Sep. 1997).;;Coulter, L. J., et al., ""A mutant of herpes simplex virus type 1 in which the UL13 protein kinase gene is disrupted,"" J. Gen. Virol. 74:387-395 (1993).;;Cunningham, C., et al., ""The UL13 virion protein of herpes simplex virus type 1 is phosphorylated by a novel virus-induced protein kinase,"" J. Gen. Virol. 73:303-311 (1992).;;Cunningham, C., and Davison, A. J., ""A Cosmid-Based System for Contructing Mutants of Herpes Simplex Virus Type 1,"" Virol. 197:116-124 (1993).;;Delecluse, H.- J., et al., ""Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells,"" Proc. Natl. Acad. Sci. USA 95:8245-8250 (Jul. 1998).;;Dornburg, R., ""Reticuloendotheliosis viruses and derived vectors,"" Gene Therapy 2:301-310 (1995).;;Evans, G. A., et al., ""High efficiency vectors for cosmid microcloning and genomic analysis,"" Gene 79:9-20 (1989).;;Ferrin, L. J., and Camerini-Otero, R. D., ""Selective Cleavage of Human DNA: RecA-Assisted Restriction Endonuclease (RARE) Cleavage,"" Science 254:1494-1497 (1991).;;Flotte, T. R., and Carter, B. J., ""Adeno-associated virus vectors for gene therapy,"" Gene Therapy 2:357-362 (1995).;;Forss-Petter, S., et al., ""Neuron-Specific Enolase: Complete Structure of Rat mRNA, Multiple Transcriptional Start Sites, and Evidence Suggesting Post-Transcriptional Control,"" J. Neuroscience Res. 16:141-156 (1986).;;Fraefel, C., et al., ""Helper Virus-Free Transfer of Herpes Simplex Virus Type 1 Plasmid Vectors into Neural Cells,"" J. Virol. 70:7190-7197 (Oct. 1996).;;Fraefel, C., et al., ""Gene Transfer into Hepatocytes Mediated by Helper Virus-Free HSV/AAV Hybrid Vectors,"" Mol. Med. 3:813-825 (Dec. 1997).;;Fraefel, C., et al., ""HSV-1 Amplicon,"" in Gene Therapy for Neurological Disorders and Brain Tumors, Chiocca, E. A. and Breakefield, X. O., eds., Humana Press Inc., Totowa, NJ., pp. 63-82 (Oct. 1998).;;Fraefel, C., ""Gene Delivery Using Helper Virus-Free HSV-1 Amplicon Vectors,"" in Current Protocols in Neuroscience, vol. 1, Crawley, J.N. et al., eds., John Wiley & Sons, Inc., New York, NY, pp. 4.14.1-4.14.15 (1999).;;Geller, A. I., et al., ""An efficient deletion mutant packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology,"" Proc. Natl. Acad. Sci. USA 87:8950-8954 (1990).;;Glorioso, J. C., et al., ""Herpes Simplex Virus as a Gene-Delivery Vector for the Central Nervous System,"" in Viral Vectors, Academic Press, Inc., San Diego, CA, pp. 1-23 (1995).;;Ioannou, P. A., et al., ""A new bacteriophage P1-derived vector for the propagation of large human DNA fragments,"" Nature Genetics 6:84-89 (1994).;;Jennings, S. R., et al., ""CD4-Positive T Lymphocytes Are Required for the Generation of the Primary but Not the Secondary CD8-Positive Cytolytic T Lymphocyte Response to Herpes Simplex Virus in C57BL/6 Mice,"" Cell. Immunol. 133:234-252 (1991).;;Johnston, K. M., et al., ""HSV/AAV Hybrid Amplicon Vectors Extend Transgene Expression in Human Glioma Cells,"" Human Gene Ther. 8:359-370 (Feb. 1997).;;Jones, C. M., et al., ""Evidence for cooperation between TCR V region and junctional sequences in determining a dominant cytotoxic T lymphocyte response to herpes simplex virus glycoprotein B,"" International Immunol. 9:1319-1328 (Sep. 1997).;;Kilby, N. J., et al., ""Site-specific recombinases: tools for genome engineering,"" Trends in Genetics 9:413-421 (1993).;;Knuchel, M., et al., ""An ELISA for detection of antibodies against porcine epidemic diarrhoea virus (PEDV) based on the specific solubility of the viral surface glycoprotein,"" Veterinary Microbiol. 32:117-134 (1992).;;Kramm, C. M., et al., ""Gene Therapy for Brain Tumors,"" Brain Pathology 5:345-381 (1995).;;Latchman, D. S., ""Herpes Simplex Virus Vectors for Gene Therapy,"" Mol. Biotech. 2:179-195 (1994).;;Lim, F., et al., ""Generation of High-Titer Defective HSV-1 Vectors Using an IE 2 Deletion Mutant and Quantitative Study of Expression in Cultured Cortical Cells,"" BioTechniques 20:460-469 (Mar. 1996).;;Lopez, C., et al., ""Immunity to Herpesvirus Infections in Humans,"" in The Human Herpesviruses, Roizman, B., et al., eds., Raven Press, Ltd., New York, NY, pp. 397-425 (1993).;;Luckow, V. A., et al., ""Efficient Generation of Infectious Recombinant Baculoviruses by Site-Specific Transposon-Mediated Insertion of Foreign Genes into a Baculovirus Genome Propagated in Escherichia coli,"" J. Virol. 67:4566-4579 (1993).;;McGeoch, D. J., et al., ""The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1,"" J. Gen. Virol. 69:1531-1574 (1988).;;Meignier, B., et al., ""Virulence of and Establishment of Latency by Genetically Engineered Deletion Mutants of Herpes Simplex Virus 1,"" Virol. 162:251-254 (1988).;;Messerle, M., et al., ""Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome,"" Proc. Natl. Acad. Sci. USA 94:14759-14763 (Dec. 1997).;;Nakanishi, M., ""Gene Introduction Into Animal Tissues,"" Crit. Rev. Ther. Drug Carrier Sys. 12:263-310 (1995).;;O'Connor, M., et al., ""Construction of Large DNA Segments in Escherichia coli,"" Science 244:1307-1312 (1989).;;Pertmer, T. M., et al., ""Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA,"" Vaccine 13:1427-1430 (1995).;;Posavad, C. M., et al., ""Tipping the scales of herpes simplex virus reactivation: The important responses are local,"" Nature Med. 4:381-382 (Apr. 1998).;;Read, G. S., et al., ""Isolation of a Herpes Simplex Virus Type 1 Mutant with a Deletion in the Virion Host Shutoff Gene and Identification of Multiple Forms of the vhs (UL41) Polypeptide,"" J. Virol. 67:7149-7160 (1993).;;Robbins, P. D., et al., ""Viral vectors for gene therapy,"" TIBTECH 16:35-40 (Jan. 1998).;;Rösen-Wolff, A., et al., ""Elimination of UL56 gene by insertion of LacZ cassette between nucleotide position 116030 to 121753 of the herpes simplex virus type 1 genome abrogates intraperitoneal pathogenicity in tree shrews and mice,"" Virus Res. 20:205-221 (1991).;;Saeki, Y., et al., ""Herpes Simplex Virus Type 1 DNA Amplified as Bacterial Artificial Chromosome in Escherichia coli: Rescue of Replication-Competent Virus Progeny and Packaging of Amplicon Vectors,"" Human Gene Therapy 9:2787-2794 (Dec. 1998).;;Salvucci, L. A., et al., ""Polymorphism within the Herpes Simplex Virus (HSV) Ribonucleotide Reductase Large Subunit (ICP6) Confers Type Specificity for Recognition by HSV Type 1-Specific Cytotoxic T Lymphocytes,"" J. Virol. 69:1122-1131 (1995).;;Shaughnessy, E., et al., ""Parvoviral Vectors for the Gene Therapy of Cancer,"" Seminars in Oncol. 23:159-171 (Feb. 1996).;;Shizuya, H., et al., ""Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector,"" Proc. Natl. Acad. Sci. USA 89:8794-8797 (1992).;;Siegrist, C.- A., et al., ""Induction of neonatal TH1 and CTL responses by live viral vaccines: a role for replication patterns within antigen presenting cells?"" Vaccine 16:1473-1478 (Aug./Sep. 1998).;;Smith, P. M., et al., ""Control of Acute Cutaneous Herpes Simplex Virus Infection: T Cell-Mediated Viral Clearance Is Dependent upon Interferon-gamma (IFN-gamma),"" Virol. 202:76-88 (1994).;;Song, S., et al., ""An HSV-1 Vector Containing the Rat Tyrosine Hydroxylase Promoter Enhances Both Long-Term and Cell Type-Specific Expression in the Midbrain,"" J. Neurochem. 68:1792-1803 (May 1997).;;Spaete, R. R., and Frenkel, N., ""The Herpes Simplex Virus Amplicon: A New Eucaryotic Defective-Virus Cloning-Amplifying Vector,"" Cell 30:295-304 (1982).;;Stavropoulos, T. A., and Strathdee, C. A., ""An Enhanced Packaging System for Helper-Dependent Herpes Simplex Virus Vectors,"" J. Virol. 72:7137-7143 (Sep. 1998).;;Suter, M., et al., ""BAC-VAC, a novel generation of (DNA) vaccines: A bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1,"" Proc. Natl. Acad. Sci. USA 96:12697-12702 (Oct. 1999).;;Valyi-Nagy, T., et al., ""Herpes Simplex Virus Type 1 Murtant Strain in1814 Establishes a Unique, Slowly Progressing Infection in SCID Mice,"" J. Virol. 66:7336-7345 (1992).;;Vasilakos, J. P., and Michael, J. G., ""Herpes Simplex Virus Class I-Restricted Peptide Induces Cytotoxic T Lymphocytes In Vivo Independent of CD4+ T Cells,"" J. Immunol. 150:2346-2355 (1993).;;Watson, J. D., et al., ""Chapter 28: Working Toward Human Gene Therapy,"" in Recombinant DNA. 2nd Ed., W. H. Freeman & Co., New York, NY, pp. 567-581 (1992).;;Willetts, N., and Skurray, R., ""64. Structure and Function of the F Factor and Mechanism of Conjugation,"" in Eschericia Coli & Salmonella Typhimurium, Cellular and Molecular Biology, vol. 2, American Society for Microbiology, Washington, DC, pp. 1110-1113 (1987).;;Wolfe, J. H., et al., ""Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice,"" Nature Genetics 1:379-384 (1992).;;Yang, X. W., et al., ""Homologous recombination based modification in Escherichia [sic] coli and germline transmission in transgenic mice of a bacterial artificial chromosome,"" Nature Biotechnol. 15:859-865 (Sep. 1997).;;Zhang, Y. and Russell, S.J., ""Vectors for cancer gene therapy,"" Cancer & Metastasis Reviews 15:385-401 (1996).;;Zhang, Y., et al., ""A new logic for DNA engineering using recombination in Escherichia coli,"" Nature Genetics 20:123-128 (Oct. 1998).",EXPIRED
73,EP,A2,EP 1153136 A2,003-022-735-925-44X,2001-11-14,2001,EP 99968472 A,1999-12-09,US 9929120 W;;US 11163098 P;;US 16137499 P,1998-12-09,ENHANCED PACKAGING OF HERPES VIRUS AMPLICONS AND GENERATION OF RECOMBINANT VIRUS VECTORS,,GEN HOSPITAL CORP;;UNIV ZUERICH;;UNIV MEDICAL CT ST RADBOUD OF;;INST MEDICAL W & E HALL,BREAKEFIELD XANDRA O;;CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;FRAEFEL CORNEL;;TOBLER KURT;;ACKERMANN MATHIAS;;SUTER MARK;;ADEMA GOSSE J;;SHORTMAN KEN,,https://lens.org/003-022-735-925-44X,Patent Application,yes,0,0,4,4,0,A61K39/00;;A61K39/245;;A61K48/00;;A61K2039/5256;;A61K2039/53;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C12N2800/204;;A61K2039/545;;A61K39/12;;C12N15/86;;C12N2800/204;;C12N2710/16634;;C12N2710/16643;;A61K39/245;;A61K48/00;;A61K39/00;;A61K2039/5256;;A61K2039/53;;A61K2039/545;;A61K39/12,A61K39/00;;A61K39/245;;A61K48/00;;C12N15/33;;C12N15/38;;C12N15/869,,0,0,,,,DISCONTINUED
74,WO,A3,WO 2000/034497 A3,176-551-596-779-039,2000-11-09,2000,US 9929120 W,1999-12-09,US 11163098 P;;US 16137499 P,1998-12-09,ENHANCED PACKAGING OF HERPES VIRUS AMPLICONS AND GENERATION OF RECOMBINANT VIRUS VECTORS,"The present invention relates to an enhanced and simplified herpes virus amplicon packaging system and method of generating recombinant herpes virus vectors by 'pac rescue'. In one embodiment of this packaging system, the HSW-1 genome is cloned and maintained as a single-copy, F-plasmid-based BAC in E.coli. Such a plasmid, containing the HSV-1 genome deleted for the pac signals, did not generate replication-competent progeny virus upon transfection into mammalian cells, but rather, supported the packaging of co-transfected amplicon DNA which contained a functional pac signal. In another embodiment, the HSV genome cloned in BAC has an intact pac signal, however, the helper HSV genome is made packaging defective by increasing or decreasing the size of the BAC. This method involves the co-introduction of DNA fragments containing a pac site flanked by homologous HSV sequences and pac-deleted helper virus genome to permissive cells. In another embodiment, any kind of modification can be introduced into the viral genome through homologous recombination in bacteria.",BREAKEFIELD XANDRA O;;CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;FRAEFEL CORNEL;;TOBLER KURT;;ACKERMANN MATHIAS;;SUTER MARK;;ADEMA GOSSE J;;SHORTMAN KEN,BREAKEFIELD XANDRA O;;CHIOCCA E ANTONIO;;SAEKI YOSHINAGA;;FRAEFEL CORNEL;;TOBLER KURT;;ACKERMANN MATHIAS;;SUTER MARK;;ADEMA GOSSE J;;SHORTMAN KEN,,https://lens.org/176-551-596-779-039,Search Report,yes,3,0,4,4,0,A61K39/00;;A61K39/245;;A61K48/00;;A61K2039/5256;;A61K2039/53;;C12N15/86;;C12N2710/16634;;C12N2710/16643;;C12N2800/204;;A61K2039/545;;A61K39/12;;C12N15/86;;C12N2800/204;;C12N2710/16634;;C12N2710/16643;;A61K39/245;;A61K48/00;;A61K39/00;;A61K2039/5256;;A61K2039/53;;A61K2039/545;;A61K39/12,A61K39/00;;A61K39/245;;A61K48/00;;C12N15/33;;C12N15/38;;C12N15/869,,3,3,079-869-700-012-027;;012-119-157-251-611;;029-114-817-824-206,10.1128/jvi.72.9.7137-7143.1998;;9696807;;pmc109935;;10535985;;10.1073/pnas.96.22.12697;;pmc23055;;8794366;;10.1128/jvi.70.10.7190-7197.1996;;pmc190772,"STAVROPOULOS T ET AL: ""An enhanced packaging system for helper-dependent herpes simplex virus vectors"", JOURNAL OF VIROLOGY., vol. 72, no. 9, September 1998 (1998-09-01), pages 7137 - 7143, XP002142149;;SUTER M ET AL: ""BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 96, no. 22, 26 October 1999 (1999-10-26), pages 12697 - 12702, XP002142150;;FRAEFEL C ET AL: ""Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells"", JOURNAL OF VIROLOGY., vol. 70, no. 10, October 1996 (1996-10-01), pages 7190 - 7197, XP002142151",PENDING
